WHO Drug Information Vol. 30, No. 1, 2016                             Recommended INN: List 75




International Nonproprietary Names
for Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names: List 75
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of
Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health
Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4
(EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary
Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does
not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in
Cumulative List No. 16, 2015 (available in CD-ROM only).



Dénominations communes internationales des Substances
pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES: Liste 75
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du
choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques
[Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9);
résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation
mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de
l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–113) et
recommandées (1–74) dans la Liste récapitulative No. 16, 2015 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales para las Sustancias
Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS: Lista 75
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones
Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud,
1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4
(EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las
denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones
Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las
Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se
encuentran reunidas en Cumulative List No. 16, 2015 (disponible sólo en CD-ROM).




                                                                                                  93
Recommended INN: List 75                        WHO Drug Information Vol. 30, No. 1, 2016




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula;
                                    Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule
                                    développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular;
                                    Fórmula desarrollada



 acalabrutinibum
 acalabrutinib                        4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-
                                      2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-
                                      2-yl)benzamide

 acalabrutinib                        4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-
                                      2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-
                                      2-yl)benzamide

 acalabrutinib                        4-{8-amino-3-[(2S)-1-(but-2-inoil)pirrolidin-
                                      2-il]imidazo[1,5-a]pirazin-1-il}-N-(piridin-
                                      2-il)benzamida

                                      C26H23N7O2

                                                                           O
                                                               NH2
                                                       N                       N      N
                                                                               H

                                                           N
                                                   O   H        N

                                                       N
                                       H3C


 afasevikumabum #
 afasevikumab                         immunoglobulin G1-kappa, anti-[Homo sapiens IL17A
                                      (interleukin 17A, IL-17A) and Homo sapiens IL17F
                                      (interleukin 17F, IL-17F)], Homo sapiens monoclonal
                                      antibody;
                                      gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV3-
                                      9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123) -
                                      IGHG1*03, G1m3 (CH1 (124-221), hinge (222-236), CH2
                                      (237-346), CH3 (347-451), CHS (452-453)) (124-453)],
                                      (226-215')-disulfide with kappa light chain (1'-215') [Homo
                                      sapiens V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01)
                                      [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (232-
                                      232'':235-235'')-bisdisulfide

 afasévikumab                         immunoglobuline G1-kappa, anti-[Homo sapiens IL17A
                                      (interleukine 17A, IL-17A) et Homo sapiens IL17F
                                      (interleukine 17F, IL-17F)], Homo sapiens anticorps
                                      monoclonal;




94
WHO Drug Information Vol. 30, No. 1, 2016                                              Recommended INN: List 75




                                      chaîne lourde gamma1 (1-453) [Homo sapiens VH
                                      (IGHV3-9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123)
                                      -IGHG1*03, G1m3 (CH1 (124-221), charnière (222-236),
                                      CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-
                                      453)], (226-215')-disulfure avec la chaîne légère kappa (1'-
                                      215') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                                      IGKJ4*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')];
                                      dimère (232-232'':235-235'')-bisdisulfure

 afasevikumab                         inmunoglobulina G1-kappa, anti-[Homo sapiens IL17A
                                      (interleukina 17A, IL-17A) y Homo sapiens IL17F
                                      (interleukina 17F, IL-17F)], anticuerpo monoclonal de
                                      Homo sapiens;
                                      cadena pesada gamma1 (1-453) [Homo sapiens VH
                                      (IGHV3-9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123)
                                      -IGHG1*03, G1m3 (CH1 (124-221), bisagra (222-236),
                                      CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-
                                      453)], (226-215')-disulfuro con la cadena ligera kappa (1'-
                                      215') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                                      IGKJ4*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')];
                                      dímero (232-232'':235-235'')-bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLVESGGG LVQPGRSLRL SCAASGFTFD                         DYAMHWVRQA   PGKGLEWVSG     50
                                       INWSSGGIGY ADSVKGRFTI SRDNAKNSLY                         LQMNSLRAED   TALYYCARDI    100
                                       GGFGEFYWNF GLWGRGTLVT VSSASTKGPS                         VFPLAPSSKS   TSGGTAALGC    150
                                       LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                         QSSGLYSLSS   VVTVPSSSLG    200
                                       TQTYICNVNH KPSNTKVDKR VEPKSCDKTH                         TCPPCPAPEL   LGGPSVFLFP    250
                                       PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                         FNWYVDGVEV   HNAKTKPREE    300
                                       QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                         NKALPAPIEK   TISKAKGQPR    350
                                       EPQVYTLPPS REEMTKNQVS LTCLVKGFYP                         SDIAVEWESN   GQPENNYKTT    400
                                       PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                         CSVMHEALHN   HYTQKSLSLS    450
                                       PGK                                                                                 453

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVLTQSPAT LSLSPGERAT LSCRASQSVR                         SYLAWYQQKP   GQAPRLLIYD 50
                                       ASNRATGIPA RFSGSGSGTD FTLTISSLEP                         EDFAVYYCQQ   RSNWPPATFG 100
                                       GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                         ASVVCLLNNF   YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                         TLSKADYEKH   KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                                 215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          150-206       267-327 373-431
                                                             22''-96'' 150''-206'' 267''-327'' 373''-431''
                                       Intra-L (C23-C104) 23'-88'        135'-195'
                                                             23'''-88''' 135'''-195'''
                                       Inter-H-L (h 5-CL 126) 226-215' 226''-215'''
                                       Inter-H-H (h 11, h 14) 232-232'' 235-235''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH VH N57:
                                       52, 52'' (2% of the glycans)
                                       H CH2 N84.4:
                                       303, 303'' (98% of the glycans)
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados



 aglatimagenum besadenovecum #
 aglatimagene besadenovec             adenovirus (serotype 5) non replicant with a deletion in the
                                      E1/E2 region containing the herpes virus thymidine kinase
                                      gene (Herpes simplex virus HSV-tk) under the control of a
                                      Rous sarcoma virus (RSV) long terminal repeat promoter

 aglatimagène bésadénovec             adénovirus (sérotype 5) non répliquant, délété de la région
                                      E1/E2, contenant le gène de la thymidine kinase du virus
                                      de l'herpès (virus Herpes simplex HSV-tk) sous le contrôle
                                      de la séquence LTR (terminale longue répétée) du virus du
                                      sarcome de Rous (RSV)




                                                                                                                                 95
Recommended INN: List 75              WHO Drug Information Vol. 30, No. 1, 2016



 aglatimagén besadenovec   adenovirus (serotipo 5), no replicante, con una deleción en
                           la región E1/E2, que contiene el gen de la timidina kinasa
                           del virus del herpes (Herpes simplex virus HSV-tk) bajo el
                           control de la secuencia LTR (secuencia larga terminal
                           repetida) del virus del sarcoma de Rous (RSV)


 alofanibum
 alofanib                  3-{[4-methyl-2-nitro-5-(pyridin-
                           3-yl)phenyl]sulfamoyl}benzoic acid

 alofanib                  acide 3-{[4-méthyl-2-nitro-5-(pyridin-
                           3-yl)phenyl]sulfamoyl}benzoïque

 alofanib                  ácido 3-{[4-metil-2-nitro-5-(piridin-
                           3-il)fenil]sulfamoil}benzoico

                           C19H15N3O6S

                              N
                                              H
                                              N
                                                S              CO2H
                                               O O
                               H3C            NO2


 altiratinibum
 altiratinib               N-{4-[(2-cyclopropanecarboxamidopyridin-4-yl)oxy]-
                           2,5-difluorophenyl}-N'-(4-fluorophenyl)cyclopropane-
                           1,1-dicarboxamide

 altiratinib               N-{4-[(2-cyclopropanecarboxamidopyridin-4-yl)oxy]-
                           2,5-difluorophényl}-N'-(4-fluorophényl)cyclopropane-
                           1,1-dicarboxamide

 altiratinib               N-{4-[(2-ciclopropanocarboxamidopiridin-4-il)oxi]-
                           2,5-difluorofenil}-N'-(4-fluorofenil)ciclopropano-
                           1,1-dicarboxamida

                           C26H21F3N4O4

                                                         F
                                      H
                                      N           O                                F
                                                                   O   O
                                  O       N
                                                               N           N
                                                               H           H
                                                         F



 amcasertibum
 amcasertib                N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-{[2-oxo-
                           5-(2-phenyl-1,3-thiazol-4-yl)-1,2-dihydro-3H-indol-
                           3-ylidene]methyl}-1H-pyrrole-3-carboxamide

 amcasertib                N-[2-(diéthylamino)éthyl]-2,4-diméthyl-5-{[2-oxo-
                           5-(2-phényl-1,3-thiazol-4-yl)-1,2-dihydro-3H-indol-
                           3-ylidène]méthyl}-1H-pyrrole-3-carboxamide




96
WHO Drug Information Vol. 30, No. 1, 2016                                Recommended INN: List 75




 amcasertib                           N-[2-(dietilamino)etil]-2,4-dimetil-5-{[5-(2-fenil-1,3-tiazol-
                                      4-il)- 2-oxo-1,2-dihidro-3H-indol-3-ilideno]metil}-1H-pirrol-
                                      3-carboxamida

                                       C31H33N5O2S

                                                                         H
                                                                         N                        CH3
                                                                               O
                                                     N                          H
                                                                                N                  N
                                                                                            CH3         CH3
                                                     S
                                                                                             NH
                                                                             H3C
                                                                                       O



 apalutamidum
 apalutamide                          4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-
                                      6-thioxo-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-
                                      N-methylbenzamide

 apalutamide                          4-{7-[6-cyano-5-(trifluorométhyl)pyridin-3-yl]-8-oxo-
                                      6-thioxo-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-
                                      N-méthylbenzamide

 apalutamida                          4-{7-[6-ciano-5-(trifluorometil)piridin-3-il]-8-oxo-
                                      6-tioxo-5,7-diazaspiro[3.4]octan-5-il}-2-fluoro-
                                      N-metilbenzamida

                                       C21H15F4N5O2S

                                                 O       F                    CF3
                                       H3C                                             CN
                                             N                   S
                                             H
                                                                                   N
                                                             N       N


                                                                     O



 ascrinvacumabum #
 ascrinvacumab                        immunoglobulin G2-kappa, anti-[Homo sapiens ACVRL1
                                      (activin A receptor type II-like 1, activin receptor-like kinase
                                      1, ALK1, ALK-1, serine/threonine-protein kinase receptor
                                      R3, SKR3, transforming growth factor-beta superfamily
                                      receptor type I, TGF-B superfamily receptor type I, TSR-I,
                                      HHT2, ORW2)], Homo sapiens monoclonal antibody;
                                      gamma2 heavy chain (1-444) [Homo sapiens VH (IGHV4-
                                      31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-118) -
                                      IGHG2*01, G2m.. (CH1 (119-216), hinge (217-228), CH2
                                      (229-337), CH3 (338-442), CHS (443-444)) (119-444)],
                                      (132-215')-disulfide with kappa light chain (1'-215') [Homo
                                      sapiens V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ5*01)
                                      [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (220-
                                      220'':221-221'':224-224'':227-227'')-tetrakisdisulfide




                                                                                                              97
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016



 ascrinvacumab             immunoglobuline G2-kappa, anti-[Homo sapiens ACVRL1
                           (réceptor de type II-like 1 de l’activine A, kinase 1 réceptor-
                           like de l’activine, ALK1, ALK-1, récepteur R3
                           sérine/thréonine-protéine kinase, SKR3, récepteur de type
                           I de la superfamille du facteur de croissance transformant
                           bêta, récepteur de type I de la superfamille TGF-B, TSR-I,
                           HHT2, ORW2)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma2 (1-444) [Homo sapiens VH
                           (IGHV4-31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-
                           118) -IGHG2*01, G2m.. (CH1 (119-216), charnière (217-
                           228), CH2 (229-337), CH3 (338-442), CHS (443-444))
                           (119-444)], (132-215')-disulfure avec la chaîne légère
                           kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01
                           (99.00%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-
                           215')]; dimère (220-220'':221-221'':224-224'':227-227'')-
                           tétrakisdisulfure

 ascrinvacumab             inmunoglobulina G2-kappa, anti-[Homo sapiens ACVRL1
                           (receptor de tipo II-like 1 de la activina A, kinasa 1
                           receptor-like de la activina, ALK1, ALK-1, receptor R3
                           serina/treonina-proteína kinasa, SKR3, receptor de tipo I
                           de la superfamilia del factor de crecimiento transformador
                           beta, receptor de type I de la superfamilia TGF-B, TSR-I,
                           HHT2, ORW2)], Homo sapiens anticuerpo monoclonal;
                           cadena pesada gamma2 (1-444) [Homo sapiens VH
                           (IGHV4-31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-
                           118) -IGHG2*01, G2m.. (CH1 (119-216), bisagra (217-
                           228), CH2 (229-337), CH3 (338-442), CHS (443-444))
                           (119-444)], (132-215')-disulfuro con la cadena ligera kappa
                           (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%)
                           -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')];
                           dimero (220-220'':221-221'':224-224'':227-227'')-
                           tetrakisdisulfuro




98
WHO Drug Information Vol. 30, No. 1, 2016                          Recommended INN: List 75




 avacincaptadum pegolum
 avacincaptad pegol                   5'-O-({[6-(1-{(2RS)-2,3-bis[ω-methoxypoly(oxyethane-1,2-
                                      diyl)]propoxy}formamido)hexyl]oxy}hydroxyphosphoryl)-2'-
                                      deoxy-2'-fluoro-cytidylyl-(3'→5')-2'-O-methylguanylyl-
                                      (3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-
                                      fluorocytidylyl-(3'→5')-guanylyl-(3'→5')-2'-deoxy-2'-
                                      fluorocytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                                      methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-
                                      deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-
                                      (3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-
                                      methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                                      methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-
                                      guanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-
                                      deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-
                                      2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-
                                      2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-
                                      (3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                      methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-
                                      methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-
                                      deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-
                                      (3'→5')-adenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-
                                      2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-
                                      (3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-
                                      fluorocytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→3')-
                                      thymidine

 avacincaptad pégol                   5'-O-({[6-(1-{(2RS)-2,3-bis[ω-méthoxypoly(oxyéthane-1,2-
                                      diyl)]propoxy}formamido)hexyl]oxy}hydroxyphosphoryl)-2'-
                                      déoxy-2'-fluoro-cytidylyl-(3'→5')-2'-O-méthylguanylyl-
                                      (3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-
                                      fluorocytidylyl-(3'→5')-guanylyl-(3'→5')-2'-déoxy-2'-
                                      fluorocytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                                      méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-
                                      déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-
                                      (3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-
                                      méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                                      méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-
                                      guanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-
                                      déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-
                                      2'-O-méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-
                                      2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-
                                      (3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                      méthylguanylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-
                                      méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-
                                      déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-
                                      (3'→5')-adénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-
                                      2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-
                                      (3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-
                                      fluorocytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→3')-
                                      thymidine




                                                                                                  99
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016


 avacincaptad pegol        5'-O-({[6-(1-{(2RS)-2,3-bis[ω-metoxipoli(oxietano-1,2-
                           diil)]propoxi}formamido)hexil]oxi}hidroxifosforil)-2'-desoxi-
                           2'-fluoro-citidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-
                           2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-
                           guanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-
                           metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-
                           desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-
                           (3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-
                           2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-
                           guanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-
                           2'-fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-
                           metiladenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-
                           desoxi-2'-fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-
                           O-metiladenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-
                           2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-
                           desoxi-2'-fluorouridilil-(3'→5')-adenilil-(3'→5')-2'-desoxi-2'-
                           fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-
                           desoxi-2'-fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-
                           desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metilguanilil-(3'→3')-
                           timidina

                           C395H492F21N142O262P39 (C2H4O)2n

                            (3'-5') R-dflC-mG-dflC-dflC-G-dflC-mG-mG-dflU-dflC-dflU-dflC-
                            mA-mG-mG-dflC-G-dflC-dflU-mG-mA-mG-dflU-dflC-dflU-mG-
                            mA-mG-dflU-dflU-dflU-A-dflC-dflC-dflU-mG-dflC-mG3'-3'dT
                            Legend                                         H            R
                                                           O       O       N
                            dfl =              H3CO                                     O =
                                                               n
                            2'-deoxy-2'-fluoro H3CO                    O            O   P
                                                           O
                            m = 2'-O-methyl                    n                        OH

 avelumabum #
 avelumab                  immunoglobulin G1-lambda1, anti-[Homo sapiens CD274
                           (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1,
                           B7H1)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-450) [Homo sapiens VH (IGHV3-
                           23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -
                           IGHG1*01, Gm17,1 (CH1 (121-218), hinge (219-233), CH2
                           (234-343), CH3 (344-448), CHS (449-450) (121-450)],
                           (223-215')-disulfide with lambda1 light chain (1'-216')
                           [Homo sapiens V-LAMBDA (IGLV2-14*01 (99.00%) -
                           IGLJ1*01) [9.3.10] (1'-110') -IGLC1*02 (111'-216')]; dimer
                           (229-229'':232-232'')-bisdisulfide

 avélumab                  immunoglobuline G1-lambda1, anti-[Homo sapiens CD274
                           (ligand 1 de mort programmée, PDL1, PD-L1, homologue
                           1 de B7, B7H1)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-450) [Homo sapiens VH
                           (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-
                           120) -IGHG1*01, Gm17,1 (CH1 (121-218), charnière (219-
                           233), CH2 (234-343), CH3 (344-448), CHS (449-450)
                           (121-450)], (223-215')-disulfure avec la chaîne légère
                           lambda1 (1'-216') [Homo sapiens V-LAMBDA (IGLV2-
                           14*01 (99.00%) -IGLJ1*01) [9.3.10] (1'-110') -IGLC1*02
                           (111'-216')]; dimère (229-229'':232-232'')-bisdisulfure




100
WHO Drug Information Vol. 30, No. 1, 2016                                              Recommended INN: List 75




 avelumab                             inmunoglobulina G1-lambda1, anti-[Homo sapiens CD274
                                      (ligando 1 de muerte programada, PDL1, PD-L1,
                                      homólogo 1 de B7, B7H1)], anticuerpo monoclonal de
                                      Homo sapiens;
                                      cadena pesada gamma1 (1-450) [Homo sapiens VH
                                      (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-
                                      120) -IGHG1*01, Gm17,1 (CH1 (121-218), bisagra (219-
                                      233), CH2 (234-343), CH3 (344-448), CHS (449-450)
                                      (121-450)], (223-215')-disulfuro con la cadena ligera
                                      lambda1 (1'-216') [Homo sapiens
                                      V-LAMBDA (IGLV2-14*01 (99.00%) -IGLJ1*01) [9.3.10]
                                      (1'-110') -IGLC1*02 (111'-216')]; dímero (229-229'':232-
                                      232'')-bisdisulfuro


                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLLESGGG LVQPGGSLRL SCAASGFTFS                         SYIMMWVRQA         PGKGLEWVSS         50
                                       IYPSGGITFY ADTVKGRFTI SRDNSKNTLY                         LQMNSLRAED         TAVYYCARIK        100
                                       LGTVTTVDYW GQGTLVTVSS ASTKGPSVFP                         LAPSSKSTSG         GTAALGCLVK        150
                                       DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                         GLYSLSSVVT         VPSSSLGTQT        200
                                       YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                         PCPAPELLGG         PSVFLFPPKP        250
                                       KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                         YVDGVEVHNA         KTKPREEQYN        300
                                       STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                         LPAPIEKTIS         KAKGQPREPQ        350
                                       VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                         AVEWESNGQP         ENNYKTTPPV        400
                                       LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                         MHEALHNHYT         QKSLSLSPGK        450

                                       Light chain / Chaîne légère / Cadena ligera
                                       QSALTQPASV SGSPGQSITI SCTGTSSDVG                         GYNYVSWYQQ         HPGKAPKLMI 50
                                       YDVSNRPSGV SNRFSGSKSG NTASLTISGL                         QAEDEADYYC         SSYTSSSTRV 100
                                       FGTGTKVTVL GQPKANPTVT LFPPSSEELQ                         ANKATLVCLI         SDFYPGAVTV 150
                                       AWKADGSPVK AGVETTKPSK QSNNKYAASS                         YLSLTPEQWK         SHRSYSCQVT 200
                                       HEGSTVEKTV APTECS                                                                      216

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          147-203 264-324       370-428
                                                             22''-96'' 147''-203'' 264''-324'' 370''-428''
                                       Intra-L (C23-C104) 22'-90'        138'-197'
                                                             22'''-90''' 138'''-197'''
                                       Inter-H-L (h 5-CL 126) 223-215' 223''-215'''
                                       Inter-H-H (h 11, h 14) 229-229'' 232-232''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       300, 300''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

                                       Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                                       modificaciones post-traduccionales
                                       H CHS K2 C-terminal lysine clipping:
                                       450, 450'




 belizatinibum
 belizatinib                          4-fluoro-N-(6-{[4-(2-hydroxypropan-2-yl)piperidin-
                                      1-yl]methyl}-1-{cis-4-[(propan-2-yl)carbamoyl]cyclohexyl}-
                                      1H-benzimidazol-2-yl)benzamide

 bélizatinib                          4-fluoro-N-(6-{[4-(2-hydroxypropan-2-yl)pipéridin-
                                      1-yl]méthyl}-1-{cis-4-[(propan-2-yl)carbamoyl]cyclohexyl}-
                                      1H-benzimidazol-2-yl)benzamide

 belizatinib                          4-fluoro-N-(6-{[4-(2-hidroxipropan-2-il)piperidin-
                                      1-il]metil}-1-{cis-4-[(propan-2-il)carbamoil]ciclohexil}-
                                      1H-benzoimidazol-2-il)benzamida




                                                                                                                                       101
Recommended INN: List 75               WHO Drug Information Vol. 30, No. 1, 2016


                           C33H44FN5O3

                                                                      H3C
                                                                  O          CH3
                                                                        NH




                                                            N
                                                N
                                                                  N
                            H3C
                                                            N                      F
                                                            H
                              HO CH3                              O


 bexagliflozinum
 bexagliflozin             (1S)-1,5-anhydro-1-C-[4-chloro-3-({4-[2-
                           (cyclopropyloxy)ethoxy]phenyl}methyl)phenyl]-
                           D-glucitol

 bexagliflozine            (1S)-1,5-anhydro-1-C-[4-chloro-3-({4-[2-
                           (cyclopropyloxy)éthoxy]phényl}méthyl)phényl]-
                           D-glucitol

 bexagliflozina            (1S)-1,5-anhidro-1-C-[3-({4-[2-
                           (ciclopropiloxi)etoxi]fenil}metil)-4-clorofenil]-D-glucitol

                           C24H29ClO7

                                                O
                                   O




                                           Cl

                            HO

                                       O
                                  OH
                            HO
                                       OH



 bictegravirum
 bictegravir               (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-[(2,4,6-
                           trifluorophenyl)methyl]-2,3,4,5,7,9,13,13a-octahydro-
                           2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-
                           10-carboxamide

 bictégravir               (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-[(2,4,6-
                           trifluorophényl)méthyl]-2,3,4,5,7,9,13,13a-octahydro-
                           2,5-méthanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazépine-
                           10-carboxamide




102
WHO Drug Information Vol. 30, No. 1, 2016                            Recommended INN: List 75




 bictegravir                          (2R,5S,13aR)-8-hidroxi-7,9-dioxo-N-[(2,4,6-
                                      trifluorofenil)metil]-2,3,4,5,7,9,13,13a-octahidro-
                                      2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepina-
                                      10-carboxamida

                                       C21H18F3N3O5

                                                H   O       OH
                                                                 O       F       F
                                                N
                                                                     H
                                                        N            N
                                            O
                                        H       H
                                                                 O           F




 bleselumabum #
 bleselumab                           immunoglobulin G4-kappa, anti-[Homo sapiens CD40
                                      (tumor necrosis factor receptor superfamily member 5,
                                      TNFRSF5)], human monoclonal antibody;
                                      gamma4 heavy chain (1-448) [Homo sapiens VH (IGHV4-
                                      39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.13] (1-121) -
                                      IGHG4*01 (CH1 (122-219), hinge S10>P (229) (220-231),
                                      CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-
                                      448)], (135-213')-disulfide with kappa light chain (1’-213’)
                                      [Homo sapiens (V-KAPPA (IGKV1-13*02 (98.90%) -
                                      IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')];
                                      dimer (227-227":230-230")-bisdisulfide

 blésélumab                           immunoglobuline G4-kappa, anti-[Homo sapiens CD40
                                      (membre 5 de la superfamille des récepteurs du TNF,
                                      TNFRSF5)], anticorps monoclonal humain;
                                      chaîne lourde gamma4 (1-448) [Homo sapiens VH
                                      (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.13] (1-
                                      121) -IGHG4*01 (CH1 (122-219), charnière S10>P (229)
                                      (220-231), CH2 (232-341), CH3 (342-446), CHS (447-
                                      448)) (122-448)], (135-213')-disulfure avec la chaîne légère
                                      kappa (1’-213’) [Homo sapiens (V-KAPPA (IGKV1-13*02
                                      (98.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-
                                      213')]; dimère (227-227":230-230")-bisdisulfure

 bleselumab                           inmunoglobulina G4-kappa, anti-[Homo sapiens CD40
                                      (miembro 5 de la superfamilia de receptores del TNF,
                                      TNFRSF5)], anticuerpo monoclonal humano;
                                      cadena pesada gamma4 (1-448) [Homo sapiens VH
                                      (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.13] (1-
                                      121) -IGHG4*01 (CH1 (122-219), bisagra S10>P (229)
                                      (220-231), CH2 (232-341), CH3 (342-446), CHS (447-
                                      448)) (122-448)], (135-213')-disulfuro con la cadena ligera
                                      kappa (1’-213’) [Homo sapiens (V-KAPPA (IGKV1-13*02
                                      (98.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-
                                      213')]; dímero (227-227":230-230")-bisdisulfuro




                                                                                               103
Recommended INN: List 75                   WHO Drug Information Vol. 30, No. 1, 2016



                           Heavy chain / Chaîne lourde / Cadena pesada
                           QLQLQESGPG LLKPSETLSL TCTVSGGSIS                          SPGYYGGWIR        QPPGKGLEWI      50
                           GSIYKSGSTY HNPSLKSRVT ISVDTSKNQF                          SLKLSSVTAA        DTAVYYCTRP     100
                           VVRYFGWFDP WGQGTLVTVS SASTKGPSVF                          PLAPCSRSTS        ESTAALGCLV     150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                          SGLYSLSSVV        TVPSSSLGTK     200
                           TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC                          PAPEFEGGPS        VFLFPPKPKD     250
                           TLMISRTPEV TCVVVDVSQE DPEVQFNWYV                          DGVEVHNAKT        KPREEQFNST     300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP                          SSIEKTISKA        KGQPREPQVY     350
                           TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV                          EWESNGQPEN        NYKTTPPVLD     400
                           SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH                          EALHNHYTQK        SLSLSLGK       448

                           Light chain / Chaîne légère / Cadena ligera
                           AIQLTQSPSS LSASVGDRVT ITCRASQGIS                          SALAWYQQKP        GKAPKLLIYD 50
                           ASNLESGVPS RFSGSGSGTD FTLTISSLQP                          EDFATYYCQQ        FNSYPTFGQG 100
                           TKVEIKRTVA APSVFIFPPS DEQLKSGTAS                          VVCLLNNFYP        REAKVQWKVD 150
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                          SKADYEKHKV        YACEVTHQGL 200
                           SSPVTKSFNR GEC                                                                         213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-97          148-204       262-322 368-426
                                                  22''-97'' 148''-204'' 262''-322'' 368''-426''
                           Intra-L (C23-C104) 23'-88' 133'-193'
                                                 23'''-88''' 133'''-193'''
                           Inter-H-L (CH1 10-CL 126) 135-213' 135''-213'''
                           Inter-H-H (h 8, h 11)            227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           298, 298''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
                           fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


 brigatinibum
 brigatinib                2-[(5-chloro-2-{2-methoxy-4-[4-(4-methylpiperazin-
                           1-yl)piperidin-1-yl]anilino}pyrimidin-
                                                           5
                           4-yl)amino]phenyl}dimethyl-λ -phosphanone

 brigatinib                2-[(5-chloro-2-{2-méthoxy-4-[4-(4-méthylpipérazin-
                           1-yl)pipéridin-1-yl]anilino}pyrimidin-
                                                           5
                           4-yl)amino]phényl}diméthyl-λ -phosphanone

 brigatinib                2-[(5-cloro-2-{2-metoxi-4-[4-(4-metilpiperazin-
                           1-il)piperidin-1-il]anilino}pirimidin-
                                                       5
                           4-il)amino]fenil}dimetil-λ -fosfanona

                           C29H39ClN7O2P


                                                                                                            O
                                                                                                        P       CH3
                                                                               H
                                                                               N        N         NH    CH3

                                                                                    N
                                                            N                  O                  Cl
                                                                               CH3
                                             N
                                    N
                            H3C



 capsaicinum
 capsaicin                 (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-
                           8-methylnon-6-enamide

 capsaïcine                (6E)-N-[(4-hydroxy-3-méthoxyphényl)méthyl]-
                           8-méthylnon-6-énamide

 capsaicina                (6E)-N-[(4-hidroxi-3-metoxifenil)metil]-8-metilnon-
                           6-enamida




104
WHO Drug Information Vol. 30, No. 1, 2016                              Recommended INN: List 75




                                       C18H27NO3

                                                                       O
                                       H3C                                                OCH3
                                                                           N
                                                                           H
                                             CH3
                                                                                          OH



 cenerimodum
 cenerimod                            (2S)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-
                                      1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}propane-
                                      1,2-diol

 cénérimod                            (2S)-3-{4-[5-(2-cyclopentyl-6-méthoxypyridin-4-yl)-
                                      1,2,4-oxadiazol-3-yl]-2-éthyl-6-méthylphénoxy}propane-
                                      1,2-diol

 cenerimod                            (2S)-3-{4-[5-(2-ciclopentil-6-metoxipiridin-4-il)-
                                      1,2,4-oxadiazol-3-il]-2-etil-6-metilfenoxi}propano-1,2-diol

                                       C25H31N3O5

                                                               O N
                                                                                 CH3
                                                                   N
                                                 N
                                                                                 O            OH
                                                       OCH3                            H OH
                                                                               CH3




 cenobamatum
 cenobamate                           (1R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl
                                      carbamate

 cénobamate                           carbamate de (1R)-1-(2-chlorophényl)-
                                      2-(2H-tétrazol-2-yl)éthyle

 cenobamato                           carbamato de (1R)-1-(2-clorofenil)-2-(2H-tetrazol-
                                      2-il)etilo

                                       C10H10ClN5O2

                                                     NH2
                                             O
                                                 H O       N N
                                                           N
                                                               N

                                                  Cl




                                                                                                   105
Recommended INN: List 75                    WHO Drug Information Vol. 30, No. 1, 2016


 cergutuzumabum amunaleukinum #
 cergutuzumab amunaleukin         immunoglobulin G1-kappa fused to IL2 (interleukin 2), anti-
                                  [Homo sapiens CEACAM5 (carcinoembryonic antigen-
                                  related cell adhesion molecule 5, CEA, CD66e)],
                                  humanized monoclonal antibody fused to IL2;
                                  gamma1 heavy chain (1-451) [humanized VH (Homo
                                  sapiens IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01)
                                  [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                  (122-219), hinge (220-234), CH2 L1.3>A (238), L1.2>A
                                  (239), P114>G (333) (235-344), CH3 Y5>C (353), T22>S
                                  (370), L24>A (372), Y86>V (411) (345-449), CHS (450-
                                  451)) (122-451)], (224-215')-disulfide with kappa light chain
                                  (1’-215’) [humanized V-KAPPA (Homo sapiens IGKV1-
                                  16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -Homo
                                  sapiens IGKC*01, Km3 (109'-215')]; gamma1 heavy chain
                                  fused to IL2 (1''-598'') [humanized VH (Homo sapiens
                                  IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1''-
                                  121'') -Homo sapiens IGHG1*01, G1m17,1 (CH1 (122''-
                                  219''), hinge (220''-234''), CH2 L1.3>A (238''), L1.2>A
                                  (239''), P114>G (333'') (235''-344''), CH3 S10>C (358''),
                                  T22>W (370''), (345''-449''), CHS K2>del (450'')) (122''-
                                  450'') -15-mer (tris(tetraglycyl-seryl)) linker (451''-465'') -
                                  Homo sapiens IL2 (Pr21-153) T23>A (468''), F62>A (507''),
                                  Y65>A (510''), L92>G (547''), C145>A (590'') (466''-598'')],
                                  (224''-215''')-disulfide with kappa light chain (1'''-215''')
                                  [humanized V-KAPPA (Homo sapiens IGKV1-16*01
                                  (82.10%) -IGKJ2*01) [6.3.10] (1'''-108''') -Homo sapiens
                                  IGKC*01, Km3 (109'''-215''')]; dimer (230-230":233-233")-
                                  bisdisulfide

 cergutuzumab amunaleukine        immunoglobuline G1-kappa fusionnée à l’IL2 (interleukine
                                  2), anti-[Homo sapiens CEACAM5 (molécule d’adhésion
                                  cellulaire 5 apparentée à l’antigène carcinoembryonaire,
                                  CEA, CD66e)], anticorps monoclonal humanisé fusionné à
                                  l’IL2;
                                  chaîne lourde gamma1 (1-451) [VH humanisé (Homo
                                  sapiens IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01)
                                  [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                  (122-219), charnière (220-234), CH2 L1.3>A (238), L1.2>A
                                  (239), P114>G (333) (235-344), CH3 Y5>C (353), T22>S
                                  (370), L24>A (372), Y86>V (411) (345-449), CHS (450-
                                  451)) (122-451)], (224-215')-disulfure avec la chaîne légère
                                  kappa (1’-215’) [V-KAPPA humanisé (Homo sapiens
                                  IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -
                                  Homo sapiens IGKC*01, Km3 (109'-215')]; chaîne lourde
                                  gamma1 fusionnée à l’IL2 (1''-598'') [VH humanisé (Homo
                                  sapiens IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01)
                                  [8.8.14] (1''-121'') -Homo sapiens IGHG1*01, G1m17,1
                                  (CH1 (122''-219''), charnière (220''-234''), CH2 L1.3>A
                                  (238''), L1.2>A (239''), P114>G (333'') (235''-344''), CH3
                                  S10>C (358''), T22>W (370''), (345''-449''), CHS K2>del
                                  (450'')) (122''-450'') -15-mer (tris(tétraglycyl-séryl)) linker
                                  (451''-465'') -Homo sapiens IL2 (Pr21-153) T23>A (468''),
                                  F62>A (507''), Y65>A (510''), L92>G (547''), C145>A
                                  (590'') (466''-598'')], (224''-215''')- disulfure avec la chaîne
                                  légère kappa (1'''-215''') [V-KAPPA humanisé (Homo
                                  sapiens IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'''-
                                  108''') -Homo sapiens IGKC*01, Km3 (109'''-215''')]; dimère
                                  (230-230":233-233")-bisdisulfure



106
WHO Drug Information Vol. 30, No. 1, 2016                                                  Recommended INN: List 75



 cergutuzumab amunaleukina            inmunoglobulina G1-kappa fusionada con IL2 (interleukina
                                      2), anti-[Homo sapiens CEACAM5 (molécula de adhesión
                                      celular 5 relacionada con el antígeno carcinoembrionario,
                                      CEA, CD66e)], anticuerpo monoclonal humanizado
                                      fusionado IL2;
                                      cadena pesada gamma1 (1-451) [VH humanizado (Homo
                                      sapiens IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01)
                                      [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (122-219), bisagra (220-234), CH2 L1.3>A (238), L1.2>A
                                      (239), P114>G (333) (235-344), CH3 Y5>C (353), T22>S
                                      (370), L24>A (372), Y86>V (411) (345-449), CHS (450-
                                      451)) (122-451)], (224-215')-disulfuro con la cadena ligera
                                      kappa (1’-215’) [V-KAPPA humanizado (Homo sapiens
                                      IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -
                                      Homo sapiens IGKC*01, Km3 (109'-215')]; cadena pesada
                                      fusionada con ’IL2 (1''-598'') [VH humanizado (Homo
                                      sapiens IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01)
                                      [8.8.14] (1''-121'') -Homo sapiens IGHG1*01, G1m17,1
                                      (CH1 (122''-219''), bisagra (220''-234''), CH2 L1.3>A
                                      (238''), L1.2>A (239''), P114>G (333'') (235''-344''), CH3
                                      S10>C (358''), T22>W (370''), (345''-449''), CHS K2>del
                                      (450'')) (122''-450'') -15-mer (tris(tetraglicil-seril))
                                      espaciador (451''-465'') -Homo sapiens IL2 (Pr21-153)
                                      T23>A (468''), F62>A (507''), Y65>A (510''), L92>G (547''),
                                      C145>A (590'') (466''-598'')], (224''-215''')- disulfuro con la
                                      cadena ligera kappa (1'''-215''') [V-KAPPA humanizado
                                      (Homo sapiens IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10]
                                      (1'''-108''') -Homo sapiens IGKC*01, Km3 (109'''-215''')];
                                      dímero (230-230":233-233")-bisdisulfuro
                                       Heavy chain H/ Chaîne lourde H/ Cadena pesada H
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT EFGMNWVRQA                           PGQGLEWMGW           50
                                       INTKTGEATY VEEFKGRVTF TTDTSTSTAY MELRSLRSDD                           TAVYYCARWD          100
                                       FAYYVEAMDY WGQGTTVTVS SASTKGPSVF PLAPSSKSTS                           GGTAALGCLV          150
                                       KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV                           TVPSSSLGTQ          200
                                       TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPEAAG                           GPSVFLFPPK          250
                                       PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN                           AKTKPREEQY          300
                                       NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALGAPIEKTI                           SKAKGQPREP          350
                                       QVCTLPPSRD ELTKNQVSLS CAVKGFYPSD IAVEWESNGQ                           PENNYKTTPP          400
                                       VLDSDGSFFL VSKLTVDKSR WQQGNVFSCS VMHEALHNHY                           TQKSLSLSPG          450
                                       K                                                                                         451

                                       Heavy chain H'' (fused to IL2) / Chaîne lourde H'' (fusionnée to IL2) / Cadena pesada
                                       H'' (fusionada con IL2)
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT EFGMNWVRQA PGQGLEWMGW 50
                                       INTKTGEATY VEEFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARWD 100
                                       FAYYVEAMDY WGQGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
                                       KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
                                       TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPEAAG GPSVFLFPPK 250
                                       PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
                                       NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALGAPIEKTI SKAKGQPREP 350
                                       QVYTLPPCRD ELTKNQVSLW CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
                                       VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
                                       GGGGSGGGGS GGGGSAPASS STKKTQLQLE HLLLDLQMIL NGINNYKNPK 500
                                       LTRMLTAKFA MPKKATELKH LQCLEEELKP LEEVLNGAQS KNFHLRPRDL 550
                                       ISNINVIVLE LKGSETTFMC EYADETATIV EFLNRWITFA QSIISTLT                              598

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCKASAAVG                      TYVAWYQQKP      GKAPKLLIYS 50
                                       ASYRKRGVPS RFSGSGSGTD FTLTISSLQP                      EDFATYYCHQ      YYTYPLFTFG 100
                                       QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT                      ASVVCLLNNF      YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                      TLSKADYEKH      KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                                 215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          148-204       265-325 371-429
                                       Intra-H (C23-C104) 22''-96'' 148''-204'' 265''-325'' 371''-429''
                                       -IL2 (Pr C78-C125) 523''-570''
                                       Intra-L (C23-C104) 23'-88'         135'-195'
                                                             23'''-88''' 135'''-195'''
                                       Inter-H-L (h 5-CL 126) 224-215' 224''-215'''
                                       Inter-H-H (h 11, h 14) 230-230'' 233-233''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       301, 301''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

                                       Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                                       modificaciones post-traduccionales
                                       H CHS K2 C-terminal lysine clipping:
                                       451




                                                                                                                                         107
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016




 ciraparantagum
                            1   1'
 ciraparantag              N ,N -[piperazine-1,4-diylbis(propane-1,3-diyl)]bis-
                           L-argininamide

                            1   1'
 ciraparantag              N ,N -[pipérazine-1,4-diylbis(propane-1,3-diyl)]bis-
                           L-argininamide

                            1   1'
 ciraparantag              N ,N -[piperazina-1,4-diilbis(propano-1,3-diil)]bis-
                           L-argininamida

                           C22H48N12O2

                                             H2N
                                                   NH                        O
                                              NH                                  NH2
                                H                          N             N
                                         H                               H
                                         N          N                            H
                            H2N                                  HN
                                     O                      HN
                                                                   NH2




 cobitolimodum
 cobitolimod               all-P-ambo-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-
                           thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-
                           deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-
                           deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-
                           (3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-
                           deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-
                           (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-
                           P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                           deoxy-P-thioguanylyl-(3'→5')-2'-deoxycytidine

 cobitolimod               tout-P-ambo-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-
                           thioguanylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-
                           déoxyadénylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-
                           déoxyadénylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-thymidylyl-
                           (3'→5')-thymidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-
                           déoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidylyl-
                           (3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-
                           P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                           déoxy-P-thioguanylyl-(3'→5')-2'-déoxycytidine

 cobitolimod               todo-P-ambo-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-
                           tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-
                           desoxiadenilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-
                           desoxiadenilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-
                           (3'→5')-timidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-
                           desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidilil-
                           (3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-P-
                           tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-
                           P-tioguanilil-(3'→5')-2'-desoxicitidina




108
WHO Drug Information Vol. 30, No. 1, 2016                                    Recommended INN: List 75


                                    C185H233N73O106P18S6


                                      (3'-5')-d-(G-G-A-A-C-A-G-T-T-C-G-T-C-C-A-T-G-G-C)
                                      Modified residues / Nucléotides modifiés / Nucleótidos modificados
                                                  B=A,G,T                                      OH
                                       (P-RS)-2'-deoxy-P-thionucleyl                                    O       N B
                                                                                          5'
                                       (P-RS)-2'-désoxy-P-thionucléyle
                                                                                      S            3'
                                       (P-RS)-2'-deoxi-P-thionucleil
                                                                                          P        O
                                                                                 O                      and epimer at P
                                                                                          OH            et l'épimère en P
                                                                                 C   5'                 y el epímero al P


 daprodustatum
 daprodustat                           N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxopyrimidin-
                                       5-yl)carbonyl]glycine

 daprodustat                           N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxopyrimidin-
                                       5-yl)carbonyl]glycine

 daprodustat                           N-[(1,3-diciclohexilhexahidro-2,4,6-trioxopirimidin-
                                       5-il)carbonil]glicina

                                       C19H27N3O6




                                              O       N       O
                                                                   H
                                                  N                N         CO2H

                                                      O       O


 difelikefalinum
 difelikefalin                         4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-
                                       lysyl)piperidine-4-carboxylic acid

 difélikéfaline                        acide 4-amino-1-(D-phénylalanyl-D-phénylalanyl-
                                       D-leucyl-D-lysyl)pipéridine-4-carboxylique

 difelicefalina                        ácido 4-amino-1-(D-fenilalanil-D-fenilalanil-D-leucil-
                                       D-lisil)piperidina-4-carboxílico

                                       C36H53N7O6


                                                                  H3 C
                                                                             CH3
                                                  H           O          H                     O
                                                      H                          H
                                                      N                          N
                                        H2N                        N                                N
                                                                   H
                                                  O     H                    O     H                            CO2H
                                                                                                               NH2
                                                                       H2N




                                                                                                                            109
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016


 dusquetidum
 dusquetide                L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alaninamide

 dusquétide                L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alaninamide

 dusquetida                L-arginil-L-isoleucil-L-valil-L-prolil-L-alaninamida

                           C25H47N9O5

                            H Arg     Ile   Val   Pro    Ala NH2
                                                          5


 efpegsomatropinum #
 efpegsomatropin           recombinant human growth hormone (somatropin) and
                           human immunoglobulin G4 Fc fragment dimer, produced in
                           Escherichia coli (nonglycosylated), linked together with
                           polyethylene glycol derivative linker:
                             α.1 1.9'
                           N ,N -[ω-(oxypropane-1,3-diyl)-α-(propane-
                           1,3-diyl)poly(oxyethylene)] human growth hormone, human
                           immunoglobulin G4 Fc fragment (IGHG4*01 H-CH2-CH3)-
                           (9'-229')-peptide dimer (11'-11'')-disulfide

 efpègsomatropine          hormone de croissance humaine (somatropine) et dimère
                           du fragment Fc de l'IgG4 humain, recombinants produits
                           par Escherichia coli (non glycosylés), liés par un pont
                           dérivé du polyéthylèneglycol :
                              α.1 1.9'
                           N ,N - [ω-(oxypropane-1,3-diyl)-α-(propane-
                           1,3-diyl)poly(oxyéthylène)] hormone de croissance
                           humaine, (11'-11'')-disulfure du dimère du fragment Fc de
                           l'immunoglobuline G4 humaine (IGHG4*01 H-CH2-CH3)-
                           (9'-229')-peptide

 efpegsomatropina          hormona humana de crecimiento (somatropina) y dímero
                           del fragmento Fc de la IgG4 humana, recombinantes,
                           producidos por Escherichia coli (no glicosilados), unidos
                           por un puente derivado del polietilenglicol :
                             α.1  1.9'
                           N ,N - [ω-(oxipropano-1,3-diil)-α-(propano-
                           1,3-diil)poli(oxietileno)] hormona humana de crecimiento,
                           (11'-11'')-disulfuro del dímero del fragmento Fc de la
                           inmunoglobulina G4 humana (IGHG4*01 H-CH2-CH3)-(9'-
                           229')-péptido




110
WHO Drug Information Vol. 30, No. 1, 2016                            Recommended INN: List 75




 elamipretidum
 elamipretide                         D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-
                                      L-phenylalaninamide

 élamiprétide                         D-arginyl-2,6-diméthyl-L-tyrosyl-L-lysyl-
                                      L-phénylalaninamide

 elamipretida                         D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida

                                       C32H49N9O5

                                                                 H2N
                                             HN
                                       HN                  H           O    H             O
                                                                 H                   H
                                              NH2                N                   N
                                                    H2N                     N                 NH2
                                                                            H
                                                             O       H           O       H
                                                                           CH3

                                                           H3C

                                                                           OH




 emicizumabum #
 emicizumab                           immunoglobulin G4-kappa, bispecific, anti-[Homo sapiens
                                      F9a (activated coagulation factor F9, activated coagulation
                                      factor IX) and anti-[Homo sapiens F10 (coagulation factor
                                      10, coagulation factor X)], humanized monoclonal
                                      antibody;
                                      gamma4 heavy chain (1-448) [humanized VH (Homo
                                      sapiens IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1-
                                      123)), IGHG4*01 (CH1 K100>Q (202) (124-221), hinge
                                      S10>P (231) (222-233), CH2 F84.3>Y (299) (234-343),
                                      CH3 E12>K (359), R88>K (412), H115>R (438), L125>P
                                      (448) (344-448), CHS>del) (124-448)], (137-214')-disulfide
                                      with kappa light chain (1’-214’) [humanized V-KAPPA
                                      (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9]
                                      (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                                      gamma4 heavy chain (1-444) [VH (Homo sapiens IGHV1-
                                      2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E (111''), T123>L
                                      (114'') (1''-119'')), IGHG4*01 (CH1 A100>Q (198'') (120''-
                                      217''), hinge S10>P (227'') (218''-229''), CH2 F84.3>Y
                                      (295''), (230''-339''), CH3 R88>K (408), K119>E (438),
                                      L125>P (444) (340''-444''), CHS>del) (120''-444'')], (133''-
                                      214''')-disulfide with kappa light chain (1'''-214''')
                                      [humanized V-KAPPA (Homo sapiens IGKV1-39*01
                                      (80.00%) -IGKJ4*01) [6.3.9] (1'''-107''') -Homo sapiens
                                      IGKC*01, Km3 (108'''-214''')]; dimer (229-225":232-228")-
                                      bisdisulfide




                                                                                                    111
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016




 émicizumab                immunoglobuline G4-kappa, bispécifique, anti-[Homo
                           sapiens F9a (facteur de coagulation F9 activé, facteur de
                           coagulation IX activé) et anti-[Homo sapiens F10 (facteur
                           de coagulation 10, facteur de coagulation X)], anticorps
                           monoclonal humanisé;
                           chaîne lourde gamma4 (1-448) [VH humanisé (Homo
                           sapiens IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1-
                           123)), IGHG4*01 (CH1 K100>Q (202) (124-221), S10>P
                           (231) (222-233), CH2 F84.3>Y (299) (234-343), CH3
                           E12>K (359), R88>K (412), H115>R (438), L125>P (448)
                           (344-448), CHS>del) (124-448)], (137-214')-disulfure avec
                           la chaîne légère kappa (1’-214’) [V-KAPPA humanisé
                           (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           chaîne lourde gamma4 (1-444) [VH humanisé (Homo
                           sapiens IGHV1-2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E
                           (111''), T123>L (114'') (1''-119'')), IGHG4*01 (CH1 A100>Q
                           (198'') (120''-217''), charnière S10>P (227'') (218''-229''),
                           CH2 F84.3>Y (295''), (230''-339''), CH3 R88>K (408),
                           K119>E (438), L125>P (444) (340''-444''), CHS>del) (120''-
                           444'')], (133''-214''')-disulfure avec la chaîne légère kappa
                           (1'''-214''') [V-KAPPA humanisé (Homo sapiens IGKV1-
                           39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'''-107''') -Homo
                           sapiens IGKC*01, Km3 (108'''-214''')]; dimère (229-
                           225":232-228")-bisdisulfure

 emicizumab                inmunoglobulina G4-kappa, biespecífica, anti-[Homo
                           sapiens F9a (factor de coagulación F9 activado, factor de
                           coagulación IX activado) y anti-[Homo sapiens F10 (factor
                           de coagulación 10, factor de coagulación X)], anticuerpo
                           monoclonal humanizado;
                           cadena pesada gamma4 (1-448) [VH humanizado (Homo
                           sapiens IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1-
                           123)), IGHG4*01 (CH1 K100>Q (202) (124-221), S10>P
                           (231) (222-233), CH2 F84.3>Y (299) (234-343), CH3
                           E12>K (359), R88>K (412), H115>R (438), L125>P (448)
                           (344-448), CHS>del) (124-448)], (137-214')-disulfuro con
                           la cadena ligera kappa (1’-214’) [V-KAPPA humanizado
                           (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           cadena pesada gamma4 (1-444) [VH humanizado (Homo
                           sapiens IGHV1-2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E
                           (111''), T123>L (114'') (1''-119'')), IGHG4*01 (CH1 A100>Q
                           (198'') (120''-217''),bisagra S10>P (227'') (218''-229''), CH2
                           F84.3>Y (295''), (230''-339''), CH3 R88>K (408), K119>E
                           (438), L125>P (444) (340''-444''), CHS>del) (120''-444'')],
                           (133''-214''')-disulfuro con la cadena ligera kappa (1'''-
                           214''') [V-KAPPA humanizado (Homo sapiens IGKV1-
                           39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'''-107''') -Homo
                           sapiens IGKC*01, Km3 (108'''-214''')]; dímero (229-
                           225":232-228")-bisdisulfuro




112
WHO Drug Information Vol. 30, No. 1, 2016                                              Recommended INN: List 75



                                       Heavy chain anti-F9a/ Chaîne lourde anti-F9a/ Cadena pesada anti-F9a
                                       QVQLVESGGG LVQPGGSLRL SCAASGFTFS YYDIQWVRQA PGKGLEWVSS                                     50
                                       ISPSGQSTYY RREVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRT                                    100
                                       GREYGGGWYF DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC                                    150
                                       LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG                                    200
                                       TQTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP                                    250
                                       KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQYN                                    300
                                       STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ                                    350
                                       VYTLPPSQKE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV                                    400
                                       LDSDGSFFLY SKLTVDKSRW QEGNVFSCSV MHEALHNRYT QKSLSLSP                                      448

                                       Heavy chain anti-F10/ Chaîne lourde anti-F10/ Cadena pesada anti-F10
                                       QVQLVQSGSE LKKPGASVKV SCKASGYTFT DNNMDWVRQA PGQGLEWMGD                                     50
                                       INTRSGGSIY NEEFQDRVIM TVDKSTDTAY MELSSLRSED TATYHCARRK                                    100
                                       SYGYYLDEWG EGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD                                    150
                                       YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY                                    200
                                       TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL                                    250
                                       MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQYNSTYR                                    300
                                       VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL                                    350
                                       PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD                                    400
                                       GSFFLYSKLT VDKSRWQEGN VFSCSVMHEA LHNHYTQESL SLSP                                          444

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCKASRNIE                         RQLAWYQQKP   GQAPELLIYQ 50
                                       ASRKESGVPD RFSGSRYGTD FTLTISSLQP                         EDIATYYCQQ   YSDPPLTFGG 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                         SVVCLLNNFY   PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                         LSKADYEKHK   VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                  214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96 150-206               264-324 370-428
                                                             22''-96'' 146''-202'' 260''-320'' 366''-424''
                                       Intra-L (C23-C104) 23'-88'        134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (CH1 10-CL 126) 137-214' 133''-214'''
                                       Inter-H-H (h 8, h 11)            229-225'' 232-228''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       300, 296''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                        complexes fucosylés / glicanos de tipo CHO biantenario complejos fucosilados


 enasidenibum
 enasidenib                           2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-
                                      6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-
                                      1,3,5-triazin-2-yl)amino]propan-2-ol

 énasidénib                           2-méthyl-1-[(4-[6-(trifluorométhyl)pyridin-2-yl]-
                                      6-{[2-(trifluorométhyl)pyridin-4-yl]amino}-
                                      1,3,5-triazin-2-yl)amino]propan-2-ol

 enasidenib                           2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-
                                      6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-
                                      2-il)amino]propan-2-ol

                                       C19H17F6N7O

                                                                                 OH
                                             CF3                 HN               CH3
                                                                             CH3
                                       N                     N         N

                                                       N          N
                                                       H
                                                                             N

                                                                                  CF3



 enerisantum
 enerisant                            [1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-
                                      1H-pyrazol-4-yl](morpholin-4-yl)methanone




                                                                                                                                  113
Recommended INN: List 75               WHO Drug Information Vol. 30, No. 1, 2016



 énérisant                 [1-(4-{3-[(2R)-2-méthylpyrrolidin-1-yl]propoxy}phényl)-
                           1H-pyrazol-4-yl](morpholin-4-yl)méthanone

 enerisant                 1-(4-{3-[(2R)-2-metilpirrolidin-1-il]propoxi}fenil)-
                           1H-pirazol-4-il](morfolin-4-il)metanona

                           C22H30N4O3

                                                                      O
                                                             N
                                                             N
                                                                       N

                                   N           O                           O
                                       CH3
                                   H



 entrectinibum
 entrectinib               N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-
                           4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide

 entrectinib               N-{5-[(3,5-difluorophényl)méthyl]-1H-indazol-3-yl}-
                           4-(4-méthylpipérazin-1-yl)-2-[(oxan-4-yl)amino]benzamide

 entrectinib               N-{5-[(3,5-difluorofenil)metil]-1H-indazol-3-il}-
                           4-(4-metilpiperazin-1-il)-2-[(oxan-4-il)amino]benzamida

                           C31H34F2N6O2                              1108743-60-7

                                                                                  F

                            H3 C
                                   N
                                           N
                                                                                      F
                                                         H
                                                         N

                                               NH    O       N NH

                                       O



 erdafitinibum
                            1                            1
 erdafitinib               N -(3,5-dimethoxyphenyl)-N -[3-(1-methyl-1H-pyrazol-
                                                  2
                           4-yl)quinoxalin-6-yl]-N -(propan-2-yl)ethane-1,2-diamine
                            1                            1
 erdafitinib               N -(3,5-diméthoxyphényl)-N -[3-(1-méthyl-1H-pyrazol-
                                                  2
                           4-yl)quinoxalin-6-yl]-N -(propan-2-yl)éthane-1,2-diamine
                            1                        1
 erdafitinib               N -(3,5-dimetoxifenil)-N -[3-(1-metil-1H-pirazol-
                                                  2
                           4-il)quinoxalin-6-il]-N -(propan-2-il)etano-1,2-diamina




114
WHO Drug Information Vol. 30, No. 1, 2016                                 Recommended INN: List 75


                                       C25H30N6O2

                                                                   H3CO             OCH3


                                                 N                                         CH3
                                       H3C   N
                                                               N           N
                                                                                       N       CH3
                                                                                       H
                                                               N

 etripamilum
 etripamil                            methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-
                                      5-methylhexyl](methyl)amino}ethyl)benzoate

 étripamil                            3-(2-{[(4S)-4-cyano-4-(3,4-diméthoxyphényl)-
                                      5-méthylhexyl](méthyl)amino}éthyl)benzoate de méthyle

 etripamilo                           3-(2-{[(4S)-4-ciano-4-(3,4-dimetoxifenil)-
                                      5-metilhexil](metil)amino}etil)benzoato de metilo

                                       C27H36N2O4

                                       O     O
                                                     CH3

                                                                            CH3

                                                           N                     CH3
                                                           CH3             CN



                                                               H3CO       OCH3

 evenamidum
 evenamide                            2-{[2-(3-butoxyphenyl)ethyl]amino}-
                                      N,N-dimethylacetamide

 événamide                            2-{[2-(3-butoxyphényl)éthyl]amino}-
                                      N,N-diméthylacétamide

 evenamida                            2-{[2-(3-butoxifenil)etil]amino}-N,N-dimetilacetamida

                                       C16H26N2O2

                                                                                           CH3
                                                                                           N
                                       H3C                 O                    N              CH3
                                                                                H
                                                                                       O

 evocalcetum
 evocalcet                            {4-[(3S)-3-{[(1R)-1-(naphthalen-1-yl)ethyl]amino}pyrrolidin-
                                      1-yl]phenyl}acetic acid

 évocalcet                            acide {4-[(3S)-3-{[(1R)-1-(naphtalén-
                                      1-yl)éthyl]amino}pyrrolidin-1-yl]phényl}acétique




                                                                                                     115
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016




 evocalcet                 ácido {4-[(3S)-3-{[(1R)-1-(naftalen-1-il)etil]amino}pirrolidin-
                           1-il]fenil}acético

                           C24H26N2O2

                                         CH3
                                     H     H
                                           N          N
                                           H
                                                                    CO2H



 ezutromidum
 ezutromid                 5-(ethanesulfonyl)-2-(naphthalen-2-yl)-1,3-benzoxazole

 ézutromid                 5-(éthanesulfonyl)-2-(naphtalén-2-yl)-1,3-benzoxazole

 ezutromid                 5-(etanosulfonil)-2-(naftalen-2-il)-1,3-benzoxazol

                           C19H15NO3S

                                                  O


                            H3 C    S             N
                                   O O




 fitusiranum
 fitusiran                 small interfering RNA (siRNA) inhibiting antithrombin liver
                           production:
                           duplex of [(2S,4R)-1-{30-(2-acetamido-2-deoxy-β-D-
                           galactopyranosyl)-14,14-bis[16-(2-acetamido-2-deoxy-β-D-
                           galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-
                           diazahexadecyl]-12,19,25-trioxo-16,30-dioxa-13,20,24-
                           triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]methyl
                           hydrogen (P-RS)-2'-deoxy-2'-fluoro-P-thioguanylyl-(3'→5')-
                           (P-RS)-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-deoxy-2'-
                           fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-
                           2'-fluoroadenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-
                           deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyladenylyl-
                           (3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-
                           fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-
                           O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-
                           2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-
                           (3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-deoxy-2'-
                           fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-
                           2'-fluorocytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-
                           deoxy-2'-fluoroadenylate and




116
WHO Drug Information Vol. 30, No. 1, 2016                         Recommended INN: List 75




                                      and (P-RS)-2'-O-methyl-P-thiouridylyl-(3'→5')-(P-RS)-2'-
                                      deoxy-2'-fluoro-P-thiouridylyl-(3'→5')-2'-O-methylguanylyl-
                                      (3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-
                                      methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-
                                      2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-
                                      (3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-
                                      fluoroadenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                                      methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-
                                      deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-
                                      2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-
                                      (3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-
                                      methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-
                                      (P-RS)-2'-O-methyl-P-thiocytidylyl-(3'→5')-(P-RS)-2'-O-
                                      methyl-P-thioadenylyl-(3'→5')-2'-O-methylguanosine


 fitusiran                            petit ARN interférant inhibant la production hépatique
                                      d'antithrombine:
                                      duplex de l’hydrogéno-(P-RS)-2'-deoxy-2'-fluoro-P-
                                      thioguanylyl-(3'→5')-(P-RS)-2'-O-méthyl-P-thioguanylyl-
                                      (3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                      méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-
                                      2'-O-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-
                                      (3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-désoxy-2'-
                                      fluorocytidylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-
                                      2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-O-méthyluridylyl-
                                      (3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                      méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-
                                      2'-O-méthylcytidylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-
                                      (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-désoxy-2'-
                                      fluorocytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-
                                      désoxy-2'-fluoroadénylate de [(2S,4R)-1-{30-(2-acétamido-
                                      2-désoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-
                                      acétamido-2-désoxy-β-D-galactopyranosyl)-5,11-dioxo-
                                      2,16-dioxa-6,10-diazahexadécyl]-12,19,25-trioxo-16,30-
                                      dioxa-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-
                                      yl]méthyle et du(P-RS)-2'-O-méthyl-P-thiouridylyl-(3'→5')
                                      (P-RS)-2'-désoxy-2'-fluoro-P-thiouridylyl-(3'→5')-2'-O-
                                      méthylguanylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-
                                      2'-O-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluoroguanylyl-
                                      (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-désoxy-2'-
                                      fluoroadénylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-
                                      désoxy-2'-fluoroadénylyl-(3'→5')-2'-O-méthyluridylyl-
                                      (3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylguanylyl-
                                      (3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                      méthylguanylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-
                                      2'-O-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-
                                      (3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-désoxy-2'-
                                      fluorocytidylyl-(3'→5')-(P-RS)-2'-O-méthyl-P-thiocytidylyl-
                                      (3'→5')-(P-RS)-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-
                                      méthylguanosine




                                                                                               117
Recommended INN: List 75                 WHO Drug Information Vol. 30, No. 1, 2016


 fitusirán                 ARN pequeño de interferencia que inhibe la producción
                           hepática de antitrombina:
                           dúplex de hidrógeno-(P-RS)-2'-desoxi-2'-fluoro-P-tioguanilil-
                           (3'→5')-(P-RS)-2'-O-metil-P-tioguanilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-
                           fluoroadenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluorocitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-
                           desoxi-2'-fluoroadenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-
                           desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-
                           desoxi-2'-fluoroadenilil-(3'→5')-2'-O-metilcitidill-(3'→5')-2'-
                           desoxi-2'-fluorouridill-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-
                           desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-
                           desoxi-2'-fluoroadenilato de [(2S,4R)-1-{30-(2-acetamido-2-
                           desoxi-β-D-galactopiranosil)-14,14-bis[16-(2-acetamido-2-
                           desoxi-β-D-galactopiranosil)-5,11-dioxo-2,16-dioxa-6,10-
                           diazahexadecil]-12,19,25-trioxo-16,30-dioxa-13,20,24-
                           triazatriacontanoil}-4-hidroxipirrolidin-2-il]metil y de (P-RS)-
                           2'-O-metil-P-tiouridilil-(3'→5') (P-RS)-2'-desoxi-2'-fluoro-P-
                           tiouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-
                           fluoroadenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluoroguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-
                           fluoroadenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluoroadenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-
                           metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-
                           fluoroadenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluorocitidilil-(3'→5')-(P-RS)-2'-O-metil-P-tiocitidilil-(3'→5')-
                           (P-RS)-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metilguanosina

                           C520H679F21N175O309P43S6

                                   (3'-5') G=G=U-U-A-A-C-A-C-C-A-U-U-U-A-C-U-U-C-A-A-R1
                                           . . . . . . . . . . . . . . . . . . . . .
                            (5'-3') G=A=C-C-A-A-U-U-G-U-G-G-U-A-A-A-U-G-A-A-G=U=U

                            Legend                                               R1   =   O        H
                                                               H                                       CH2
                                                      R        N       O
                            X : 2'-deoyx-2'-fluoro                                            N
                                                      R       R
                            X : 2'-O-methyl
                                                                                                  H OH
                            O OH
                                                          O        O                                   O
                             P                 HO                                                          CH2
                                                                           O
                                                                                      NH HN
                                                 HO                N
                            O       SH                             H                                   =
                                                          OH               CH3    O           O
                                P
                                                                                                   R




 fosnetupitantum
 fosnetupitant             {4-[5-{2-[3,5-bis(trifluoromethyl)phenyl]-
                           N,2-dimethylpropanamido}-4-(2-methylphenyl)pyridin-
                           2-yl]-1-methylpiperazin-1-ium-1-yl}methyl hydrogen
                           phosphate

 fosnétupitant             hydrogénophosphate de {4-[5-{2-[3,5-
                           bis(trifluorométhyl)phényl]-N,2-diméthylpropanamido}-
                           4-(2-méthylphényl)pyridin-2-yl]-1-méthylpipérazin-1-ium-
                           1-yl}méthyle




118
WHO Drug Information Vol. 30, No. 1, 2016                                 Recommended INN: List 75


 fosnetupitant                        hidrógenofosfato de {4-[5-{2-[3,5-bis(trifluorometil)fenil]-
                                      N,2-dimetilpropanamido}-4-(2-metilfenil)piridin-2-il]-
                                      1-metilpiperazin-1-io-1-il}metilo
                                       C31H35F6N4O5P
                                                        H3C
                                                                              H3C
                                                O             N
                                                    P   O            N
                                              O                                                  CF3
                                       H            O
                                                                         N              CH3
                                                                                    N

                                                                                O                        CF3
                                                                                    H3C    CH3

 glembatumumabum vedotinum #
 glembatumumab vedotin                immunoglobulin G2-kappa, anti-[Homo sapiens GPNMB
                                      (glycoprotein (transmembrane) nmb, glycoprotein
                                      transmembrane NMB, glycoprotein nonmetastatic
                                      melanoma protein B, CG56972, osteoactivin,
                                      hematopoietic growth factor inducible neurokinin-1 type,
                                      HGFIN) extracellular domain], Homo sapiens monoclonal
                                      antibody conjugated to auristatin E;
                                      gamma2 heavy chain (1-445) [Homo sapiens VH (IGHV4-
                                      31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -
                                      IGHG2*01, G2m.. (CH1 (120-217), hinge (218-229), CH2
                                      (230-338), CH3 (339-443), CHS (444-445)) (120-445)],
                                      (133-215')-disulfide with kappa light chain (1'-215') [Homo
                                      sapiens V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01)
                                      [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (221-
                                      221'':222-222'':225-225'':228-228'')-tetrakisdisulfide;
                                      conjugated, on an average of 5 cysteinyl, to
                                      monomethylauristatin E (MMAE), via a cleavable
                                      maleimidocaproyl-valyl-citrullinyl-
                                      p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
                                      For the vedotin part, please refer to the document “INN for pharmaceutical
                                      substances: Names for radicals, groups and others”*.



 glembatumumab védotine               immunoglobuline G2-kappa, anti-[Homo sapiens GPNMB
                                      (glycoprotéine (transmembranaire) nmb, glycoprotéine
                                      transmembranaire NMB, protéine B glycoprotéine de
                                      mélanome non métastatique, CG56972, ostéoactivine,
                                      facteur de croissance hématopoïétique inductible type
                                      neurokinine-1, HGFIN) domaine extracellulaire], Homo
                                      sapiens anticorps monoclonal conjugué à l’auristatine E;
                                      chaîne lourde gamma2 (1-445) [Homo sapiens VH
                                      (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-
                                      119) -IGHG2*01, G2m.. (CH1 (120-217), charnière (218-
                                      229), CH2 (230-338), CH3 (339-443), CHS (444-445))
                                      (120-445)], (133-215')-disulfure avec la chaîne légère
                                      kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-15*01
                                      (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01, Km3
                                      (109'-215')]; dimère (221-221'':222-222'':225-225'':228-
                                      228'')-tétrakisdisulfure; conjugué, sur 5 cystéinyl en
                                      moyenne, au monométhylauristatine E (MMAE), via un
                                      linker clivable de type maléimidocaproyl-valyl-citrullinyl-p-
                                      aminobenzyloxycarbonyl (mc-val-cit-PABC)
                                      Pour la partie védotine, veuillez-vous référer au document “INN for
                                      pharmaceutical substances: Names for radicals, groups and others”*.




                                                                                                               119
Recommended INN: List 75                   WHO Drug Information Vol. 30, No. 1, 2016



 glembatumumab vedotina    inmunoglobulina G2-kappa, anti-[Homo sapiens GPNMB
                           (glicoproteína (transmembrana) nmb, glicoproteina
                           transmembrana NMB, proteína B glicoproteína de
                           melanoma no metastásico, CG56972, osteoactivina, factor
                           de crecimiento hematopoyético inducible tipo neurokinina-
                           1, HGFIN) dominio extracelular], Homo sapiens anticuerpo
                           monoclonal conjugado con auristatina E;
                           cadena pesada gamma2 (1-445) [Homo sapiens VH
                           (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-
                           119) -IGHG2*01, G2m.. (CH1 (120-217), bisagra (218-
                           229), CH2 (230-338), CH3 (339-443), CHS (444-445))
                           (120-445)], (133-215')-disulfuro con la cadena ligera kappa
                           (1'-215') [Homo sapiens V-KAPPA (IGKV3-15*01 (96.80%)
                           -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')];
                           dímero (221-221'':222-222'':225-225'':228-228'')-
                           tetrakisdisulfuro; conjugado, en una media de 5 restos
                           cisteinil, con monometilauristatina E (MMAE), mediante un
                           espaciadorescindible de tipo maleimidocaproil-valil-
                           citrulinil-p-aminobenciloxicarbonil (mc-val-cit-PABC)
                           La fracción vedotina, la pueden encontrar en el documento “INN for
                           pharmaceutical substances: Names for radicals, groups and others”*.



                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQESGPG LVKPSQTLSL TCTVSGGSIS                        SFNYYWSWIR         HHPGKGLEWI             50
                           GYIYYSGSTY SNPSLKSRVT ISVDTSKNQF                        SLTLSSVTAA         DTAVYYCARG            100
                           YNWNYFDYWG QGTLVTVSSA STKGPSVFPL                        APCSRSTSES         TAALGCLVKD            150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                        LYSLSSVVTV         PSSNFGTQTY            200
                           TCNVDHKPSN TKVDKTVERK CCVECPPCPA                        PPVAGPSVFL         FPPKPKDTLM            250
                           ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV                        EVHNAKTKPR         EEQFNSTFRV            300
                           VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI                        EKTISKTKGQ         PREPQVYTLP            350
                           PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE                        SNGQPENNYK         TTPPMLDSDG            400
                           SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                        HNHYTQKSLS         LSPGK                 445

                           Light chain / Chaîne légère / Cadena ligera
                           EIVMTQSPAT LSVSPGERAT LSCRASQSVD                        NNLVWYQQKP         GQAPRLLIYG 50
                           ASTRATGIPA RFSGSGSGTE FTLTISSLQS                        EDFAVYYCQQ         YNNWPPWTFG 100
                           QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                        ASVVCLLNNF         YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL                        TLSKADYEKH         KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                                      215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-97           146-202 259-319       365-423
                                                  22''-97'' 146''-202'' 259''-319'' 365''-423''
                           Intra-L (C23-C104) 23'-88'          135'-195'
                                                   23'''-88''' 135'''-195'''
                           Inter-H-L (CH1 10-CL 126) 133-215' 133''-215'''
                           Inter-H-H (h 4, h 5, h 8, h 11) 221-221'' 222-222'' 225-225'' 228-228''
                           *Two or three of the inter-chain disulfide bridges are not present, an average of 5 cysteinyl
                           being conjugated each via a thioether bond to a drug linker.
                           *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 5 cystéinyl en moyenne
                           étant chacun conjugué via une liaison thioéther à un linker-principe actif.
                           *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 5 cisteinil está conjugada
                           a conectores de principio activo.

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           295, 295''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
                            fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 graunimotidum
 graunimotide              L-lysyl-L-arginyl-L-tyrosyl-L-phenylalanyl-L-lysyl-L-leucyl-
                           L-seryl-L-histidyl-L-leucyl-L-glutaminyl-L-methionyl-
                           L-histidyl-L-seryl-L-arginyl-L-lysyl-L-histidine;
                           human Wilms tumor protein (WT33) (332-347)-peptide




120
WHO Drug Information Vol. 30, No. 1, 2016                                     Recommended INN: List 75




 graunimotide                         L-lysyl-L-arginyl-L-tyrosyl-L-phénylalanyl-L-lysyl-L-leucyl-
                                      L-séryl-L-histidyl-L-leucyl-L-glutaminyl-L-méthionyl-
                                      L-histidyl-L-séryl-L-arginyl-L-lysyl-L-histidine;
                                      protéine tumorale Wilms humaine (WT33) (332-347)-
                                      peptide

 graunimotida                         L-lisil-L-arginil-L-tiyrosil-L-fenilalanil-L-lisil-L-leucil-L-seril-
                                      L-histidil-L-leucil-L-glutaminil-L-metionyl-L-histidil-L-seril-
                                      L-arginil-L-lisil-L-histidina;
                                      proteína de tumor de Wilms humano (WT33) (332-347)-
                                      péptido

                                       C94H150N32O21S

                                       H Lys      Arg       Tyr       Phe    Lys   Leu      Ser      His   Leu

                                            Gln   Met       His       Ser    Arg   Lys      His OH
                                            10                                                  16



 guadecitabinum
 guadecitabine                        2'-deoxy-5-azacytidylyl-(3'→5')-2'-deoxyguanosine

 guadécitabine                        2'-déoxy-5-azacytidylyl-(3'→5')-2'-déoxyguanosine

 guadecitabina                        2'-desoxi-5-azacitidilil-(3'→5')-2'-desoxiguanosina

                                       C18H24N9O10P

                                                                  NH2
                                                        N                      H        O
                                                                  N            N
                                                  O                   H2 N
                                                        N
                                                                             N              N
                                                  O
                                                                                   N
                                       HO
                                                                              O
                                                      O            O
                                                              P
                                                          O       OH               OH



 inebilizumabum
 inebilizumab                         immunoglobulin G1-kappa, anti-[Homo sapiens CD19 (B
                                      lymphocyte surface antigen B4, Leu-12)], humanized
                                      monoclonal antibody;
                                      gamma1 heavy chain (1-451) [humanized VH (Homo
                                      sapiens IGHV3-15*06 (83.70%) -(IGHD)-IGHJ4*01)
                                      [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (122-219), hinge (220-234), CH2 (235-344), CH3 (345-
                                      449), CHS (450-451)) (122-451)], (224-218')-disulfide with
                                      kappa light chain (1’-218’) [humanized V-KAPPA (Homo
                                      sapiens IGKV6-21*01 (79.80%) -IGKJ4*01) [10.3.9] (1'-
                                      111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimer
                                      (230-230":233-233")-bisdisulfide




                                                                                                                 121
Recommended INN: List 75                 WHO Drug Information Vol. 30, No. 1, 2016




 inébilizumab              immunoglobuline G1-kappa, anti-[Homo sapiens CD19
                           (antigène de surface B4 des lymphocytes B, Leu-12)],
                           anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-451) [VH humanisé (Homo
                           sapiens IGHV3-15*06 (83.70%) -(IGHD)-IGHJ4*01)
                           [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (122-219), charnière (220-234), CH2 (235-344), CH3 (345-
                           449), CHS (450-451)) (122-451)], (224-218')-disulfure avec
                           la chaîne légère kappa (1’-218’) [V-KAPPA humanisé
                           (Homo sapiens IGKV6-21*01 (79.80%) -IGKJ4*01) [10.3.9]
                           (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')];
                           dimère (230-230":233-233")-bisdisulfure

 inebilizumab              inmunoglobulina G1-kappa, anti-[Homo sapiens CD19
                           (antígeno de superficie B4 de los linfocitos B, Leu-12)],
                           anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-451) [VH humanizada (Homo
                           sapiens IGHV3-15*06 (83.70%) -(IGHD)-IGHJ4*01)
                           [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-
                           449), CHS (450-451)) (122-451)], (224-218')-disulfuro con
                           la cadena ligera kappa (1’-218’) [V-KAPPA humanizada
                           (Homo sapiens IGKV6-21*01 (79.80%) -IGKJ4*01) [10.3.9]
                           (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')];
                           dímero (230-230":233-233")-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  SSWMNWVRQA       PGKGLEWVGR        50
                           IYPGDGDTNY NVKFKGRFTI SRDDSKNSLY                  LQMNSLKTED       TAVYYCARSG       100
                           FITTVRDFDY WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                           K                                                                                   451

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPDF QSVTPKEKVT ITCRASESVD                  TFGISFMNWF       QQKPDQSPKL 50
                           LIHEASNQGS GVPSRFSGSG SGTDFTLTIN                  SLEAEDAATY       YCQQSKEVPF 100
                           TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                           QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                           THQGLSSPVT KSFNRGEC                                                           218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          148-204 265-325        371-429
                                                 22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L (C23-C104) 23'-92'         138'-198'
                                                 23'''-92''' 138'''-198'''
                           Inter-H-L (h 5-CL 126) 224-218' 224''-218'''
                           Inter-H-H (h 11, h 14) 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           301, 301''
                           Afucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
                           complexes afucosylés / Glicanos de tipo CHO biantenarios complejos no fucosilados



 ingenoli disoxas
 ingenol disoxate          (1aR,2S,3Z,5R,5aS,6S,8aS,9R,10aR)-5,5a-dihydroxy-
                           4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-
                           1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-
                           methanocyclopenta[a]cyclpropa[e][10]annulen-6-yl
                           3,5-diethylisoxazole-4-carboxylate




122
WHO Drug Information Vol. 30, No. 1, 2016                                    Recommended INN: List 75




 disoxate d’ingénol                        3,5-diéthylisoxazole-4-carboxylate de
                                           (1aR,2S,3Z,5R,5aS,6S,8aS,9R,10aR)-5,5a-dihydroxy-
                                           4-(hydroxyméthyl)-1,1,7,9-tétraméthyl-11-oxo-
                                           1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-
                                           méthanocyclopenta[a]cyclpropa[e][10]annulén-6-yle

 disoxato de ingenol                       3,5-dietillisoxazol-4-carboxilato de
                                           (1aR,2S,3Z,5R,5aS,6S,8aS,9R,10aR)-5,5a-dihidroxi-
                                           4-(hidroximetil)-1,1,7,9-tetrametil-11-oxo-
                                           1a,2,5,5a,6,9,10,10a-octahidro-1H-2,8a-
                                           metanociclopenta[a]ciclpropa[e][10]anulen-6-ilo

                                            C28H37NO7

                                                                  H3 C
                                             H3 C         O                  H CH3
                                                              H
                                                             O                 O
                                                    N
                                                             HO                      H
                                                      O      H           H
                                                             HO                        CH3
                                                        H3C HO                 H     CH3




              131
 iodinum ( I) derlotuximabum biotinum #
         131
 iodine ( I) derlotuximab biotin        immunoglobulin G1-kappa, anti-[Homo sapiens
                                        DNA/histone 1 (H1) complex], chimeric monoclonal
                                        antibody radiolabeled with iodine-131 and biotinylated;
                                        gamma1 heavy chain (1-450) [Mus musculus VH (IGHV2-
                                        6-5*01 -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - Homo sapiens
                                        IGHG1*01, G1m17,1 (CH1 V121>A (218) (121-218), hinge
                                        (219-233), CH2 (234-343), CH3 (344-448), CHS (449-
                                        450)) (121-450)], (223-215')-disulfide with kappa light chain
                                        (1'-215') [Mus musculus V-KAPPA (IGKV4-57-1*01 -
                                        IGKJ1*01) [7.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                                                                                 131
                                        (109'-215')]; dimer (229-229'':232-232'')-bisdisulfide; ( I)
                                        iodinatedwith iodine-131 covalently linked to tyrosines, and
                                        biotinylated
        131
 iodine (   I) derlotuximab biotine        immunoglobuline G1-kappa, anti-[Homo sapiens complexe
                                           ADN/histone 1 (H1)], anticorps monoclonal chimérique
                                           biotinylé et marqué à l’iode 131;
                                           chaîne lourde gamma1 (1-450) [Mus musculus VH
                                           (IGHV2-6-5*01 -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - Homo
                                           sapiens IGHG1*01, G1m17,1 (CH1 V121>A (218) (121-
                                           218), charnière (219-233), CH2 (234-343), CH3 (344-448),
                                           CHS (449-450)) (121-450)], (223-215')-disulfure avec la
                                           chaîne légère kappa (1'-215') [Mus musculus V-KAPPA
                                           (IGKV4-57-1*01 -IGKJ1*01) [7.3.9] (1'-107') -Homo
                                           sapiens IGKC*01, Km3 (109'-215')]; dimère (229-229'':232-
                                                                                     131
                                           232'')-bisdisulfure; marqué à l’iode 131 ( I) lié de manière
                                           covalente à des tyrosines, et biotinylé




                                                                                                   123
Recommended INN: List 75                            WHO Drug Information Vol. 30, No. 1, 2016


      131
 iodo (   I) derlotuximab biotina   inmunoglobulina G1-kappa, anti-[Homo sapiens complejo
                                    ADN/histona 1 (H1)], anticuerpo monoclonal quimérico
                                    biotinilado y marcado con iodo 131;
                                    cadena pesada gamma1 (1-450) [Mus musculus VH
                                    (IGHV2-6-5*01 -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - Homo
                                    sapiens IGHG1*01, G1m17,1 (CH1 V121>A (218) (121-
                                    218), bisagra(219-233), CH2 (234-343), CH3 (344-448),
                                    CHS (449-450)) (121-450)], (223-215')-disulfuro con la
                                    cadena ligera kappa (1'-215') [Mus musculus V-KAPPA
                                    (IGKV4-57-1*01 -IGKJ1*01) [7.3.9] (1'-107') -Homo
                                    sapiens IGKC*01, Km3 (109'-215')]; dímero (229-229'':232-
                                                                               131
                                    232'')-bisdisulfuro; marcado con iodo 131 ( I) unido
                                    covalentemente a tirosinas, y biotinilado
                                    Heavy chain / Chaîne lourde / Cadena pesada
                                    QVQLKESGPG LVAPSQSLSI TCTVSGFSLT                         DYGVRWIRQP     PGKGLEWLGV       50
                                    IWGGGSTYYN SALKSRLSIS KDNSKSQVFL                         KMNSLQTDDT     AMYYCAKEKR      100
                                    RGYYYAMDYW GQGTSVTVSS ASTKGPSVFP                         LAPSSKSTSG     GTAALGCLVK      150
                                    DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                         GLYSLSSVVT     VPSSSLGTQT      200
                                    YICNVNHKPS NTKVDKKAEP KSCDKTHTCP                         PCPAPELLGG     PSVFLFPPKP      250
                                    KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                         YVDGVEVHNA     KTKPREEQYN      300
                                    STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                         LPAPIEKTIS     KAKGQPREPQ      350
                                    VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                         AVEWESNGQP     ENNYKTTPPV      400
                                    LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                         MHEALHNHYT     QKSLSLSPGK      450

                                    Light chain / Chaîne légère / Cadena ligera
                                    ENVLTQSPAI MSASPGEKVT MTCRASSSVS                         SSYLHWYQQK     SGASPKLWIY 50
                                    STSNLASGVP ARFSGSGSGT SYSLTISSVE                         AEDAATYYCQ     QYSGYPLTFG 100
                                    GGTKLEIKRT VAAPSVFIFP PSDEQLKSGT                         ASVVCLLNNF     YPREAKVQWK 150
                                    VDNALQSGNS QESVTEQDSK DSTYSLSSTL                         TLSKADYEKH     KVYACEVTHQ 200
                                    GLSSPVTKSF NRGEC                                                                   215

                                    Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                    Intra-H (C23-C104) 22-95         147-203       264-324  370-428
                                                          22''-95'' 147''-203'' 264''-324'' 370''-428''
                                    Intra-L (C23-C104) 23'-89' 135'-195'
                                                         23'''-89''' 135'''-195'''
                                    Inter-H-L (h 5-CL 126) 223-215' 223''-215'''
                                    Inter-H-H (h 11, h 14) 229-229'' 232-232''

                                    N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                    H CH2 N84.4:
                                    300, 300''
                                    Fucosylated complex bi-antennary NS0-type glycans / glycanes de type NS0 bi-antennaires complexes
                                    fucosylés / glicanos de tipo NS0 biantenario complejos fucosilados

                                    Modified residues / Résidus modifiés / Restos modificados
                                                                                                                H
                                                                    HO                                    H H                  CO2H
                                                  Y                                                       N
                                      are partly radiolabeled                         H    NH2
                                                                                                     O              S
                                        3-[131I]iodotyrosine
                                                                  [131I]                    CO2H          N
                                                                                                          H H                   biotin




 isunakinrum #
 isunakinra                         human interleukin-1 beta-(1-8)-peptide fusion protein with
                                    human interleukin-1 receptor antagonist protein-(14-45)-
                                    peptide fusion protein with human interleukin-1 beta-(42-
                                    120)-peptide fusion protein with human interleukin-1
                                    receptor antagonist protein-(120-147)-peptide fusion
                                    protein with human interleukin-1 beta-(148-153)-peptide
                                    non-glycosylated

 isunakinra                         interleukine-1 bêta humaine-(1-8)-peptide protéine de
                                    fusion avec l’antagoniste protéique du récepteur de
                                    l’interleukine-1 humain-(14-45)-peptide protéine de fusion
                                    avec l’interleukine-1 bêta humaine-(42-120)-peptide
                                    protéine de fusion avec l’antagoniste protéique du
                                    récepteur de l’interleukine-1 humain-(120-147)-peptide
                                    protéine de fusion avec l’interleukine-1 bêta humaine-(148-
                                    153)-peptide non-glycosylé




124
WHO Drug Information Vol. 30, No. 1, 2016                        Recommended INN: List 75




 isunakinra                           interleukina-1 beta humana-(1-8)-péptido proteína de
                                      fusión con el antagonista proteíco del receptor de la
                                      interleukina-1 humana-(14-45)-péptido proteína de fusión
                                      con la interleukina-1 beta humana-(42-120)-péptido
                                      proteína de fusión con el antagonista proteíco del receptor
                                      de la interleukina-1 humana-(120-147)-péptido proteína de
                                      fusión con la interleukina-1 beta humana-(148-153)-
                                      péptido no-glicosilado
                                       APVRSLNCRI WDVNQKTFYL RNNQLVAGYL QGPNVNLEEK FSMSFVQGEE 50
                                       SNDKIPVALG LKEKNLYLSC VLKDDKPTLQ LESVDPKNYP KKKMEKRFVF 100
                                       NKIEINNKLE FESAQFPNWF LCTAMEADQP VSLTNMPDEG VMVTKFYMQF 150
                                       VSS                                                    153


 labetuzumabum govitecanum #
 labetuzumab govitecan                immunoglobulin G1-kappa, anti-[Homo sapiens CEACAM5
                                      (carcinoembryonic antigen-related cell adhesion molecule
                                      5, CEA, CD66e)], monoclonal antibody conjugated to
                                      7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite
                                      of irinotecan;
                                      gamma1 heavy chain (1-449) [humanized VH (Homo
                                      sapiens IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01)
                                      [8.8.12] (1-119) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (120-217), hinge (218-232), CH2 (233-342), CH3 (343-
                                      447), CHS (448-449)) (120-449)], (222-213')-disulfide with
                                      kappa light chain (1’-213’) [humanized V-KAPPA (Homo
                                      sapiens IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8] (1'-106')
                                      -Homo sapiens IGKC*01, Km3 (107'-213')]; dimer (228-
                                      228":231-231")-bisdisulfide; conjugated, on an average of
                                      6 cysteinyl, to 7-ethyl-10-hydroxycamptothecin (SN-38),
                                      active metabolite of irinotecan (CPT-11, camptothecin-11),
                                      via a maleimide-type cleavable linker (carbonate group,
                                      4-aminobenzyl alcohol and cathepsine-B-cleavable
                                      dipeptide Phe-Lys) and containing a triazoline group and a
                                      spacer PEG (n=8)

 labétuzumab govitécan                immunoglobuline G1-kappa, anti-[Homo sapiens
                                      CEACAM5 (molécule d’adhésion cellulaire 5 apparentée à
                                      l’antigène carcinoembryonaire, CEA, CD66e)], anticorps
                                      monoclonal conjugué à la 7-éthyl-
                                      10-hydroxycamptothécine (SN-38), métabolite actif de
                                      l’irinotécan;
                                      chaîne lourde gamma1 (1-449) [humanized VH (Homo
                                      sapiens IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01)
                                      [8.8.12] (1-119) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (120-217), charnière (218-232), CH2 (233-342), CH3 (343-
                                      447), CHS (448-449)) (120-449)], (222-213')-disulfure avec
                                      la chaîne légère kappa (1’-213’) [V-KAPPA humanisé
                                      (Homo sapiens IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8]
                                      (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')];
                                      dimère (228-228":231-231")-bisdisulfure; conjugué, sur 6
                                      cystéinyl en moyenne, à la 7-éthyl-
                                      10-hydroxycamptothécine (SN-38), métabolite actif de
                                      l’irinotécan (CPT-11, camptothécine-11), via un linker de
                                      type maléimide, clivable (liaison carbonate, 4-aminobenzyl
                                      alcool et dipeptide Phe-Lys clivable par la cathepsine B) et
                                      comprenant un groupe triazoline et un espaceur PEG
                                      (n=8)




                                                                                              125
Recommended INN: List 75                       WHO Drug Information Vol. 30, No. 1, 2016



 labetuzumab govitecán     inmunoglobulina G1-kappa, anti-[Homo sapiens
                           CEACAM5 (molècula de adhesión celular 5 relacionada
                           con el antígeno carcinoembrionario, CEA, CD66e)],
                           anticuerpo monoclonal conjugado con la 7-etil-
                           10-hidroxicamptotecina (SN-38), metabolito activo del
                           irinotecán;
                           cadena pesada gamma1 (1-449) [humanizado VH (Homo
                           sapiens IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01)
                           [8.8.12] (1-119) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-
                           447), CHS (448-449)) (120-449)], (222-213')-disulfuro con
                           la cadena ligera kappa (1’-213’) [V-KAPPA humanizado
                           (Homo sapiens IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8]
                           (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')];
                           dímero (228-228":231-231")-bisdisulfuro; conjugado, en
                           una media de 6 restos cisteinil, con la 7-etil-
                           10-hidroxicamptotecina (SN-38), metabolito activo del
                           irinotecán (CPT-11, camptotecina-11), mediante un
                           espaciador de tipo maleimida, escindible (enlace
                           carbonato, 4-aminobencil alcohol y dipéptido Phe-Lys
                           escindible por catepsina B) y que comprende un grupo
                           triazolina y un espaciador PEG (n=8)
                            Heavy chain / Chaîne lourde / Cadena pesada
                            EVQLVESGGG VVQPGRSLRL SCSASGFDFT                         TYWMSWVRQA              PGKGLEWIGE          50
                            IHPDSSTINY APSLKDRFTI SRDNAKNTLF                         LQMDSLRPED              TGVYFCASLY         100
                            FGFPWFAYWG QGTPVTVSSA STKGPSVFPL                         APSSKSTSGG              TAALGCLVKD         150
                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                         LYSLSSVVTV              PSSSLGTQTY         200
                            ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                         CPAPELLGGP              SVFLFPPKPK         250
                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                         VDGVEVHNAK              TKPREEQYNS         300
                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                         PAPIEKTISK              AKGQPREPQV         350
                            YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                         VEWESNGQPE              NNYKTTPPVL         400
                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                         HEALHNHYTQ              KSLSLSPGK          449

                            Light chain / Chaîne légère / Cadena ligera
                            DIQLTQSPSS LSASVGDRVT ITCKASQDVG                         TSVAWYQQKP              GKAPKLLIYW 50
                            TSTRHTGVPS RFSGSGSGTD FTFTISSLQP                         EDIATYYCQQ              YSLYRSFGQG 100
                            TKVEIKRTVA APSVFIFPPS DEQLKSGTAS                         VVCLLNNFYP              REAKVQWKVD 150
                            NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                         SKADYEKHKV              YACEVTHQGL 200
                            SSPVTKSFNR GEC                                                                              213

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            Intra-H (C23-C104) 22-96 146-202                263-323  369-427
                                                   22''-96'' 146''-202'' 263''-323'' 369''-427''
                            Intra-L (C23-C104) 23'-88' 133'-193'
                                                  23'''-88''' 133'''-193'''
                            Inter-H-L (h 5-CL 126) * 222-213' 222''-213'''
                            Inter-H-H (h 11, h 14) * 228-228'' 231-231''
                            *Three of the inter-chain disulfide bridges are not present, an average of 6 cysteinyl being conjugated
                            each via a thioether bond to a drug linker.
                            *Trois des ponts disulfures inter-chaînes ne sont pas présents, 6 cystéinyl en moyenne étant chacun
                            conjugué via une liaison thioéther à un linker-principe actif.
                            *Faltan tres puentes disulfuro inter-catenarios, una media de 6 cisteinil está conjugada a conectores
                            de principio activo.

                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                            H CH2 N84.4:
                            299, 299''
                            Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires
                            complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

                            Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales
                                          C*
                                                                                         O
                                 213'-213'''-222-222''-                  CH3                                       H2N      CO2H
                                  228-228''-231-231''
                                                                                     N                   O             H        S
                           * an average of 6 are substituted
                           * en moyenne, 6 sont substitués
                           * una media de 6 está sustituída                                                  O
                                                                                 N                                          O             O
                                                               HO                                O           CH3                      N

                                                                                             O       O
                                                           O                                                       O
                                                                    Lys N                                N    N
                                                                        H    H
                                                                             N                       N                 NH
                                                                    O                    O           8
                                                                         O




126
WHO Drug Information Vol. 30, No. 1, 2016                                                  Recommended INN: List 75


 landogrozumabum #
 landogrozumab                        immunoglobulin G4-kappa, anti-[Homo sapiens MSTN
                                      (myostatin, growth differentiation factor 8, GDF8, GDF-8)],
                                      humanized monoclonal antibody;
                                      gamma4 heavy chain (1-439) [humanized VH (Homo
                                      sapiens IGHV3-23*04 (89.80%) -(IGHD)-IGHJ4*01 [8.8.6]
                                      (1-113)) , IGHG4*01 (CH1 (114-211), hinge S10>P (221)
                                      (212-223), CH2 (224-333), CH3 (334-438), CHS K2>del
                                      (439)) (114-439)], (127-215')-disulfide with kappa light
                                      chain (1’-215’) [humanized V-KAPPA (Homo sapiens
                                      IGKV3-20*01 (89.10%) -IGKJ4*01) [7.3.9] (1'-108') -Homo
                                      sapiens IGKC*01 (109'-215')]; dimer (219-219":222-222")-
                                      bisdisulfide

 landogrozumab                        immunoglobuline G4-kappa, anti-[Homo sapiens MSTN
                                      (myostatine, facteur de croissance et de différenciation 8,
                                      GDF8, GDF-8)], anticorps monoclonal humanisé;
                                      chaîne lourde gamma4 (1-441) [VH humanisé (Homo
                                      sapiens IGHV3-23*04 (89.80%) -(IGHD)-IGHJ4*01 [8.8.6]
                                      (1-113)) , IGHG4*01 (CH1 (114-211), charnière S10>P
                                      (221) (212-223), CH2 (224-333), CH3 (334-438), CHS
                                      K2>del (439)) (114-439)], (127-215')-disulfure avec la
                                      chaîne légère kappa (1’-215’) [V-KAPPA humanisé (Homo
                                      sapiens IGKV3-20*01 (89.10%) -IGKJ4*01) [7.3.9] (1'-108')
                                      -Homo sapiens IGKC*01 (109'-215')]; dimère (219-
                                      219":222-222")-bisdisulfure

 landogrozumab                        inmunoglobulina G4-kappa, anti-[Homo sapiens MSTN
                                      (miostatina, factor de crecimiento y de diferenciación 8,
                                      GDF8, GDF-8)], anticuerpo monoclonal humanizado;
                                      cadena pesada gamma4 (1-441) [VH humanizado (Homo
                                      sapiens IGHV3-23*04 (89.80%) -(IGHD)-IGHJ4*01 [8.8.6]
                                      (1-113)) , IGHG4*01 (CH1 (114-211),bisagra S10>P (221)
                                      (212-223), CH2 (224-333), CH3 (334-438), CHS K2>del
                                      (439)) (114-439)], (127-215')-disulfuro con la cadena ligera
                                      kappa (1’-215’) [V-KAPPA humanizado (Homo sapiens
                                      IGKV3-20*01 (89.10%) -IGKJ4*01) [7.3.9] (1'-108') -Homo
                                      sapiens IGKC*01 (109'-215')]; dímero (219-219":222-
                                      222")-bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLVESGGG LVQPGGSLRL SCAASGLTFS                          RYPMSWVRQA   PGKGLVWVSA          50
                                       ITSSGGSTYY SDTVKGRFTI SRDNAKNTLY                          LQMNSLRAED   TAVYYCARLP         100
                                       DYWGQGTLVT VSSASTKGPS VFPLAPCSRS                          TSESTAALGC   LVKDYFPEPV         150
                                       TVSWNSGALT SGVHTFPAVL QSSGLYSLSS                          VVTVPSSSLG   TKTYTCNVDH         200
                                       KPSNTKVDKR VESKYGPPCP PCPAPEFLGG                          PSVFLFPPKP   KDTLMISRTP         250
                                       EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA                          KTKPREEQFN   STYRVVSVLT         300
                                       VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS                          KAKGQPREPQ   VYTLPPSQEE         350
                                       MTKNQVSLTC LVKGFYPSDI AVEWESNGQP                          ENNYKTTPPV   LDSDGSFFLY         400
                                       SRLTVDKSRW QEGNVFSCSV MHEALHNHYT                          QKSLSLSLG                       439

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVLTQSPGT LSLSPGERAT LSCRASSSVS                          SSYLHWYQQK   PGQAPRLLIY 50
                                       STSNLVAGIP DRFSGSGSGT DFTLTISRLE                          PEDFAVYYCQ   HHSGYHFTFG 100
                                       GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                          ASVVCLLNNF   YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                          TLSKADYEKH   KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                                  215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          140-196       254-314  360-418
                                                              22''-96'' 140''-196'' 254''-314'' 360''-418''
                                       Intra-L (C23-C104) 23'-89' 135'-195'
                                                             23'''-89''' 135'''-195'''
                                       Inter-H-L (CH1 10-CL 126) 127-215' 127''-215'''
                                       Inter-H-H (h 8, h 11)            219-219'' 222-222''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       290, 290''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




                                                                                                                                       127
Recommended INN: List 75             WHO Drug Information Vol. 30, No. 1, 2016



 lefitolimodum
 lefitolimod               DNA based immunomodulator agent:
                           cyclo-(3'→5')[2'-deoxy-(A-A-A-A-C-G-T-T-C-T-T-C-G-G-G-
                           G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-
                           G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-G-A-A-A-A-C-G-T-
                           T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-
                           C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-
                           G)]

 léfitolimod               immunomodulateur de type ADN:
                           cyclo-(3'→5')[2'-déoxy-(A-A-A-A-C-G-T-T-C-T-T-C-G-G-G-
                           G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-
                           G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-G-A-A-A-A-C-G-T-
                           T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-
                           C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-
                           G)]

 lefitolimod               inmunomodulador de tipo ADN:
                           ciclo-(3'→5')[2'-desoxi-(A-A-A-A-C-G-T-T-C-T-T-C-G-G-G-
                           G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-
                           G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-G-A-A-A-A-C-G-T-
                           T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-
                           C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-
                           G)]

                                                      3'   5'
                            CTTCGGGGCGTTCTTAGGTGGTAACCCCTAGGGGTTACCACCTTCATTGGAAAACGTT
                                           ............................
                            TTGCAAAAGGTTACTTCCACCATTGGGGATCCCCAATGGTGGATTCTTGCGGGGCTTC


 maralixibati chloridum
 maralixibat chloride      1-{[4-({4-[(4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-
                                                               6
                           1,1-dioxo-2,3,4,5-tetrahydro-1H-1λ -benzothiepin-
                           5-yl]phenoxy}methyl)phenyl]methyl}-
                           1,4-diazabicyclo[2.2.2]octan-1-ium chloride

 chlorure de maralixibat   chlorure de 1-{[4-({4-[(4R,5R)-3,3-dibutyl-
                           7-(diméthylamino)-4-hydroxy-1,1-dioxo-2,3,4,5-tétrahydro-
                                 6
                           1H-1λ -benzothiépin-5-yl]phénoxy}méthyl)phényl]méthyl}-
                           1,4-diazabicyclo[2.2.2]octan-1-ium

 cloruro de maralixibat    cloruro de 1-{[4-({4-[(4R,5R)-3,3-dibutil-7-(dimetilamino)-
                                                                           6
                           4-hidroxi-1,1-dioxo-2,3,4,5-tetrahidro-1H-1λ -benzotiepin-
                           5-il]fenoxi}metil)fenil]metil}-1,4-diazabiciclo[2.2.2]octan-1-io

                           C40H56ClN3O4S

                                  H3C
                                                                               N
                                                                     O               N
                                              OH
                                                   H
                            H3C

                                                       H                                 Cl
                                        O S
                                         O
                                                               CH3
                                                           N
                                                           CH3




128
WHO Drug Information Vol. 30, No. 1, 2016                                        Recommended INN: List 75


 marzeptacogum alfa (activatum) #
 marzeptacog alfa (activated)         recombinant DNA derived human blood coagulation factor
                                      VIIa analogue:
                                      [128-L-asparagine(T>N),129-L-alanine(P>A),286-L-
                                      arginine(Q>R),298-L-glutamine(M>Q)]activated human
                                      coagulation factor VII (proconvertine, SPCA), produced in
                                      Chinese hamster ovary (CHO) cells, glycoform alfa

 marzeptacog alfa (activé)            analogue du facteur VIIa de coagulation sanguine humain
                                      produit à partir d’ADN recombinant :
                                      [128-L-asparagine(T>N),129-L-alanine(P>A),286-L-
                                      arginine(Q>R),298-L-glutamine(M>Q)]facteur VII de
                                      coagulation humain activé (proconvertine, SPCA), produite
                                      par des cellules ovariennes de hamster chinois (CHO),
                                      forme glycosylée alfa

 marzeptacog alfa (activado)          análogo del factor VIIa de coagulación sanguínea humano
                                      producido a partir de ADN recombinante :
                                      [128-L-asparagina(T>N),129-L-alanina(P>A),286-L-
                                      arginina(Q>R),298-L-glutamina(M>Q)]factor VII de
                                      coagulación humano activado (proconvertina, SPCA),
                                      producida por células ováricas de hamster chino (CHO),
                                      forma glicosilada alfa
                                       Light chain / Chaîne légère / Cadena ligera
                                       ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50
                                       ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
                                       YCSDHTGTKR SCRCHEGYSL LADGVSCNAT VEYPCGKIPI LEKRNASKPQ 150
                                       GR                                                     152

                                       Heavy chain / Chaîne lourde / Cadena pesada
                                         IVGGKVCP KGECPWQVLL LVNGAQLCGG                   TLINTIWVVS       AAHCFDKIKN       200
                                       WRNLIAVLGE HDLSEHDGDE QSRRVAQVII                   PSTYVPGTTN       HDIALLRLHQ       250
                                       PVVLTDHVVP LCLPERTFSE RTLAFVRFSL                   VSGWGRLLDR       GATALELQVL       300
                                       NVPRLMTQDC LQQSRKVGDS PNITEYMFCA                   GYSDGSKDSC       KGDSGGPHAT       350
                                       HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV                   SQYIEWLQKL       MRSEPRPGVL       400
                                       LRAPFP                                                                               406

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       17-22      50-61     55-70      72-81      91-102 98-112
                                       114-127 135-262 159-164 178-194 310-329 340-368

                                       Modified residues / Résidus modifiés / Restos modificados
                                               E              HO2C                         D                  H   NH2
                                                                       H   NH2
                                         6-7-14-16-19                                      63        HO2C
                                        20-25-26-29-35                                                             CO2H
                                         4-carboxyGlu     HO2C              CO2H
                                                                                     3-hydroxyAsp
                                                                                                         HO H
                                       Glycosylation sites (S or N) / Sites de glycosylation (S ou N) / Posiciones de glicosilación
                                       (S o N)
                                       Ser-52 Ser-60 Asn-128 Asn-145 Asn-322



 mecapegfilgrastimum #
 mecapegfilgrastim                    [1-[N-(3-{[(3RS)-1-{3-[(2-{[ω-methoxypoly(oxyethane-
                                      1,2-diyl)]formamido}ethyl)amino]-3-oxopropyl}-
                                      2,5-dioxopyrrolidin-3-yl]sulfanyl}propyl)-
                                      L-methionine]]human granulocyte colony-stimulating factor
                                      (pluripoietin) isoform Short

 mécapegfilgrastim                    [1-[N-(3-{[(3RS)-1-{3-[(2-{[ω-méthoxypoly(oxyéthane-
                                      1,2-diyl)]formamido}éthyl)amino]-3-oxopropyl}-
                                      2,5-dioxopyrrolidin-3-yl]sulfanyl}propyl)-
                                      L-méthionine]]isoforme court (Short) du facteur de
                                      stimulation des colonies de granulocytes humain
                                      (pluripoiétine)




                                                                                                                              129
Recommended INN: List 75                          WHO Drug Information Vol. 30, No. 1, 2016




 mecapegfilgrastim                [1-[N-(3-{[(3RS)-1-{3-[(2-{[ω-metoxipoli(oxietano-
                                  1,2-diil)]formamido}etil)amino]-3-oxopropil}-
                                  2,5-dioxopirrolidin-3-il]sulfanil}propil)-L-metionina]]isoforma
                                  corta (Short) del factor humano de estimulación de
                                  colonias de granulocitos (pluripoyetina)
                                  Sequence / Séquence / Secuencia
                                  MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
                                  LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100
                                  GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGAMPA FASAFQRRAG 150
                                  GVLVASHLQS FLEVSYRVLR HLAQP     175

                                  Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                  37-43 65-75

                                  Modified residue / Résidu modifié / Resto modificado                    H
                                                                                                  O           S
                                      M                                     HN
                                       1                                                                                H
                                    PEG-Met                  O                       HN               N                 N   CO2H
                                                       H3C              O        O
                                                                       n                                                    H
                                                                                          O               O
                                                                                                              H3C   S




 merestinibum
 merestinib                       N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-
                                  5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-
                                  1,2-dihydropyridine-3-carboxamide

 mérestinib                       N-(3-fluoro-4-{[1-méthyl-6-(1H-pyrazol-4-yl)-1H-indazol-
                                  5-yl]oxy}phényl)-1-(4-fluorophényl)-6-méthyl-2-oxo-
                                  1,2-dihydropyridine-3-carboxamide

 merestinib                       N-(3-fluoro-4-{[1-metil-6-(1H-pirazol-4-il)-1H-indazol-
                                  5-il]oxi}fenil)-1-(4-fluorofenil)-6-metil-2-oxo-
                                  1,2-dihidropiridina-3-carboxamida

                                  C30H22F2N6O3
                                                                                                               HN       N

                                                                                              F
                                   F                                                                      O
                                                             O          O

                                                        N                        N                                          N CH3
                                                                                 H
                                                                                                                            N
                                              H3 C




 mirvetuximabum soravtansinum #
 mirvetuximab soravtansine        immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1
                                  (folate receptor 1, folate receptor alpha, FR-alpha, adult
                                  folate-binding protein, FBP, ovarian tumor-associated
                                  antigen MOv18)], chimeric monoclonal antibody
                                  conjugated to maytansinoid DM4;




130
WHO Drug Information Vol. 30, No. 1, 2016                        Recommended INN: List 75




                                      gamma1 heavy chain (1-447) [Mus musculus VH (IGHV1-
                                      37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens
                                      IGHG1*01, G1m17,1 (CH1 (119-216), hinge (217-231),
                                      CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-
                                      447)], (221-218')-disulfide with kappa light chain (1'-218')
                                      [Mus musculus V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9]
                                      (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimer
                                      (227-227'':230-230'')-bisdisulfide;conjugated, on an
                                      average of 3 or 4 lysyl, to maytansinoid DM4 [N2'-deacetyl-
                                      N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the
                                      reducible sulfo-SPDB linker [N-succinimidyl 4-(2-
                                      pyridyldithio)-2-sulfobutanoate]


 mirvétuximab soravtansine            immunoglobuline G1-kappa, anti-[Homo sapiens FOLR1
                                      (réceptor 1 du folate, récepteur alpha du folate, FR-alpha,
                                      protéine de l’adulte liant le folate, FBP, antigène MOv18
                                      associé à des tumeurs ovariennes)], anticorps monoclonal
                                      chimérique conjugué au maytansinoïde DM4;
                                      chaîne lourde gamma1 (1-447) [Mus musculus VH
                                      (IGHV1-37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                                      sapiens IGHG1*01, G1m17,1 (CH1 (119-216), charnière
                                      (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del
                                      (447)) (119-447)], (221-218')-disulfure avec la chaîne
                                      légère kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-
                                      9*01 -IGKJ2*01) [10.3.9] (1'-111') -Homo sapiens
                                      IGKC*01, Km3 (112'-218')]; dimère (227-227'':230-230'')-
                                      bisdisulfure; conjugué, sur 3 ou 4 lysyl en moyenne, au
                                      maytansinoïde DM4 [N2'-déacétyl-N2'-(4-mercapto-4-
                                      méthyl-1-oxopentyl)-maytansine] via le linker sulfo-SPDB
                                      réductible [4-(2-pyridyldithio)-2-sulfobutanoate de N-
                                      succinimidyle]


 mirvetuximab soravtansina            inmunoglobulina G1-kappa, anti-[Homo sapiens FOLR1
                                      (receptor 1 de folato, receptor alfa de folato, FR-alfa,
                                      proteína del adulto que liga el folato, FBP, antígeno
                                      MOv18 asociado a tumores ováricos)], anticuerpo
                                      monoclonal quimérico conjugado con el maitansinoide
                                      DM4;
                                      cadena pesada gamma1 (1-447) [Mus musculus VH
                                      (IGHV1-37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                                      sapiens IGHG1*01, G1m17,1 (CH1 (119-216), cbisagra
                                      (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del
                                      (447)) (119-447)], (221-218')-disulfuro con la cadena
                                      ligera-Homo sapiens IGKC*01, Km3 (112'-218')]; dímero
                                      (227-227'':230-230'')-bisdisulfuro; conjugado en 3-4 grupos
                                      lisil por término medio con el maitansinoide DM4 [N2'-
                                      desacetil-N2'-(4-mercapto-4-metil-1-oxopentil)-maitansina]
                                      mediante el espaciador sulfo-SPDB reducible [4-(2-
                                      piridilditio)butanoato de N-succinimidilo]




                                                                                              131
Recommended INN: List 75                   WHO Drug Information Vol. 30, No. 1, 2016




                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VVKPGASVKI SCKASGYTFT                           GYFMNWVKQS      PGQSLEWIGR      50
                           IHPYDGDTFY NQKFQGKATL TVDKSSNTAH                           MELLSLTSED      FAVYYCTRYD     100
                           GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA                           PSSKSTSGGT      AALGCLVKDY     150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                           YSLSSVVTVP      SSSLGTQTYI     200
                           CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                           PAPELLGGPS      VFLFPPKPKD     250
                           TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                           DGVEVHNAKT      KPREEQYNST     300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                           APIEKTISKA      KGQPREPQVY     350
                           TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                           EWESNGQPEN      NYKTTPPVLD     400
                           SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                           EALHNHYTQK      SLSLSPG        447

                           Light chain / Chaîne légère / Cadena ligera
                           DIVLTQSPLS LAVSLGQPAI ISCKASQSVS                           FAGTSLMHWY      HQKPGQQPRL 50
                           LIYRASNLEA GVPDRFSGSG SKTDFTLTIS                           PVEAEDAATY      YCQQSREYPY 100
                           TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK                           SGTASVVCLL      NNFYPREAKV 150
                           QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                           STLTLSKADY      EKHKVYACEV 200
                           THQGLSSPVT KSFNRGEC                                                                   218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96 145-201               262-322  368-426
                                                 22''-96'' 145''-201'' 262''-322'' 368''-426''
                           Intra-L (C23-C104) 23'-92' 138'-198'
                                                23'''-92''' 138'''-198'''
                           Inter-H-L (h 5-CL 126) 221-218' 221''-218'''
                           Inter-H-H (h 11, h 14) 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           298, 298''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                           complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

                                           soravtansine / soravtansine / soravtansina
                               Ig(NH2)n = Immunoglobulin

                                                                                  O    H CH3
                                                                H3C
                                                                                                 O
                                               HO3S        H   H3C                    N
                                              H                       S    H3C        CH3   O
                                         Ig   N    C   *          S
                                                                              O              H CH3     Cl
                                                  O
                                                                       H 3C                    N            OCH3
                                                and epimer at C*
                                                                                      H
                                                                          H       H
                                                et l'épimère en C*                           O
                                                y el epímero al C*        O
                                                                                      H
                                                                      O       N
                                                                              H OH
                                                                                  OCH3               CH3     n




 monalizumabum #
 monalizumab               immunoglobulin G4-kappa, anti-[Homo sapiens KLRC1
                           (killer cell lectin-like receptor subfamily C member 1,
                           NKG2-A, NKG2A, CD159a, CD94)],humanized monoclonal
                           antibody;
                           gamma4 heavy chain (1-452) [humanized VH (Homo
                           sapiens IGHV1-18*01 (89.80%) -(IGHD)-IGHJ2*01
                           R120>Q (117), L123>T (130)) [8.8.18] (1-125)), IGHG4*01
                           (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-
                           345), CH3 (346-450), CHS (451-452)) (126-452)], (139-
                           214')-disulfide with kappa light chain (1’-214’) [humanized
                           V-KAPPA (Homo sapiens IGKV1-39*01 (87.40%) -
                           IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                           (108'-214')]; dimer (231-231":234-234")-bisdisulfide

 monalizumab               immunoglobuline G4-kappa, anti-[Homo sapiens KLRC1
                           (membre 1 de la sous-famille C des récepteurs de type
                           lectine des cellules NK, NKG2-A, NKG2A, CD159a,
                           CD94)], anticorps monoclonal humanisé;




132
WHO Drug Information Vol. 30, No. 1, 2016                                                Recommended INN: List 75


                                      chaîne lourde gamma4 (1-452) [VH humanisé (Homo
                                      sapiens IGHV1-18*01 (89.80%) -(IGHD)-IGHJ2*01
                                      R120>Q (117), L123>T (130)) [8.8.18] (1-125)), IGHG4*01
                                      (CH1 (126-223), charnière S10>P (233) (224-235), CH2
                                      (236-345), CH3 (346-450), CHS (451-452)) (126-452)],
                                      (139-214')-disulfure avec la chaîne légère kappa (1’-214’)
                                      [V-KAPPA humanisé (Homo sapiens IGKV1-39*01
                                      (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                                      IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-
                                      bisdisulfure

 monalizumab                          inmunoglobulina G4-kappa, anti-[Homo sapiens KLRC1
                                      (miembro 1 de la subfamilia C de receptores de tipo lectina
                                      de las células NK, NKG2-A, NKG2A, CD159a, CD94)],
                                      anticuerpo monoclonal humanizado;
                                      cadena pesada gamma4 (1-452) [VH humanizado (Homo
                                      sapiens IGHV1-18*01 (89.80%) -(IGHD)-IGHJ2*01
                                      R120>Q (117), L123>T (130)) [8.8.18] (1-125)), IGHG4*01
                                      (CH1 (126-223), bisagra S10>P (233) (224-235), CH2
                                      (236-345), CH3 (346-450), CHS (451-452)) (126-452)],
                                      (139-214')-disulfuro con la cadena ligera kappa (1’-214’)
                                      [V-KAPPA humanizado (Homo sapiens IGKV1-39*01
                                      (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                                      IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-
                                      bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT                         SYWMNWVRQA   PGQGLEWMGR        50
                                       IDPYDSETHY AQKLQGRVTM TTDTSTSTAY                         MELRSLRSDD   TAVYYCARGG       100
                                       YDFDVGTLYW FFDVWGQGTT VTVSSASTKG                         PSVFPLAPCS   RSTSESTAAL       150
                                       GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA                         VLQSSGLYSL   SSVVTVPSSS       200
                                       LGTKTYTCNV DHKPSNTKVD KRVESKYGPP                         CPPCPAPEFL   GGPSVFLFPP       250
                                       KPKDTLMISR TPEVTCVVVD VSQEDPEVQF                         NWYVDGVEVH   NAKTKPREEQ       300
                                       FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                         KGLPSSIEKT   ISKAKGQPRE       350
                                       PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS                         DIAVEWESNG   QPENNYKTTP       400
                                       PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC                         SVMHEALHNH   YTQKSLSLSL       450
                                       GK                                                                                     452

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCRASENIY                         SYLAWYQQKP   GKAPKLLIYN 50
                                       AKTLAEGVPS RFSGSGSGTD FTLTISSLQP                         EDFATYYCQH   HYGTPRTFGG 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                         SVVCLLNNFY   PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                         LSKADYEKHK   VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                  214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          152-208 266-326       372-430
                                                             22''-96'' 152''-208'' 266''-326'' 372''-430''
                                       Intra-L (C23-C104) 23'-88'         134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (CH1 10-CL 126) 139-214' 139''-214'''
                                       Inter-H-H (h 8, h 11)           231-231'' 234-234''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       302, 302''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
                                       fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


 murepavadinum
 murepavadin                          cyclo[L-alanyl-L-seryl-D-prolyl-L-prolyl-L-threonyl-
                                      L-tryptophyl-L-isoleucyl-(2S)-2,4-diaminobutanoyl-
                                      L-ornithyl-(2R)-2,4-diaminobutanoyl-(2S)-2,4-
                                      diaminobutanoyl-L-tryptophyl-(2S)-2,4-diaminobutanoyl-
                                      (2S)-2,4-diaminobutanoyl]

 murépavadine                         cyclo[L-alanyl-L-séryl-D-prolyl-L-prolyl-L-thréonyl-
                                      L-tryptophyl-L-isoleucyl-(2S)-2,4-diaminobutanoyl-
                                      L-ornithyl-(2R)-2,4-diaminobutanoyl-(2S)-2,4-
                                      diaminobutanoyl-L-tryptophyl-(2S)-2,4-diaminobutanoyl-
                                      (2S)-2,4-diaminobutanoyl]



                                                                                                                                     133
Recommended INN: List 75                  WHO Drug Information Vol. 30, No. 1, 2016



 murepavadina              ciclo[L-alanil-L-seril-D-prolil-L-prolil-L-treonil-L-triptofil-
                           L-isoleucil-(2S)-2,4-diaminobutanoil-L-ornitil-(2R)-2,4-
                           diaminobutanoil-(2S)-2,4-diaminobutanoil-L-triptofil-(2S)-
                           2,4-diaminobutanoil-(2S)-2,4-diaminobutanoil]

                           C73H112N22O16

                                          O
                                                  Ala         Ser       D-Pro   Pro   Thr   Trp Ile   NH
                                      H                                                                    H
                                                  O                        O          O
                                                              H                  H          H
                                          HN                  N     Trp          N          N Orn
                            H2N                                                                        O       NH2
                                                   H                        H          H
                                                                    NH2               NH2       NH2


 nadorameranum #
 nadorameran               an mRNA molecule encoding the rabies virus glycoprotein
                           RAV-G containing elements for expression within
                           eukaryotic cells; manufactured by enzymatic in vitro
                           transcription from linearized plasmid DNA

 nadoraméran               ARN messager codant la glycoprotéine G du virus de la
                           rage contenant les éléments pour son expression dans des
                           cellules eucaryotes; obtenu par transcription enzymatique
                           in vitro à partir d'ADN de plasmide linéarisé

 nadoramerán               ARN mensajero que codifica la glicoproteína G del virus de
                           la rabia y contiene los elementos para su expresión en
                           células eucariotas; obtenido por transcripción enzimática in
                           vitro a partir de ADN de plásmido transformado en lineal


 nastorazepidum
 nastorazepide             3-({[(3R)-5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-
                           2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-
                           3-yl]carbamoyl}amino)benzoic acid

 nastorazépide             acide 3-({[(3R)-5-cyclohexyl-1-(3,3-diméthyl-2-oxobutyl)-
                           2-oxo-2,3,4,5-tétrahydro-1H-1,5-benzodiazépin-
                           3-yl]carbamoyl}amino)benzoïque

 nastorazepida             ácido 3-({[(3R)-5-cyclohexyl-1-(3,3-dimetil-2-oxobutil)-
                           2-oxo-2,3,4,5-tetrahidro-1H-1,5-benzodiazepin-
                           3-il]carbamoil}amino)benzoico

                           C29H36N4O5

                                      CH3
                            H3C         CH3


                                  O                   O
                                              N                O
                                                          H
                                                          N         N             CO2H
                                              N           H         H




134
WHO Drug Information Vol. 30, No. 1, 2016                                               Recommended INN: List 75




 natrii cinhyaluronas
 cinhyaluronate sodium                sodium salt of hyaluronic acid partly amidified with
                                      3-{[(2E)-3-phenylprop-2-enoyl]oxy}propan-1-amine

 cinhyaluronate de sodium             sel sodique de l’acide hyaluronique partiellement amidifié
                                      par la 3-{[(2E)-3-phénylprop-2-énoyl]oxy}propan-1-amine

 cinhialuronato de sodio              sal sódica del ácido hialurónico parcialmente amidificado
                                      por la 3-{[(2E)-3-fenilprop-2-enoil]oxi}propan-1-amina

                                       [(C26H34N2O12)a(C14H20NNaO11)b]nH2O




                                            O                                                        OH
                                                 O                                                             NaO2C
                                                                           O                              O                 O
                                            HO                HN                            HO                     O                     OH
                                                         O                     O
                                            HO                    O                              O            NH       HO       OH
                                                                                                     O
                                       H         O           NH       HO           OH                         CH3
                                                                                                                                     b
                                                     O
                                                             CH3
                                                                                        a                                                n




 navivumabum #
 navivumab                            immunoglobulin G1-kappa, anti-[influenza A virus
                                      hemagglutinin HA], Homo sapiens monoclonal antibody;
                                      gamma1 heavy chain (1-456) [Homo sapiens VH (IGHV1-
                                      18*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -
                                      IGHG1*07, G1m17,1,2 (CH1 (127-224), hinge (225-239),
                                      CH2 (240-349), CH3 (350-454), CHS (455-456)) (127-
                                      456)], (229-215')-disulfide with kappa light chain (1'-215')
                                      [Homo sapiens V-KAPPA (IGKV3-20*01 (82.30%) -
                                      IGKJ1*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')];
                                      dimer (235-235'':238-238'')-bisdisulfide

 navivumab                            immunoglobuline G1-kappa, anti-[hémagglutinine HA du
                                      virus de la grippe A], Homo sapiens anticorps monoclonal;
                                      chaîne lourde gamma1 (1-456) [Homo sapiens VH
                                      (IGHV1-18*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.19] (1-
                                      126) -IGHG1*07, G1m17,1,2 (CH1 (127-224), charnière
                                      (225-239), CH2 (240-349), CH3 (350-454), CHS (455-
                                      456)) (127-456)], (229-215')-disulfure avec la chaîne légère
                                      kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01
                                      (82.30%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-
                                      215')]; dimère (235-235'':238-238'')-bisdisulfure




                                                                                                                                              135
Recommended INN: List 75                    WHO Drug Information Vol. 30, No. 1, 2016


 navivumab                  inmunoglobulina G1-kappa, anti-[hemaglutinina HA del
                            virus de la gripe A], anticuerpo monoclonal Homo sapiens;
                            cadena pesada gamma1 (1-456) [Homo sapiens VH
                            (IGHV1-18*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.19] (1-
                            126) -IGHG1*07, G1m17,1,2 (CH1 (127-224), bisagra
                            (225-239), CH2 (240-349), CH3 (350-454), CHS (455-
                            456)) (127-456)], (229-215')-disulfuro con la cadena ligera
                            kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01
                            (82.30%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-
                            215')]; dímero (235-235'':238-238'')-bisdisulfuro
                            Heavy chain / Chaîne lourde / Cadena pesada
                            QVQLVQSGAE VKKPGASVKV SCKTSGYSFS                         TYGVSWVRQA         PGQGPEWVGW         50
                            ISAYTGITDY AQKFQGRVTL TTDATTATAF                         LDLRSLRPDD         TATYFCARDK        100
                            VQGRVEVGSG GRHDYWGQGT LVIVSSASTK                         GPSVFPLAPS         SKSTSGGTAA        150
                            LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP                         AVLQSSGLYS         LSSVVTVPSS        200
                            SLGTQTYICN VNHKPSNTKV DKKVEPKSCD                         KTHTCPPCPA         PELLGGPSVF        250
                            LFPPKPKDTL MISRTPEVTC VVVDVSHEDP                         EVKFNWYVDG         VEVHNAKTKP        300
                            REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC                         KVSNKALPAP         IEKTISKAKG        350
                            QPREPQVYTL PPSRDELTKN QVSLTCLVKG                         FYPSDIAVEW         ESNGQPENNY        400
                            KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN                         VFSCSVMHEG         LHNHYTQKSL        450
                            SLSPGK                                                                                        456

                            Light chain / Chaîne légère / Cadena ligera
                            EVVLTQSPGT LALPPGERAT LSCRASHRVG                         STYIAWYQQK         SGQAPRRLIY 50
                            GASNRATDIP DRFSGSGSGT DFTLTIRRLE                         PEDSAVYYCQ         QFSVSPWTFG 100
                            QGTRVEIKRT VAAPSVFIFP PSDEQLKSGT                         ASVVCLLNNF         YPREAKVQWK 150
                            VDNALQSGNS QESVTEQDSK DSTYSLSSTL                         TLSKADYEKH         KVYACEVTHQ 200
                            GLSSPVTKSF NRGEC                                                                       215

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            Intra-H (C23-C104) 22-96          153-209       270-330 376-434
                                                  22''-96'' 153''-209'' 270''-330'' 376''-434''
                            Intra-L (C23-C104) 23'-89'         135'-195'
                                                  23'''-89''' 135'''-195'''
                            Inter-H-L (h 5-CL 126) 229-215' 229''-215'''
                            Inter-H-H (h 11, h 14) 235-235'' 238-238''

                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                            H CH2 N84.4:
                            306, 306''

                            Other post-translational modifications / Autres modifications post-traductionnelles /
                            Otras modificaciones post-traduccionales
                            H CHS K2 C-terminal lysine clipping:
                            456, 456''




 neladenosoni bialanas
 neladenoson bialanate      2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-
                            4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-
                            4-yl]phenoxy}ethyl L-alanyl-L-alaninate

 bialanate de néladénoson   L-alanyl-L-alaninate de 2-{4-[2-({[2-(4-chlorophényl)-
                            1,3-thiazol-4-yl]méthyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-
                            1-yl)pyridin-4-yl]phénoxy}éthyle

 bialanato de neladenosón   L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-
                            4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-
                            4-il]fenoxi}etilo

                            C35H34ClN7O4S2

                                                                                                                         O
                                                                                                                                CH3
                                                                               N                                    HN           H
                                                                                         CN                O              H NH2
                                                                           N
                                                                                                                         CH3
                                                       N                                                        O
                                                                      S
                             Cl
                                                                               CN
                                                       S                                              O




136
WHO Drug Information Vol. 30, No. 1, 2016                         Recommended INN: List 75


 netarsudilum
 netarsudil                           {4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-
                                      2-yl]phenyl}methyl 2,4-dimethylbenzoate

 nétarsudil                           2,4-diméthylbenzoate de {4-[(2S)-3-amino-1-(isoquinoléin-
                                      6-ylamino)-1-oxopropan-2-yl]phényl}méthyle

 netarsudil                           2,4-dimetilbenzoato de {4-[(2S)-3-amino-1-(isoquinolein-
                                      6-ilamino)-1-oxopropan-2-il]fenil}metilo

                                       C28H27N3O3

                                                     O

                                                         O                O                 N

                                       H3 C          CH3                      N
                                                                              H
                                                                H2N      H


 obiltoxaximabum #
 obiltoxaximab                        immunoglobulin G1-kappa, anti-[Bacillus anthracis anthrax
                                      toxin protective antigen (PA)], chimeric monoclonal
                                      antibody;
                                      gamma1 heavy chain (1-449) [Mus musculus VH (IGHV1-
                                      82*01 -(IGHD)-Homo sapiens IGHJ4*01) [8.8.12] (1-119) -
                                      Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), hinge
                                      (218-232), CH2 (233-342), CH3 (343-447), CHS (448-
                                      449)) (120-449)], (222-214')-disulfide with kappa light chain
                                      (1'-214') [Mus musculus V-KAPPA (IGKV10-96*01 -Homo
                                      sapiens IGKJ1*01 K127>R (107) [6.3.9] (1'-107') -Homo
                                      sapiens IGKC*01, Km3 (108'-214')]; dimer (228-228'':231-
                                      231'')-bisdisulfide

 obiltoxaximab                        immunoglobuline G1-kappa, anti-[antigène protecteur (AP)
                                      de la toxine de Bacillus anthracis de la maladie du
                                      charbon], anticorps monoclonal chimérique;
                                      chaîne lourde gamma1 (1-449) [Mus musculus VH
                                      (IGHV1-82*01 -(IGHD)-Homo sapiens IGHJ4*01) [8.8.12]
                                      (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-
                                      217), charnière (218-232), CH2 (233-342), CH3 (343-447),
                                      CHS (448-449)) (120-449)], (222-214')-disulfure avec la
                                      chaîne légère kappa (1'-214') [Mus musculus V-KAPPA
                                      (IGKV10-96*01 -Homo sapiens IGKJ1*01 K127>R (107)
                                      [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                                      dimère (228-228'':231-231'')-bisdisulfure

 obiltoxaximab                        inmunoglobulina G1-kappa, anti-[antigeno protector (AP)
                                      de la toxina de Bacillus anthracis, del carbunco],
                                      anticuerpo monoclonal quimérico;
                                      cadena pesada gamma1 (1-449) [Mus musculus VH
                                      (IGHV1-82*01 -(IGHD)-Homo sapiens IGHJ4*01) [8.8.12]
                                      (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-
                                      217), bisagra (218-232), CH2 (233-342), CH3 (343-447),
                                      CHS (448-449)) (120-449)], (222-214')-disulfuro con la
                                      cadena ligera kappa (1'-214') [Mus musculus V-KAPPA
                                      (IGKV10-96*01 -Homo sapiens IGKJ1*01 K127>R (107)
                                      [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                                      dimero (228-228'':231-231'')-bisdisulfuro




                                                                                                137
Recommended INN: List 75                 WHO Drug Information Vol. 30, No. 1, 2016



                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQSGPE LKKPGASVKV SCKDSGYAFS                  SSWMNWVRQA       PGQGLEWIGR        50
                           IYPGDGDTNY NGKFQGRVTI TADKSSSTAY                  MELSSLRSED       TAVYFCARSG       100
                           LLRYAMDYWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQDIR                  NYLNWYQQKP       GKAVKLLIYY 50
                           TSRLLPGVPS RFSGSGSGTD YSLTISSQEQ                  EDIGTYFCQQ       GNTLPWTFGQ 100
                           GTKVEIRRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          146-202       263-323   369-427
                                                 22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L (C23-C104) 23'-88'         134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 222-214' 222''-214'''
                           Inter-H-H (h 11, h 14) 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           299, 299''




 omaveloxolonum
 omaveloxolone             N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-
                           2,2-difluoropropanamide

 omavéloxolone             N-(2-cyano-3,12-dioxo-28-noroléana-1,9(11)-dién-17-yl)-
                           2,2-difluoropropanamide

 omaveloxolona             N-(2-ciano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-il)-
                           2,2-difluoropropanamida

                           C33H44F2N2O3

                                                              H3C    CH3

                                                     O
                                                          H                 O
                                                                                     CH3
                                           CH3       CH3      H        N
                            NC                                         H
                                                                              F    F
                                                          CH3
                             O
                             H3C CH H
                                   3


 opicinumabum #
 opicinumab                immunoglobulin G1-kappa, anti-[Homo sapiens LINGO1
                           (leucine-rich repeat and Ig-like domain-containing nogo
                           receptor-interacting protein 1, LINGO-1, leucine-rich repeat
                           neuronal protein 1, LERN1, leucine-rich repeat neuronal
                           protein 6A, LRRN6A)], Homo sapiens monoclonal
                           antibody;
                           gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV3-
                           23*01 (91.80%) -(IGHD)-IGHJ3*02) [8.8.11] (1-118) -
                           IGHG1*01, G1m17,1 (CH1 (119-216), hinge (217-231),
                           CH2 T85.3>A (300) (232-341), CH3 (342-446), CHS
                           K2>del (447)) (119-447)], (221-215')-disulfide with kappa
                           light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-
                           11*01 (96.80%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01,
                           Km3 (109'-215')]; dimer (227-227'':230-230'')-bisdisulfide




138
WHO Drug Information Vol. 30, No. 1, 2016                                         Recommended INN: List 75




 opicinumab                           immunoglobuline G1-kappa, anti-[Homo sapiens LINGO1
                                      (protéine 1 interagissant avec le récepteur de nogo et
                                      contenant des répétitions riches en leucine et un domaine
                                      Ig-like, LINGO-1, protéine neuronale 1 contenant des
                                      répétitions riches en leucine, LERN1, protéine neuronale
                                      6A contenant des répétitions riches en leucine, LRRN6A)],
                                      Homo sapiens anticorps monoclonal;
                                      chaîne lourde gamma1 (1-447) [Homo sapiens VH
                                      (IGHV3-23*01 (91.80%) -(IGHD)-IGHJ3*02) [8.8.11] (1-
                                      118) -IGHG1*01, G1m17,1 (CH1 (119-216), charnière
                                      (217-231), CH2 T85.3>A (300) (232-341), CH3 (342-446),
                                      CHS K2>del (447)) (119-447)], (221-215')-disulfure avec la
                                      chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA
                                      (IGKV3-11*01 (96.80%) -IGKJ2*01) [6.3.10] (1'-108') -
                                      IGKC*01, Km3 (109'-215')]; dimère (227-227'':230-230'')-
                                      bisdisulfure

 opicinumab                           inmunoglobulina G1-kappa, anti-[Homo sapiens LINGO1
                                      (proteína 1 que interacciona con el receptor de nogo y
                                      contiene repeticiones ricas en leucina y un dominio Ig-like,
                                      LINGO-1, proteína neuronal 1, que contiene repeticiones
                                      ricas en leucina,LERN1, proteína neuronal 6A que
                                      contiene repeticiones ricas en leucina, LRRN6A)],
                                      anticuerpo monoclonal de Homo sapiens ;
                                      cadena pesada gamma1 (1-447) [Homo sapiens VH
                                      (IGHV3-23*01 (91.80%) -(IGHD)-IGHJ3*02) [8.8.11] (1-
                                      118) -IGHG1*01, G1m17,1 (CH1 (119-216), bisagra (217-
                                      231), CH2 T85.3>A (300) (232-341), CH3 (342-446), CHS
                                      K2>del (447)) (119-447)], (221-215')-disulfuro con la
                                      cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA
                                      (IGKV3-11*01 (96.80%) -IGKJ2*01) [6.3.10] (1'-108') -
                                      IGKC*01, Km3 (109'-215')]; dímero (227-227'':230-230'')-
                                      bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLLESGGG LVQPGGSLRL SCAASGFTFS                  AYEMKWVRQA       PGKGLEWVSV        50
                                       IGPSGGFTFY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCATEG       100
                                       DNDAFDIWGQ GTTVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                       FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                       CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                       TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNSA       300
                                       YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                       TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                       SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPG          447

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                       ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPMYTFG 100
                                       QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                              215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          145-201 262-322        368-426
                                                             22''-96'' 145''-201'' 262''-322'' 368''-426''
                                       Intra-L (C23-C104) 23'-88'         135'-195'
                                                             23'''-88''' 135'''-195'''
                                       Inter-H-L (h 5-CL 126) 221-215' 221''-215'''
                                       Inter-H-H (h 11, h 14) 227-227'' 230-230''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       298, 298'' but no glycosylation owing to / mais pas de glycosylation dû à / pero ningún
                                       glicosilación debida a H CH2 T85.3>A (300, 300'')




                                                                                                                                 139
Recommended INN: List 75              WHO Drug Information Vol. 30, No. 1, 2016


 osimertinibum
 osimertinib               N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-
                           5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-
                           2-yl]amino}phenyl)prop-2-enamide

 osimertinib               N-(2-{[2-(diméthylamino)éthyl](méthyl)amino}-4-méthoxy-
                           5-{[4-(1-méthyl-1H-indol-3-yl)pyrimidin-
                           2-yl]amino}phényl)prop-2-énamide

 osimertinib               N-(2-{[2-(dimetilamino)etil](metil)amino}-4-metoxi-5-{[4-(1-
                           metil-1H-indol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida

                           C28H33N7O2

                                                         O
                                              H2C
                                                             NH     CH3
                                                                    N         CH3
                                                 N                        N
                                                                          CH3
                            H3C              N       N
                                  N                  H
                                                             OCH3




 pamrevlumabum #
 pamrevlumab               immunoglobulin G1-kappa, anti-[Homo sapiens CTGF
                           (connective tissue growth factor, CCN family member 2,
                           CCN2, hypertrophic chondrocyte-specific protein 24,
                           HCS24, insulin-like growth factor-binding protein 8, IGFBP-
                           8)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-
                           48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -
                           IGHG1*03, G1m3 (CH1 (121-218), hinge (219-233), CH2
                           (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)],
                           (223-214')-disulfide with kappa light chain (1'-214') [Homo
                           sapiens V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01)
                           [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer(229-
                           229'':232-232'')-bisdisulfide

 pamrevlumab               immunoglobuline G1-kappa, anti-[Homo sapiens CTGF
                           (facteur de croissance du tissu conjonctif, membre 2 de la
                           famille CCN, CCN2, protéine 24 spécifique de
                           l’hypertrophie des chondrocytes, HCS24, protéine 8 liant le
                           facteur de croissance analogue à l’insuline, IGFBP-8)],
                           Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-449) [Homo sapiens VH
                           (IGHV3-48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-
                           120) -IGHG1*03, G1m3 (CH1 (121-218), charnière (219-
                           233), CH2 (234-343), CH3 (344-448), CHS K2>del (449))
                           (121-449)], (223-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01
                           (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3
                           (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure




140
WHO Drug Information Vol. 30, No. 1, 2016                                              Recommended INN: List 75




 pamrevlumab                          inmunoglobulina G1-kappa, anti-[Homo sapiens CTGF
                                      (factor de crecimiento de tejido conjunctivo, miembro 2 de
                                      la familia CCN, CCN2, proteína 24 específica de la
                                      hipertrofia de condrocitos, HCS24, proteína 8 que ligada el
                                      factor de crecimiento análogo a la insulina, IGFBP-8)],
                                      Homo sapiens anticuerpo monoclonal;
                                      cadena pesada gamma1 (1-449) [Homo sapiens VH
                                      (IGHV3-48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-
                                      120) -IGHG1*03, G1m3 (CH1 (121-218), bisagra (219-
                                      233), CH2 (234-343), CH3 (344-448), CHS K2>del (449))
                                      (121-449)], (223-214')-disulfuro con la cadena ligera kappa
                                      (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01
                                      (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3
                                      (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro


                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EGQLVQSGGG LVHPGGSLRL SCAGSGFTFS                         SYGMHWVRQA         PGKGLEWVSG          50
                                       IGTGGGTYST DSVKGRFTIS RDNAKNSLYL                         QMNSLRAEDM         AVYYCARGDY         100
                                       YGSGSFFDCW GQGTLVTVSS ASTKGPSVFP                         LAPSSKSTSG         GTAALGCLVK         150
                                       DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                         GLYSLSSVVT         VPSSSLGTQT         200
                                       YICNVNHKPS NTKVDKRVEP KSCDKTHTCP                         PCPAPELLGG         PSVFLFPPKP         250
                                       KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                         YVDGVEVHNA         KTKPREEQYN         300
                                       STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                         LPAPIEKTIS         KAKGQPREPQ         350
                                       VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                         AVEWESNGQP         ENNYKTTPPV         400
                                       LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                         MHEALHNHYT         QKSLSLSPG          449

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCRASQGIS                         SWLAWYQQKP         EKAPKSLIYA 50
                                       ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                         EDFATYYCQQ         YNSYPPTFGQ 100
                                       GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                         SVVCLLNNFY         PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                         LSKADYEKHK         VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                        214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-95          147-203 264-324       370-428
                                                             22''-95'' 147''-203'' 264''-324'' 370''-428''
                                       Intra-L (C23-C104) 23'-88'         134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 223-214' 223''-214'''
                                       Inter-H-H (h 11, h 14) 229-229'' 232-232''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       300, 300''
                                       Fucosylated complex bi-antennary CHO-type glycans/ glycanes de type CHO bi-antennaires complexes
                                       fucosylés/ glicanos de tipo CHO biantenarios complejos fucosilados

                                       Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones
                                       post-traduccionales
                                       H VH CDR3 C117 (109, 109''): cysteinylation with either Cys, Cys-Gly, glutathione, or no cysteinylation
                                       cystéinylation avec soit Cys, Cys-Gly, glutathion, ou absence de cystéinylation / cisteinilación con Cis, o
                                       Cis-Gli, o glutatión, o ausencia de cisteinilación




 pegcantratinibum
 pegcantratinib                       (5'R,9S,12R)-9-methyl-3'-[α-methylpoly(oxyethane-
                                      1,2-diyl)]-2,3,11,12-tetrahydro-1H,9H-spiro[9,12-
                                      epoxydiindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
                                      i][1,6]benzodiazocine-10,5'-oxazolidine]-1,2',4'-trione

 pegcantratinib                       (5'R,9S,12R)-9-méthyl-3'-[α-méthylpoly(oxyéthane-
                                      1,2-diyl)]-2,3,11,12-tétrahydro-1H,9H-spiro[9,12-
                                      époxydiindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
                                      i][1,6]benzodiazocine-10,5'-oxazolidine]-1,2',4'-trione

 pegcantratinib                       (5'R,9S,12R)-9-metil-3'-[α-metilpoli(oxietano-1,2-diil)]-
                                      2,3,11,12-tetrahidro-1H,9H-espiro[9,12-epoxidiindolo[1,2,3-
                                      fg:3',2',1'-kl]pirrolo[3,4-i][1,6]benzodiazocina-
                                      10,5'-oxazolidina]-1,2',4'-triona




                                                                                                                                          141
Recommended INN: List 75                      WHO Drug Information Vol. 30, No. 1, 2016


                           C28H20N4O5[C2H4O]n

                                                  H
                                          O       N




                                              N           N
                                                  O
                                                                  CH3
                                      H
                                                                   O
                                                   O
                                                              N                 CH3
                                                                            O
                                                                                n
                                                      O

 pemafibratum
 pemafibrate               (2R)-2-[3-({(1,3-benzoxazol-2-yl)[3-(4-methoxyphenoxy)
                           propyl]amino}methyl)phenoxy]butanoic acid

 pémafibrate               acide (2R)-2-[3-({(1,3-benzoxazol-2-yl)[3-(4-
                           méthoxyphénoxy)propyl]amino}méthyl)phénoxy]
                           butanoïque

 pemafibrato               ácido (2R)-2-[3-({(benzoxazol-2-il)[3-(4-metoxifenoxi)
                           propil]amino}metil)fenoxi]butanoico

                           C28H30N2O6

                                                          O                               CH3
                                                                                           H
                                                              O         N
                            H3CO                                                      O     CO2H
                                                                   N



 piclidenosonum
 piclidenoson              1-deoxy-1-(6-{[(3-iodophenyl)methyl]amino}-9H-purin-9-yl)-
                           N-methyl-β-D-ribofuranuronamide

 piclidénoson              1-déoxy-1-(6-{[(3-iodophényl)méthyl]amino}-9H-purin-9-yl)-
                           N-méthyl-β-D-ribofuranuronamide

 piclidenosón              1-desoxi-1-(6-{[(3-iodofenil)metil]amino}-9H-purin-9-il)-
                           N-metil-β-D-ribofuranuronamida

                           C18H19IN6O4

                                                  NH

                                                          N
                                              N
                                  I
                                                  N       N
                                      H
                                      N       O
                            H3C                   O




                                              OH       OH




142
WHO Drug Information Vol. 30, No. 1, 2016                        Recommended INN: List 75




 plozalizumabum #
 plozalizumab                         immunoglobulin G1-kappa, anti-[Homo sapiens CCR2
                                      (chemokine (C-C motif) receptor 2, C-C chemokine
                                      receptor 2, CC-CKR-2, CKR-2, monocyte chemoattractant
                                      protein 1 receptor, MCP-1-R, CD192)], humanized
                                      monoclonal antibody;
                                      gamma1 heavy chain (1-447) [humanized VH (Homo
                                      sapiens IGHV3-73*01 (86.90%) -(IGHD)-IGHJ1*01)
                                      [8.10.8] (1-117) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (118-215), hinge (216-230), CH2 L1.2>A (235), G1>A
                                      (237) (231-340), CH3 (341-445), CHS (446-447)) (118-
                                      447)], (220-219')-disulfide with kappa light chain (1’-219’)
                                      [humanized V-KAPPA (Homo sapiens IGKV2-30*01
                                      (90.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens
                                      IGKC*01 (113'-219')]; dimer (226-226":229-229")-
                                      bisdisulfide


 plozalizumab                         immunoglobuline G1-kappa, anti-[Homo sapiens CCR2
                                      (récepteur 2 de chimiokine (C-C motif), récepteur 2 de
                                      chimiokine C-C, CC-CKR-2, CKR-2, récepteur de la
                                      protéine 1 chimio-attractive du monocyte, MCP-1-R,
                                      CD192)], anticorps monoclonal humanisé;
                                      chaîne lourde gamma1 (1-447) [VH humanisé (Homo
                                      sapiens IGHV3-73*01 (86.90%) -(IGHD)-IGHJ1*01)
                                      [8.10.8] (1-117) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (118-215), charnière (216-230), CH2 L1.2>A (235), G1>A
                                      (237) (231-340), CH3 (341-445), CHS (446-447)) (118-
                                      447)], (220-219')-disulfure avec la chaîne légère kappa (1’-
                                      219’) [V-KAPPA humanisé (Homo sapiens IGKV2-30*01
                                      (90.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens
                                      IGKC*01 (113'-219')]; dimère (226-226":229-229")-
                                      bisdisulfure


 plozalizumab                         inmunoglobulina G1-kappa, anti-[Homo sapiens CCR2
                                      (receptor 2 de quimiokina (C-C motif), receptor 2 de
                                      quimiokina C-C, CC-CKR-2, CKR-2, receptor de la
                                      proteína 1 quimioatrayente de monocitos, MCP-1-R,
                                      CD192)], anticuerpo monoclonal humanizado;
                                      cadena pesada gamma1 (1-447) [VH humanizada (Homo
                                      sapiens IGHV3-73*01 (86.90%) -(IGHD)-IGHJ1*01)
                                      [8.10.8] (1-117) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (118-215), bisagra (216-230), CH2 L1.2>A (235), G1>A
                                      (237) (231-340), CH3 (341-445), CHS (446-447)) (118-
                                      447)], (220-219')-disulfuro con la cadena ligera kappa (1’-
                                      219’) [V-KAPPA humanizado (Homo sapiens IGKV2-30*01
                                      (90.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens
                                      IGKC*01 (113'-219')]; dímero (226-226":229-229")-
                                      bisdisulfuro




                                                                                              143
Recommended INN: List 75                  WHO Drug Information Vol. 30, No. 1, 2016




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVKPGGSLRL SCAASGFTFS                    AYAMNWVRQA        PGKGLEWVGR           50
                           IRTKNNNYAT YYADSVKDRF TISRDDSKNT                    LYLQMNSLKT        EDTAVYYCTT          100
                           FYGNGVWGQG TLVTVSSAST KGPSVFPLAP                    SSKSTSGGTA        ALGCLVKDYF          150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                    SLSSVVTVPS        SSLGTQTYIC          200
                           NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                    APELAGAPSV        FLFPPKPKDT          250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                    GVEVHNAKTK        PREEQYNSTY          300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                    PIEKTISKAK        GQPREPQVYT          350
                           LPPSRDELTK NQVSLTCLVK GFYPSDIAVE                    WESNGQPENN        YKTTPPVLDS          400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                    ALHNHYTQKS        LSLSPGK             447

                           Light chain / Chaîne légère / Cadena ligera
                           DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL                    DSDGKTFLNW        FQQRPGQSPR 50
                           RLIYLVSKLD SGVPDRFSGS GSGTDFTLKI                    SRVEAEDVGV        YYCWQGTHFP 100
                           YTFGQGTRLE IKRTVAAPSV FIFPPSDEQL                    KSGTASVVCL        LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                    SSTLTLSKAD        YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                             219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-98          144-200       261-321 367-425
                                                 22''-98'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L (C23-C104) 23'-93'        139'-199'
                                                 23'''-93''' 139'''-199'''
                           Inter-H-L (h 5-CL 126) 220-219' 220''-219'''
                           Inter-H-H (h 11, h 14) 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           297, 297''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                           complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 ravidasvirum
 ravidasvir                methyl N-[(2S)-1-{(2S)-2-[5-(6-{2-[(2S)-1-{(2S)-2-
                           [(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-
                           2-yl]-1H-imidazol-4-yl}naphthalen-2-yl)-1H-benzimidazol-
                           2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate

 ravidasvir                N-[(2S)-1-{(2S)-2-[5-(6-{2-[(2S)-1-{(2S)-2-
                           [(méthoxycarbonyl)amino]-3-méthylbutanoyl}pyrrolidin-
                           2-yl]-1H-imidazol-4-yl}naphtalén-2-yl)-1H-benzimidazol-
                           2-yl]pyrrolidin-1-yl}-3-méthyl-1-oxobutan-2-yl]carbamate de
                           méthyle

 ravidasvir                N-[(2S)-1-{(2S)-2-[5-(6-{2-[(2S)-1-{(2S)-2-
                           [(metoxicarbonil)amino]-3-metilbutanoil}pirrolidin-2-il]-
                           1H-imidazol-4-il}naftalen-2-il)-1H-benzoimidazol-
                           2-il]pirrolidin-1-il}-3-metil-1-oxobutan-2-il]carbamato de
                           metilo

                           C42H50N8O6

                                               CH3
                                           O                                                         H
                                                                                                     N H
                            H3 C    HN         O
                                               O                                                     N         N
                            H3 C    H           H                                                        O
                                           N           N                                                             H
                                                                                                     O                     CH3
                                                       N                                                     NH
                                                       H                                             O               CH3
                                                                                                         CH3




144
WHO Drug Information Vol. 30, No. 1, 2016                                                    Recommended INN: List 75


 rinucumabum #
 rinucumab                            immunoglobulin G4-kappa, anti-[Homo sapiens PDGFRB
                                      (platelet-derived growth factor receptor beta subunit,
                                      PDGFR-1, CD140b)], human monoclonal antibody;
                                      gamma4 heavy chain (1-449) [Homo sapiens VH (IGHV4-
                                      39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.14] (1-122) -
                                      IGHG4*01 (CH1 (123-220), hinge S10>P (230) (221-232),
                                      CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-
                                      449)], (136-215')-disulfide with kappa light chain (1’-215’)
                                      [Homo sapiens (V-KAPPA (IGKV3-20*01 (91.70%) -
                                      IGKJ3*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')];
                                      dimer (228-228":231-231")-bisdisulfide

 rinucumab                            immunoglobuline G4-kappa, anti-[Homo sapiens PDGFRB
                                      (sous-unité bêta du récepteur du facteur de croissance
                                      dérivé des plaquettes, PDGFR-1, CD140b)], anticorps
                                      monoclonal humain;
                                      chaîne lourde gamma4 (1-449) [Homo sapiens VH
                                      (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.14] (1-
                                      122) -IGHG4*01 (CH1 (123-220), charnière S10>P (230)
                                      (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)
                                      (123-449)], (136-215')-disulfure avec la chaîne légère
                                      kappa (1’-215’) [Homo sapiens (V-KAPPA (IGKV3-20*01
                                      (91.70%) -IGKJ3*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-
                                      215')]; dimère (228-228":231-231")-bisdisulfure

 rinucumab                            inmunoglobulina G4-kappa, anti-[Homo sapiens PDGFRB
                                      (subunidad beta del receptor del factor de crecimiento
                                      derivado de plaquetas, PDGFR-1, CD140b)], anticuerpo
                                      monoclonal humano;
                                      cadena pesada gamma4 (1-449) [Homo sapiens VH
                                      (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.14] (1-
                                      122) -IGHG4*01 (CH1 (123-220), bisagra S10>P (230)
                                      (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)
                                      (123-449)], (136-215')-disulfuro con la cadena ligera kappa
                                      (1’-215’) [Homo sapiens (V-KAPPA (IGKV3-20*01
                                      (91.70%) -IGKJ3*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-
                                      215')]; dímero (228-228":231-231")-bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QLQLQESGPG LVKPSETLSL TCTVSGGSIT                         SSSYYWGWIR   QPPGKGLEWI           50
                                       GSIYYRGSTN YNPSLKSRVT ISVDSSKNQF                         YLKVSSVTAV   DTAVYYCARQ          100
                                       NGAARPSWFD PWGQGTLVTV SSASTKGPSV                         FPLAPCSRST   SESTAALGCL          150
                                       VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                         SSGLYSLSSV   VTVPSSSLGT          200
                                       KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP                         CPAPEFLGGP   SVFLFPPKPK          250
                                       DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY                         VDGVEVHNAK   TKPREEQFNS          300
                                       TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL                         PSSIEKTISK   AKGQPREPQV          350
                                       YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA                         VEWESNGQPE   NNYKTTPPVL          400
                                       DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM                         HEALHNHYTQ   KSLSLSLGK           449

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVLTQSPDT ISLSPGERAT LSCRASQSIS                         SIYLAWYQQK   PGQAPRLLIY 50
                                       GASSRVTGIP DRFSVSGSGT DFTLTISRLE                         PEDFAVYYCQ   HYGISPFTFG 100
                                       PGTKVDIRRT VAAPSVFIFP PSDEQLKSGT                         ASVVCLLNNF   YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                         TLSKADYEKH   KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                                 215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-97 149-205               263-323 369-427
                                                             22''-97'' 149''-205'' 263''-323'' 369''-427''
                                       Intra-L (C23-C104) 23'-89'        135'-195'
                                                             23'''-89''' 135'''-195'''
                                       Inter-H-L (CH1 10-CL 126) 136-215' 136''-215'''
                                       Inter-H-H (h 8, h 11)            228-228'' 231-231''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       299, 299''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

                                       Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                                       modificaciones post-traduccionales
                                       H CHS K2 C-terminal lysine clipping:
                                       449, 449''




                                                                                                                                         145
Recommended INN: List 75                     WHO Drug Information Vol. 30, No. 1, 2016


 risankizumabum #
 risankizumab              immunoglobulin G1-kappa, anti-[Homo sapiens IL23A
                           (interleukin 23 subunit alpha, IL-23A, IL23 subunit p19,
                           IL23p19)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-449) [humanized VH (Homo
                           sapiens IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01)
                           [8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (121-218), hinge (219-233), CH2 L1.3>A (237), L1.2>A
                           (238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-
                           449)], (223-214')-disulfide with kappa light chain (1’-214’)
                           [humanized V-KAPPA (Homo sapiens IGKV1-27*01
                           (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01, Km3 (108'-214')]; dimer (229-229":232-232")-
                           bisdisulfide

 risankizumab              immunoglobuline G1-kappa, anti-[Homo sapiens IL23A
                           (interleukine 23 sous-unité alpha, IL-23A, IL23 sous-unité
                           p19, IL23p19)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo
                           sapiens IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01)
                           [8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (121-218), charnière (219-233), CH2 L1.3>A (237), L1.2>A
                           (238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-
                           449)], (223-214')-disulfure avec la chaîne légère kappa (1’-
                           214’) [V-KAPPA humanisé (Homo sapiens IGKV1-27*01
                           (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01, Km3 (108'-214')]; dimère (229-229":232-232")-
                           bisdisulfure

 risankizumab              inmunoglobulina G1-kappa, anti-[Homo sapiens IL23A
                           (interleukina 23 subunidad alfa, IL-23A, IL23 subunidad
                           p19, IL23p19)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-449) [VH humanizado (Homo
                           sapiens IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01)
                           [8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (121-218), bisagra (219-233), CH2 L1.3>A (237), L1.2>A
                           (238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-
                           449)], (223-214')-disulfuro con la cadena ligera kappa (1’-
                           214’) [V-KAPPA humanizado (Homo sapiens IGKV1-27*01
                           (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01, Km3 (108'-214')]; dímero (229-229":232-232")-
                           bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGSSVKV SCKASGYTFT                  DQTIHWMRQA       PGQGLEWIGY        50
                           IYPRDDSPKY NENFKGKVTI TADKSTSTAY                  MELSSLRSED       TAVYYCAIPD       100
                           RSGYAWFIYW GQGTLVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                           YICNVNHKPS NTKVDKRVEP KSCDKTHTCP                  PCPAPEAAGG       PSVFLFPPKP       250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                           STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                           VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPG        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCKASRDVA                  IAVAWYQQKP       GKVPKLLIYW 50
                           ASTRHTGVPS RFSGSGSRTD FTLTISSLQP                  EDVADYFCHQ       YSSYPFTFGS 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96         147-203       264-324 370-428
                                                 22''-96'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L (C23-C104) 23'-88' 134'-194'
                                                23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 223-214' 223''-214'''
                           Inter-H-H (h 11, h 14) 229-229'' 232-232''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           300, 300''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                           complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




146
WHO Drug Information Vol. 30, No. 1, 2016                       Recommended INN: List 75




 rivabazumabum pegolum #
 rivabazumab pegol                    immunoglobulin Fab' G1-kappa pegylated, anti-
                                      [Pseudomonas aeruginosa type III secretion system
                                      (TTSS) PcrV protein], pegylated humanized monoclonal
                                      antibody;
                                      gamma1 heavy chain fragment VH-(CH1-hinge) (1-238)
                                      [humanized VH (Homo sapiens IGHV3-30*06 (92.90%) -
                                      (IGHD)-IGHJ6*01) [8.8.17] (1-124) -Homo sapiens
                                      IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237),
                                      CH2 (238)) (125-238)], noncovalently associated with
                                      kappa light chain (1’-214’) [humanized V-KAPPA (Homo
                                      sapiens IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -
                                      Homo sapiens IGKC*01 C126>S (214') (108'-214')];
                                      conjugated via a linker of the maleimide group (thioether
                                      bond with cysteinyl H h 11 (C233) and H h 14 (236)) to two
                                      linear chains of methoxy polyethylene glycol 30 (mPEG30).


 rivabazumab pégol                    immunoglobuline Fab' G1-kappa pégylé, anti-[protéine
                                      PcrV du système de sécrétion type III (TTSS) de
                                      Pseudomonas aeruginosa], anticorps monoclonal
                                      humanisé pégylé;
                                      fragment VH-(CH1-charnière) de la chaîne lourde gamma1
                                      (1-238) [VH humanisé (Homo sapiens IGHV3-30*06
                                      (92.90%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -Homo
                                      sapiens IGHG1*01 (CH1 (125-222), charnière C5>S (227)
                                      (223-237), CH2 (238)) (125-238)], associé de manière non
                                      covalente avec la chaîne légère kappa (1’-214’) [V-KAPPA
                                      humanisé (Homo sapiens IGKV1-5*01 (84.60%) -
                                      IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                      C126>S (214') (108'-214')]; conjugué via un linker du
                                      groupe maléimide (liaison thioéther avec les cystéinyl H h
                                      11 (C233) et H h 14 (C236)) à deux chaînes linéaires de
                                      méthoxy polyéthylène glycol 30 (mPEG30).


 rivabazumab pegol                    inmunoglobulina Fab' G1-kappa pegilada, anti-[proteína
                                      PcrV del sistema de secreción tipo III (TTSS) de
                                      Pseudomonas aeruginosa], anticuerpo monoclonal
                                      humanizado pegilado;
                                      fragmento VH-(CH1-bisagra) de la cadena ligera gamma1
                                      (1-238) [VH humanizado (Homo sapiens IGHV3-30*06
                                      (92.90%) -(IGHD)-IGHJ6*01) [8.8.117] (1-124) -Homo
                                      sapiens IGHG1*01 (CH1(125-222), bisagra C5>S (227)
                                      (223-237), CH2 (238)) (125-238)], asociado de modo no
                                      covalente con la cadena ligera kappa (1’-214’) [V-KAPPA
                                      humanizado (Homo sapiens IGKV1-5*01 (84.60%) -
                                      IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                      C126>S (214') (108'-214')]; conjugado mediante un
                                      espaciador del grupo maleimida (unión tioéter con los
                                      cisteinil H h 11 (C233) et H h 14 (C236)) con dos cadenas
                                      lineales de metoxi polietilen glicol 30 (mPEG30).




                                                                                            147
Recommended INN: List 75                 WHO Drug Information Vol. 30, No. 1, 2016




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG VVQPGRSLRL SCAASGFTFS                  NYPMHWVRQA       PGKGLEWVAV 50
                           ISYDGSEKWY ADSVKGRFTI SRDNSKNTLY                  LEMNSLRPED       TAVYYCARNR 100
                           GDIYYDFTYA MDIWGQGTTV TVSSASTKGP                  SVFPLAPSSK       STSGGTAALG 150
                           CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL 200
                           GTQTYICNVN HKPSNTKVDK KVEPKSSDKT                  HTCPPCPA                    238

                           Light chain / Chaîne légère / Cadena ligera
                           DIQLTQSPST LSASVGDSVT ITCRASEGVD                  RWLAWYQQKP       GRAPKLLIYD 50
                           ASTLQSGVPS RFSGSGSGTE FSLTISSLQP                  DDVATYYCQH       FWGTPYTFGQ 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGES                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96 151-207
                           Intra-L (C23-C104) 23'-88' 134'-194'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           None

                           Pegylation site / Site de pegylation / Posiciones de pegilación
                           H hinge h 11, h 14
                           C233, C236




 ronopterinum
 ronopterin                (1R,2S)-1-[(6RS)-2,4-diamino-5,6,7,8-tetrahydropteridin-
                           6-yl]propane-1,2-diol

 ronoptérine               (1R,2S)-1-[(6RS)-2,4-diamino-5,6,7,8-tétrahydroptéridin-
                           6-yl]propane-1,2-diol

 ronopterina               (1R,2S)-1-[(6RS)-2,4-diamino-5,6,7,8-tetrahidropteridin-
                           6-il]propano-1,2-diol

                           C9H16N6O2

                                         NH2          H       OH
                                                  H H
                                                  N                  CH3       and epimer at C*
                                    N                                          et l'épimère en C*
                                                    *
                                                                               y el epímero al C*
                                                           HO      H
                            H2 N         N        N
                                                  H




 rovalpituzumabum #
 rovalpituzumab            immunoglobulin G1-kappa, anti-[Homo sapiens DLL3
                           (delta-like ligand 3)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-447) [humanized VH (Homo
                           sapiens IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01)
                           [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (119-216), hinge (217-231), CH2 (232-341), CH3 (342-
                           446), CHS K2>del (447)) (119-447)], (221-214')-disulfide
                           with kappa light chain (1’-214’) [humanized V-KAPPA
                           (Homo sapiens IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                           (227-227":230-230")-bisdisulfide




148
WHO Drug Information Vol. 30, No. 1, 2016                                              Recommended INN: List 75




 rovalpituzumab                       immunoglobuline G1-kappa, anti-[Homo sapiens DLL3
                                      (delta-like ligand 3)], anticorps monoclonal humanisé;
                                      chaîne lourde gamma1 (1-447) [VH humanisé (Homo
                                      sapiens IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01)
                                      [8.8.11] (1-118) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                      (119-216), charnière (217-231), CH2 (232-341), CH3 (342-
                                      446), CHS K2>del (447)) (119-447)], (221-214')-disulfure
                                      avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé
                                      (Homo sapiens IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9]
                                      (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                                      dimère (227-227":230-230")-bisdisulfure


 rovalpituzumab                       inmunoglobulina G1-kappa, anti-[Homo sapiens DLL3
                                      (delta-like ligando 3)], anticuerpo monoclonal humanizado;
                                      cadena pesada gamma1 (1-447) [VH humanizado (Homo
                                      sapiens IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01)
                                      [8.8.11] (1-118) -Homo sapiens IGHG1*01 G1m17,1 (CH1
                                      (119-216), bisagra(217-231), CH2 (232-341), CH3 (342-
                                      446), CHS K2>del (447)) (119-447)], (221-214')-disulfuro
                                      con la cadena ligera kappa (1’-214’) [V-KAPPA
                                      humanizado (Homo sapiens IGKV3-15*01 (87.40%) -
                                      IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                      (108'-214')]; dímero (227-227":230-230")-bisdisulfuro


                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT                         NYGMNWVRQA   PGQGLEWMGW        50
                                       INTYTGEPTY ADDFKGRVTM TTDTSTSTAY                         MELRSLRSDD   TAVYYCARIG       100
                                       DSSPSDYWGQ GTLVTVSSAS TKGPSVFPLA                         PSSKSTSGGT   AALGCLVKDY       150
                                       FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                         YSLSSVVTVP   SSSLGTQTYI       200
                                       CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                         PAPELLGGPS   VFLFPPKPKD       250
                                       TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                         DGVEVHNAKT   KPREEQYNST       300
                                       YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                         APIEKTISKA   KGQPREPQVY       350
                                       TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                         EWESNGQPEN   NYKTTPPVLD       400
                                       SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                         EALHNHYTQK   SLSLSPG          447

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVMTQSPAT LSVSPGERAT LSCKASQSVS                         NDVVWYQQKP   GQAPRLLIYY 50
                                       ASNRYTGIPA RFSGSGSGTE FTLTISSLQS                         EDFAVYYCQQ   DYTSPWTFGQ 100
                                       GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                         SVVCLLNNFY   PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                         LSKADYEKHK   VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                  214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96         145-201 262-322        368-426
                                                             22''-96'' 145''-201'' 262''-322'' 368''-426''
                                       Intra-L (C23-C104) 23'-88'        134'-194'
                                                            23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 221-214' 221''-214'''
                                       Inter-H-H (h 11, h 14) 227-227'' 230-230''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       298, 298''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
                                       fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




                                                                                                                                149
Recommended INN: List 75                 WHO Drug Information Vol. 30, No. 1, 2016




 rovalpituzumabum tesirinum #
 rovalpituzumab tesirine        immunoglobulin G1-kappa, anti-[Homo sapiens DLL3
                                (delta-like ligand 3)], humanized monoclonal antibody
                                conjugated to the pyrrolobenzodiazepine (PBD) dimer
                                SCX;
                                gamma1 heavy chain (1-447) [humanized VH (Homo
                                sapiens IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01)
                                [8.8.11] (1-118) -Homo sapiens IGHG1*01 G1m17,1 (CH1
                                (119-216), hinge (217-231), CH2 (232-341), CH3 (342-
                                446), CHS K2>del (447)) (119-447)], (221-214')-disulfide
                                with kappa light chain (1’-214’) [humanized V-KAPPA
                                (Homo sapiens IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9]
                                (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                                (227-227":230-230")-bisdisulfide; conjugated, on an
                                average of 2 cysteines, to the pyrrolobenzodiazepine
                                (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide
                                as cathepsine B cleavage site) maleimide type linker
                                containing a spacer PEG (n=8)

 rovalpituzumab tésirine        immunoglobuline G1-kappa, anti-[Homo sapiens DLL3
                                (delta-like ligand 3)], anticorps monoclonal humanisé
                                conjugué au dimère de pyrrolobenzodiazépine (PDB) SCX;
                                chaîne lourde gamma1 (1-447) [VH humanisé (Homo
                                sapiens IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01)
                                [8.8.11] (1-118) -Homo sapiens IGHG1*01 G1m17,1 (CH1
                                (119-216), charnière (217-231), CH2 (232-341), CH3 (342-
                                446), CHS K2>del (447)) (119-447)], (221-214')-disulfure
                                avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé
                                (Homo sapiens IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9]
                                (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                                dimère (227-227":230-230")-bisdisulfure; conjugué, sur 2
                                cystéines en moyenne, au dimère de
                                pyrrolobenzodiazépine (PBD) SCX, via un linker clivable
                                (dipeptide valine-alanine clivable par la cathepsine B) de
                                type maléimide et comprenant un espaceur PEG (n=8)

 rovalpituzumab tesirina        inmunoglobulina G1-kappa, anti-[Homo sapiens DLL3
                                (delta-like ligando 3)], anticuerpo monoclonal humanizado
                                conjugado con el dímero de pirrolobenzodiazepina (PDB)
                                SCX;
                                cadena pesada gamma1 (1-447) [VH humanizado (Homo
                                sapiens IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01)
                                [8.8.11] (1-118) -Homo sapiens IGHG1*01 G1m17,1 (CH1
                                (119-216), bisagra(217-231), CH2 (232-341), CH3 (342-
                                446), CHS K2>del (447)) (119-447)], (221-214')-disulfuro
                                con la cadena ligera kappa (1’-214’) [V-KAPPA
                                humanizado (Homo sapiens IGKV3-15*01 (87.40%) -
                                IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                (108'-214')]; dímero (227-227":230-230")-bisdisulfuro;
                                conjugado, en una media de 2 cisteinas, al dímero de
                                pirrolobenzodiazepina (PBD) SCX, mediante un
                                espaciador escindible (dipéptido valina-alanina escindible
                                por la catepsina B) de tipo maleimida que comprende un
                                espaciador PEG (n=8)




150
WHO Drug Information Vol. 30, No. 1, 2016                                                    Recommended INN: List 75



                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT                           NYGMNWVRQA      PGQGLEWMGW           50
                                       INTYTGEPTY ADDFKGRVTM TTDTSTSTAY                           MELRSLRSDD      TAVYYCARIG          100
                                       DSSPSDYWGQ GTLVTVSSAS TKGPSVFPLA                           PSSKSTSGGT      AALGCLVKDY          150
                                       FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                           YSLSSVVTVP      SSSLGTQTYI          200
                                       CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                           PAPELLGGPS      VFLFPPKPKD          250
                                       TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                           DGVEVHNAKT      KPREEQYNST          300
                                       YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                           APIEKTISKA      KGQPREPQVY          350
                                       TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                           EWESNGQPEN      NYKTTPPVLD          400
                                       SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                           EALHNHYTQK      SLSLSPG             447

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVMTQSPAT LSVSPGERAT LSCKASQSVS                           NDVVWYQQKP      GQAPRLLIYY 50
                                       ASNRYTGIPA RFSGSGSGTE FTLTISSLQS                           EDFAVYYCQQ      DYTSPWTFGQ 100
                                       GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                           SVVCLLNNFY      PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                           LSKADYEKHK      VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                       214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          145-201 262-322        368-426
                                                             22''-96'' 145''-201'' 262''-322'' 368''-426''
                                       Intra-L (C23-C104) 23'-88'        134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126)* 221-214' 221''-214'''
                                       Inter-H-H (h 11, h 14)* 227-227'' 230-230''
                                       *One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being
                                       conjugated each via a thioether bond to a drug linker.
                                       *Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun
                                       conjugué via une liaison thioéther à un linker-principe actif.
                                       *Faltan uno o dos puentes disulfuro inter-catenarios, una media de 2 cisteinil está conjugada a conectores
                                       de principio activo.

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       298, 298''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
                                       fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

                                       Potential modified residues / Résidus modifies potentiels / Restos modificados potenciales
                                         C 214',214''' ; 221,221'' ; 227,227'' ; 230,230''           "S-tesirine Cysteine"
                                                                        O                                               O
                                                   H3C                                                                                CH3
                                                                    N              OCH3              H3CO                    N

                                                               H                                                                  H
                                                                O       N          O                        O           N        OH
                                                                                       and epimer at C*                      H
                                                                                       et l'épimère en C*           O       O
                                                           
                                                                N           O
                                                  H                                    y el epímero al C*
                                                       S                    HN                O
                                                               O
                                                   H
                                                                                     O             Val Ala N
                                                                                                           H
                                               H2N         CO2H                               8



 sacituzumabum govitecanum #
 sacituzumab govitecan                immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2
                                      (tumor-associated calcium signal transducer 2, membrane
                                      component chromosome 1 surface marker 1, M1S1,
                                      gastrointestinal tumor-associated antigen GA7331,
                                      pancreatic carcinoma marker protein GA733-1, epithelial
                                      glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface
                                      glycoprotein Trop-2, TROP2)], humanized monoclonal
                                      antibody conjugated to 7-ethyl-10-hydroxycamptothecin
                                      (SN-38), active metabolite of irinotecan;
                                      gamma1 heavy chain (1-451) [humanized VH (Homo
                                      sapiens IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01)
                                      [8.8.14] (1-121) -Homo sapiens IGHG1*03, Gm3 (CH1
                                      (122-219), hinge (220-234), CH2 (235-344), CH3 (345-
                                      449), CHS (450-451)) (122-451)], (224-214')-disulfide with
                                      kappa light chain (1’-214’) [humanized V-KAPPA (Homo
                                      sapiens IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -
                                      Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (230-
                                      230":233-233")-bisdisulfide; conjugated, on an average of
                                      6 cysteinyl, to 7-ethyl-10-hydroxycamptothecin (SN-38),
                                      active metabolite of irinotecan (CPT-11, camptothecin-
                                      11),via a maleimide-type cleavable linker (carbonate
                                      group, self-immolative 4-aminobenzyl alcohol and
                                      cathepsine-B-cleavable dipeptide Phe-Lys) and containing
                                      a triazoline group and a spacer PEG (n=8).




                                                                                                                                                    151
Recommended INN: List 75            WHO Drug Information Vol. 30, No. 1, 2016




 sacituzumab govitecan     immunoglobuline G1-kappa, anti-[Homo sapiens
                           TACSTD2 (transducteur 2 de signaux calciques associé
                           aux tumeurs, composant membranaire du chromosome 1
                           marqueur de surface 1, M1S1, antigène GA7331 associé
                           aux tumeurs gastrointestinales, protéine GA733-1
                           marqueur de carcinomes pancréatiques, glycoprotéine
                           épithéliale 1, EGP-1, antigène 2 du trophoblaste,
                           glycoprotéine Trop-2 à la surface des cellules, TROP2)],
                           anticorps monoclonal humanisé conjugué à la 7-éthyl-
                           10-hydroxycamptothécine (SN-38), métabolite actif de
                           l’irinotécan;
                           chaîne lourde gamma1 (1-451) [VH humanisé (Homo
                           sapiens IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01)
                           [8.8.14] (1-121) -Homo sapiens IGHG1*03, Gm3 (CH1
                           (122-219), charnière (220-234), CH2 (235-344), CH3 (345-
                           449), CHS (450-451)) (122-451)], (224-214')-disulfure avec
                           la chaîne légère kappa (1’-214’) [V-KAPPA humanisé
                           (Homo sapiens IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           dimère (230-230":233-233")-bisdisulfure; conjugué, sur 6
                           cystéinyl en moyenne, à la 7-éthyl-10-
                           hydroxycamptothécine (SN-38), métabolite actif de
                           l’irinotécan (CPT-11, camptothécine-11),via un linker de
                           type maléimide, clivable (liaison carbonate et
                           4-aminobenzyl alcool et dipeptide Phe-Lys clivable par la
                           cathepsine B) et comprenant un groupe triazoline et un
                           espaceur PEG (n=8)

 sacituzumab govitecán     inmunoglobulina G1-kappa, anti-[Homo sapiens TACSTD2
                           (transductor 2 de señales de calcio asociado a los
                           tumores, componente de membrana del cromosoma 1
                           marcador de superficie 1, M1S1, antígeno GA7331
                           asociado a tumores gastrointestinales, proteína GA733-1
                           marcador de carcinomes pancreáticos glicoproteína
                           epitelial 1, EGP-1, antígeno 2 de trofoblasto, glicoproteína
                           Trop-2 de la superficie celular, TROP2)], anticuerpo
                           monoclonal humanizado conjugado con la 7-etil-
                           10-hidroxicamptotecina (SN-38), metabolito activo del
                           irinotecán;
                           cadena pesada gamma1 (1-451) [VH humanizado (Homo
                           sapiens IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01)
                           [8.8.14] (1-121) -Homo sapiens IGHG1*03, Gm3 (CH1
                           (122-219), bisagra(220-234), CH2 (235-344), CH3 (345-
                           449), CHS (450-451)) (122-451)], (224-214')-disulfuro con
                           la cadena ligera kappa (1’-214’) [V-KAPPA humanizado
                           (Homo sapiens IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           dímero (230-230":233-233")-bisdisulfuro; conjugado, en
                           una media de 6 restos cisteinil, con la 7-etil-
                           10-hidroxicamptotecina (SN-38), metabolito activo del
                           irinotecán (CPT-11, camptotecina-11), mediante un
                           espaciadorde tipo maleimida, escindible (enlace carbonato
                           y 4-aminobencil alcohol y dipéptido Phe-Lys escindible por
                           catepsina B) y que comprende un grupo triazolina y un
                           espaciador PEG (n=8).




152
WHO Drug Information Vol. 30, No. 1, 2016                                                 Recommended INN: List 75



                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLQQSGSE LKKPGASVKV SCKASGYTFT                           NYGMNWVKQA                    PGQGLKWMGW            50
                                       INTYTGEPTY TDDFKGRFAF SLDTSVSTAY                           LQISSLKADD                    TAVYFCARGG           100
                                       FGSSYWYFDV WGQGSLVTVS SASTKGPSVF                           PLAPSSKSTS                    GGTAALGCLV           150
                                       KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                           SGLYSLSSVV                    TVPSSSLGTQ           200
                                       TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                           PPCPAPELLG                    GPSVFLFPPK           250
                                       PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                           WYVDGVEVHN                    AKTKPREEQY           300
                                       NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                           ALPAPIEKTI                    SKAKGQPREP           350
                                       QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                           IAVEWESNGQ                    PENNYKTTPP           400
                                       VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                           VMHEALHNHY                    TQKSLSLSPG           450
                                       K                                                                                                             451

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQLTQSPSS LSASVGDRVS ITCKASQDVS                           IAVAWYQQKP                    GKAPKLLIYS 50
                                       ASYRYTGVPD RFSGSGSGTD FTLTISSLQP                           EDFAVYYCQQ                    HYITPLTFGA 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                           SVVCLLNNFY                    PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                           LSKADYEKHK                    VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                                     214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          148-204       265-325 371-429
                                                              22''-96'' 148''-204'' 265''-325'' 371''-429''
                                       Intra-L (C23-C104) 23'-88' 134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) * 224-214' 224''-214'''
                                       Inter-H-H (h 11, h 14) * 230-230'' 233-233''
                                       *Three of the inter-chain disulfide bridges are not present, an average of 6 cysteinyl being conjugated
                                       each via a thioether bond to a drug linker.
                                       *Trois des ponts disulfures inter-chaînes ne sont pas présents, 6 cystéinyl en moyenne étant chacun
                                       conjugué via une liaison thioéther à un linker-principe actif.
                                       *Faltan tres puentes disulfuro inter-catenarios, una media de 6 cisteinil está conjugada a conectores de
                                       principio activo.

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       301, 301''
                                       Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires
                                       complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

                                       Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales

                                                                                                      O
                                                                                       CH3                                       H2 N    CO2H
                                                        C*
                                                                                                  N                   O              H       S
                                               214'-214'''-224-224''-
                                                230-230''-233-233''                                                       O
                                                                                              N                                          O             O
                                                                             HO                               O           CH3                    N
                                         * an average of 6 are substituted
                                         * en moyenne, 6 sont substitués
                                         * una media de 6 está sustituída                                 O       O
                                                                             O                                                  O
                                                                                  Lys N                               N    N
                                                                                      H   H
                                                                                          N                       N                 NH
                                                                                  O                   O           8
                                                                                      O



 sacubitrilatum
 sacubitrilat                         (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(3-carboxypropanamido)-
                                      2-methylpentanoic acid

 sacubitrilate                        acide (2R,4S)-5-([1,1'-biphényl]-4-yl)-
                                      4-(3-carboxypropanamido)-2-méthylpentanoïque

 sacubitrilat                         ácido (2R,4S)-5-([1,1'-bifenil]-4-il)-
                                      4-(3-carboxipropanamido)-2-metilpentanoico

                                       C22H25NO5

                                                                        H
                                       HO2C                             N                     CO2H

                                             H3C        H H                  O




                                                                                                                                                           153
Recommended INN: List 75               WHO Drug Information Vol. 30, No. 1, 2016




 selonsertibum
 selonsertib               5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-
                           N-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-
                           2-yl}benzamide

 sélonsertib               5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-méthyl-
                           N-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-
                           2-yl}benzamide

 selonsertib               5-(4-ciclopropil-1H-imidazol-1-il)-2-fluoro-4-metil-N-{6-[4-
                           (propan-2-il)-4H-1,2,4-triazol-3-il]piridin-2-yl}benzamida

                           C24H24FN7O



                                                                       H3C
                                                   O                              CH3
                              N
                                       N                                     N
                                                       N         N
                                                       H
                                                                           N N
                                   H3 C            F



 solnatidum
 solnatide                 L-cysteinylglycyl-[human tumor necrosis factor, membrane
                           form-(178-191)-peptidyl]-L-cysteine, cyclic (1→17)-disulfide
                           or
                           L-cysteinylglycyl-[human tumor necrosis factor, soluble
                           form-(102-115)-peptidyl]-L-cysteine, cyclic (1→17)-disulfide

 solnatide                 (1→17)-disulfure cyclique de L-cystéinylglycyl-[forme
                           membranaire du facteur de nécrose tumorale humain-
                           (178-191)-peptidyl]-L-cystéine
                           ou
                           (1→17)-disulfure cyclique de L-cystéinylglycyl-[forme
                           soluble du facteur de nécrose tumorale humain-(102-115)-
                           peptidyl]-L-cystéine

 solnatida                 (1→17)-disulfuro cíclico de L-cisteinilglicil-[forma de
                           membrana del factor de necrosis tumoral humano-(178-
                           191)-peptidil]-L-cisteina
                           o
                           (1→17)-disulfuro cíclico de L-cisteinilglicil-[forma soluble
                           del factor de necrosis tumoral humano-(102-115)-peptidil]-
                           L-cisteina

                           C82H119N23O27S2

                            H Cys      Gly   Gln   Arg     Glu       Thr    Pro   Glu   Gly

                               Ala     Glu   Ala   Lys     Pro       Trp   Tyr    Cys OH
                                  10                                              17




154
WHO Drug Information Vol. 30, No. 1, 2016                                      Recommended INN: List 75


 sparsentanum
 sparsentan                           4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-
                                      N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)[1,1'-
                                      biphenyl]-2-sulfonamide

 sparsentan                           4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-én-3-yl)méthyl]-
                                      N-(4,5-diméthyl-1,2-oxazol-3-yl)-2'-(éthoxyméthyl)[1,1'-
                                      biphényle]-2-sulfonamide

 esparsentán                          4'-[(2-butil-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-il)metil]-
                                      N-(4,5-dimetil-1,2-oxazol-3-il)-2'-(etoximetil)[1,1'-bifenilo]-
                                      2-sulfonamida

                                       C32H40N4O5S

                                       H3C                                                           CH3
                                                                                       O       H
                                                                                               N
                                                          N                        O       S               CH3
                                                  N
                                                                                                   N O
                                                              O

                                                       H3C        O


 tavilermidum
 tavilermide                          3-{(4S,7S,10S)-7-(4-aminobutyl)-
                                      4-[(carboxymethyl)carbamoyl]-14-nitro-6,9,12-trioxo-
                                      3,4,5,6,7,8,9,10,11,12-decahydro-2H-1,5,8,11-
                                      benzoxatriazacyclotetradecin-10-yl}propanoic acid

 tavilermide                          acide 3-{(4S,7S,10S)-7-(4-aminobutyl)-
                                      4-[(carboxyméthyl)carbamoyl]-14-nitro-6,9,12-trioxo-
                                      3,4,5,6,7,8,9,10,11,12-décahydro-2H-1,5,8,11-
                                      benzoxatriazacyclotétradécin-10-yl}propanoïque

 tavilermida                          ácido 3-{(4S,7S,10S)-7-(4-aminobutil)-
                                      4-[(carboximetil)carbamoil]-14-nitro-6,9,12-trioxo-
                                      3,4,5,6,7,8,9,10,11,12-decahidro-2H-1,5,8,11-
                                      benzoxatriazaciclotetradecin-10-il}propanoico

                                       C24H32N6O11

                                               O2N


                                                                      O
                                                                          H                H
                                                                                           N       CO2H
                                                     HN       O           HN
                                       HO2C
                                                              H
                                                              N                    O
                                                                               O
                                                   H
                                                          O       H                        NH2


 tegoprazanum
 tegoprazan                           7-{[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-
                                      4-yl]oxy}-N,N,2-trimethyl-1H-benzimidazole-5-carboxamide

 tégoprazan                           7-{[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-
                                      4-yl]oxy}-N,N,2-triméthyl-1H-benzimidazole-5-carboxamide




                                                                                                                 155
Recommended INN: List 75               WHO Drug Information Vol. 30, No. 1, 2016



 tegoprazán                7-{[(4S)-5,7-difluoro-3,4-dihidro-2H-1-benzopiran-4-il]oxi}-
                           N,N,2-trimetil-1H-benzoimidazol-5-carboxamida

                           C20H19F2N3O3

                                      H3 C
                                             N
                                       HN
                                                         CH3
                                        H
                            O                            N
                                        O                    CH3

                                        F            O


                            F

 tesevatinibum
 tesevatinib               N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-
                           7-{[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-
                           5-yl]methoxy}quinazolin-4-amine

 tésévatinib               N-(3,4-dichloro-2-fluorophényl)-6-méthoxy-
                           7-{[(3aR,5r,6aS)-2-méthyloctahydrocyclopenta[c]pyrrol-
                           5-yl]méthoxy}quinazolin-4-amine

 tesevatinib               N-(3,4-dicloro-2-fluorofenil)- 7-{[(3aR,5r,6aS)-2-
                           metiloctahidrociclopenta[c]pirrol-5-il]metoxi}-6-metoxi-
                           quinazolin-4-amina

                           C24H25Cl2FN4O2

                                         H
                                                 H
                            H3C   N                  O              N

                                         H                              N
                                                 H3CO                       F
                                                                   HN           Cl


                                                                                Cl

 tezepelumabum #
 tezepelumab               immunoglobulin G2-lambda, anti-[Homo sapiens TSLP
                           (thymic stromal lymphopoietin)], Homo sapiens monoclonal
                           antibody;
                           gamma2 heavy chain (1-448) [Homo sapiens VH (IGHV3-
                           33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -
                           IGHG2*01, G2m.. (CH1 (123-220), hinge (221-232), CH2
                           (233-341), CH3 (342-446), CHS (447-448)) (123-448)],
                           (136-213')-disulfide with lambda light chain (1'-214’) [Homo
                           sapiens V-LAMBDA (IGLV3-21*02 (96.90%) -IGLJ2*01)
                           [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimer (224-
                           224'':225-225'':228-228'':231-231'')-tetrakisdisulfide




156
WHO Drug Information Vol. 30, No. 1, 2016                                              Recommended INN: List 75


 tézépelumab                          immunoglobuline G2-lambda, anti-[Homo sapiens TSLP
                                      (lymphopoïétine stromale thymique)], Homo sapiens
                                      anticorps monoclonal;
                                      chaîne lourde gamma2 (1-448) [Homo sapiens VH
                                      (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-
                                      122) -IGHG2*01, G2m.. (CH1 (123-220), charnière (221-
                                      232), CH2 (233-341), CH3 (342-446), CHS (447-448))
                                      (123-448)], (136-213')-disulfure avec la chaîne légère
                                      lambda (1'-214’) [Homo sapiens V-LAMBDA (IGLV3-21*02
                                      (96.90%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-
                                      214')]; dimère (224-224'':225-225'':228-228'':231-231'')-
                                      tétrakisdisulfure

 tezepelumab                          inmunoglobulina G2-lambda, anti-[Homo sapiens TSLP
                                      (linfopoyetina estromal tímica)], Homo sapiens anticuerpo
                                      monoclonal;
                                      cadena pesada gamma2 (1-448) [Homo sapiens VH
                                      (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-
                                      122) -IGHG2*01, G2m.. (CH1 (123-220),bisagra (221-232),
                                      CH2 (233-341), CH3 (342-446), CHS (447-448)) (123-
                                      448)], (136-213')-disulfuro con la cadena ligera lambda (1'-
                                      214’) [Homo sapiens V-LAMBDA (IGLV3-21*02 (96.90%) -
                                      IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero
                                      (224-224'':225-225'':228-228'':231-231'')-tetrakisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QMQLVESGGG VVQPGRSLRL SCAASGFTFR                          TYGMHWVRQA         PGKGLEWVAV           50
                                       IWYDGSNKHY ADSVKGRFTI TRDNSKNTLN                          LQMNSLRAED         TAVYYCARAP          100
                                       QWELVHEAFD IWGQGTMVTV SSASTKGPSV                          FPLAPCSRST         SESTAALGCL          150
                                       VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                          SSGLYSLSSV         VTVPSSNFGT          200
                                       QTYTCNVDHK PSNTKVDKTV ERKCCVECPP                          CPAPPVAGPS         VFLFPPKPKD          250
                                       TLMISRTPEV TCVVVDVSHE DPEVQFNWYV                          DGVEVHNAKT         KPREEQFNST          300
                                       FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP                          APIEKTISKT         KGQPREPQVY          350
                                       TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                          EWESNGQPEN         NYKTTPPMLD          400
                                       SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                          EALHNHYTQK         SLSLSPGK            448

                                       Light chain / Chaîne légère / Cadena ligera
                                       SYVLTQPPSV SVAPGQTARI TCGGNNLGSK                          SVHWYQQKPG         QAPVLVVYDD 50
                                       SDRPSWIPER FSGSNSGNTA TLTISRGEAG                          DEADYYCQVW         DSSSDHVVFG 100
                                       GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN                          KATLVCLISD         FYPGAVTVAW 150
                                       KADSSPVKAG VETTTPSKQS NNKYAASSYL                          SLTPEQWKSH         RSYSCQVTHE 200
                                       GSTVEKTVAP TECS                                                                         214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96           149-205 262-322        368-426
                                                              22''-96'' 149''-205'' 262''-322'' 368''-426''
                                       Intra-L (C23-C104) 22'-87' 136'-195'
                                                              22'''-87''' 136'''-195'''
                                       Inter-H-L (CH1 10-CL 126) 136-213' 136''-213'''
                                       Inter-H-H (h 4, h 5, h 8, h 11) 224-224'' 225-225'' 228-228'' 231-231''
                                       *In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 224-136'' and
                                       an inter-H-L (h 4- CL 126) 224''-213''', instead of the inter-H-H (h 4 - h 4) 224-224'' and of one of the two
                                       inter-H-L (CH1 10-CL 126) 136''-213'''.
                                       *En plus de l'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 224-136'' et un
                                       inter-H-L (h 4- CL 126) 224''-213''', au lieu de l'inter-H-H (h 4 - h 4) 224-224'' et de l'un des deux
                                       inter-H-L (CH1 10-CL 126) 136''-213'''.
                                       * además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h 4 - CH1 10) 224-136'' y un
                                       inter-H-L (h 4- CL 126) 224''-213''', en lugar del inter-H-H (h 4 - h 4) 224-224'' y uno de los dos
                                       inter-H-L (CH1 10-CL 126) 136''-213'''.

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       298, 298''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de typeCHO bi-antennaires complexes
                                       fucosylés / glicanosde tipo CHO biantenarios complejos fucosilados




 tisotumabum #
 tisotumab                            immunoglobulin G1-kappa, anti-[Homo sapiens F3
                                      (coagulation factor III (thromboplastin, tissue factor),
                                      CD142)], Homo sapiens monoclonal antibody;




                                                                                                                                           157
Recommended INN: List 75                   WHO Drug Information Vol. 30, No. 1, 2016




                           gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-
                           23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -
                           IGHG1*03, G1m3 (CH1 (119-216), hinge (217-231), CH2
                           (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                           (221-214')-disulfide with kappa light chain (1'-214') [Homo
                           sapiens V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01)
                           [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (227-
                           227'':230-230'')-bisdisulfide

 tisotumab                 immunoglobuline G1-kappa, anti-[Homo sapiens F3
                           (facteur de coagulation III (thromboplastine, facteur
                           tissulaire), CD142)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-448) [Homo sapiens VH
                           (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-
                           118) -IGHG1*03, G1m3 (CH1 (119-216), charnière (217-
                           231), CH2 (232-341), CH3 (342-446), CHS (447-448))
                           (119-448)], (221-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01
                           (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                           214')]; dimère (227-227'':230-230'')-bisdisulfure

 tisotumab                 inmunoglobulina G1-kappa, anti-[Homo sapiens F3 (factor
                           de coagulación III (tromboplastina, factor tisular), CD142)],
                           Homo sapiens anticuerpo monoclonal ;
                           cadena pesada gamma1 (1-448) [Homo sapiens VH
                           (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-
                           118) -IGHG1*03, G1m3 (CH1 (119-216), bisagra (217-
                           231), CH2 (232-341), CH3 (342-446), CHS (447-448))
                           (119-448)], (221-214')-disulfuro con la cadena ligera kappa
                           (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01
                           (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                           214')]; dímero (227-227'':230-230'')-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLLESGGG LVQPGGSLRL SCAASGFTFS                         NYAMSWVRQA   PGKGLEWVSS           50
                           ISGSGDYTYY TDSVKGRFTI SRDNSKNTLY                         LQMNSLRAED   TAVYYCARSP          100
                           WGYYLDSWGQ GTLVTVSSAS TKGPSVFPLA                         PSSKSTSGGT   AALGCLVKDY          150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                         YSLSSVVTVP   SSSLGTQTYI          200
                           CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC                         PAPELLGGPS   VFLFPPKPKD          250
                           TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                         DGVEVHNAKT   KPREEQYNST          300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                         APIEKTISKA   KGQPREPQVY          350
                           TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                         EWESNGQPEN   NYKTTPPVLD          400
                           SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                         EALHNHYTQK   SLSLSPGK            448

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPPS LSASAGDRVT ITCRASQGIS                         SRLAWYQQKP   EKAPKSLIYA 50
                           ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                         EDFATYYCQQ   YNSYPYTFGQ 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                         SVVCLLNNFY   PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                         LSKADYEKHK   VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                                  214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96 145-201               262-322  368-426
                                                 22''-96'' 145''-201'' 262''-322'' 368''-426''
                           Intra-L (C23-C104) 23'-88' 134'-194'
                                                23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 221-214' 221''-214'''
                           Inter-H-H (h 11, h 14) 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           298, 298''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                           complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




158
WHO Drug Information Vol. 30, No. 1, 2016                                 Recommended INN: List 75




 tisotumabum vedotinum #
 tisotumab vedotin                    immunoglobulin G1-kappa, anti-[Homo sapiens F3
                                      (coagulation factor III (thromboplastin, tissue factor),
                                      CD142)], Homo sapiens monoclonal antibody conjugated
                                      to auristatin E;
                                      gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-
                                      23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -
                                      IGHG1*03, G1m3 (CH1 (119-216), hinge (217-231), CH2
                                      (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                                      (221-214')-disulfide with kappa light chain (1'-214') [Homo
                                      sapiens V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01)
                                      [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (227-
                                      227'':230-230'')-bisdisulfide; conjugated, on an average of
                                      3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a
                                      cleavable maleimidocaproyl-valyl-citrullinyl-
                                      p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
                                      For the vedotin part, please refer to the document “INN for pharmaceutical
                                      substances: Names for radicals, groups and others”*.


 tisotumab védotine                   immunoglobuline G1-kappa, anti-[Homo sapiens F3
                                      (facteur de coagulation III (thromboplastine, facteur
                                      tissulaire), CD142)], Homo sapiens anticorps monoclonal
                                      conjugué à l’auristatine E;
                                      chaîne lourde gamma1 (1-448) [Homo sapiens VH
                                      (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-
                                      118) -IGHG1*03, G1m3 (CH1 (119-216), charnière (217-
                                      231), CH2 (232-341), CH3 (342-446), CHS (447-448))
                                      (119-448)], (221-214')-disulfure avec la chaîne légère
                                      kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01
                                      (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                                      214')]; dimère (227-227'':230-230'')-bisdisulfure; conjugué,
                                      sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine
                                      E (MMAE), via un linker clivable de type maléimidocaproyl-
                                      valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-
                                      PABC)
                                      Pour la partie védotine, veuillez-vous référer au document “INN for
                                      pharmaceutical substances: Names for radicals, groups and others”*.


 tisotumab vedotina                   inmunoglobulina G1-kappa, anti-[Homo sapiens F3 (factor
                                      de coagulación III (tromboplastina, factor tisular), CD142)],
                                      Homo sapiens anticuerpo monoclonal conjugado con la
                                      auristatina E;
                                      cadena pesada gamma1 (1-448) [Homo sapiens VH
                                      (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-
                                      118) -IGHG1*03, G1m3 (CH1 (119-216), bisagra(217-231),
                                      CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-
                                      448)], (221-214')-disulfuro con la cadena ligera kappa (1'-
                                      214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (96.80%) -
                                      IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')];
                                      dímero (227-227'':230-230'')-bisdisulfuro; conjugado, en
                                      3 - 4 restos cisteinil por termino medio, con
                                      monometilauristatina E (MMAE), mediante un espaciador
                                      escindible de tipo maleimidocaproil-valil-citrulinil-
                                      p-aminobenciloxicarbonil (mc-val-cit-PABC)
                                      La fracción vedotina, la pueden encontrar en el documento “INN for
                                      pharmaceutical substances: Names for radicals, groups and others”*.




                                                                                                               159
Recommended INN: List 75                   WHO Drug Information Vol. 30, No. 1, 2016



                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLLESGGG LVQPGGSLRL SCAASGFTFS                        NYAMSWVRQA         PGKGLEWVSS          50
                           ISGSGDYTYY TDSVKGRFTI SRDNSKNTLY                        LQMNSLRAED         TAVYYCARSP         100
                           WGYYLDSWGQ GTLVTVSSAS TKGPSVFPLA                        PSSKSTSGGT         AALGCLVKDY         150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                        YSLSSVVTVP         SSSLGTQTYI         200
                           CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC                        PAPELLGGPS         VFLFPPKPKD         250
                           TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                        DGVEVHNAKT         KPREEQYNST         300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                        APIEKTISKA         KGQPREPQVY         350
                           TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                        EWESNGQPEN         NYKTTPPVLD         400
                           SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                        EALHNHYTQK         SLSLSPGK           448

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPPS LSASAGDRVT ITCRASQGIS                        SRLAWYQQKP         EKAPKSLIYA 50
                           ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                        EDFATYYCQQ         YNSYPYTFGQ 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                        SVVCLLNNFY         PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                        LSKADYEKHK         VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                                       214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96 145-201               262-322 368-426
                                                 22''-96'' 145''-201'' 262''-322'' 368''-426''
                           Intra-L (C23-C104) 23'-88' 134'-194'
                                                23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126)* 221-214' 221''-214'''
                           Inter-H-H (h 11, h 14)* 227-227'' 230-230''
                           *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being
                           conjugated each via a thioether bond to a drug linker.
                           *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant
                           chacun conjugué via une liaison thioéther à un linker-principe actif.
                           *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a
                           conectores de principio activo.

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           298, 298''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                           complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 trevogrumabum #
 trevogrumab               immunoglobulin G4-kappa, anti-[Homo sapiens MSTN
                           (myostatin, growth differentiation factor 8, GDF8, GDF-8)],
                           human monoclonal antibody;
                           gamma4 heavy chain (1-447) [Homo sapiens VH (IGHV3-
                           23*01 (93.90%) -(IGHD)-IGHJ6*01 T125>I (117) [8.8.13]
                           (1-120) -IGHG4*01 (CH1 (121-218), hinge S10>P (228)
                           (219-230), CH2 (231-340), CH3 (341-445), CHS (446-
                           447)) (121-447)], (134-214')-disulfide with kappa light chain
                           (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-27*01
                           (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                           214')]; dimer (226-226":229-229")-bisdisulfide

 trévogrumab               immunoglobuline G4-kappa, anti-[Homo sapiens MSTN
                           (myostatine, facteur de croissance et de différenciation 8,
                           GDF8, GDF-8)], anticorps monoclonal humain;
                           chaîne lourde gamma4 (1-447) [Homo sapiens VH
                           (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01 T125>I (117)
                           [8.8.13] (1-120) -IGHG4*01 (CH1 (121-218), charnière
                           S10>P (228) (219-230), CH2 (231-340), CH3 (341-445),
                           CHS (446-447)) (121-447)], (134-214')-disulfure avec la
                           chaîne légère kappa (1’-214’) [Homo sapiens (V-KAPPA
                           (IGKV1-27*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -
                           IGKC*01, Km3 (108'-214')]; dimère (226-226":229-229")-
                           bisdisulfure

 trevogrumab               inmunoglobulina G4-kappa, anti-[Homo sapiens MSTN
                           (miostatina, factor de crecimiento y diferenciación 8,
                           GDF8, GDF-8)], anticuerpo monoclonal humano;




160
WHO Drug Information Vol. 30, No. 1, 2016                                           Recommended INN: List 75


                                      cadena pesada gamma4 (1-447) [Homo sapiens VH
                                      (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01 T125>I (117)
                                      [8.8.13] (1-120) -IGHG4*01 (CH1 (121-218), bisagra
                                      S10>P (228) (219-230), CH2 (231-340), CH3 (341-445),
                                      CHS (446-447)) (121-447)], (134-214')-disulfuro con la
                                      cadena ligera kappa (1’-214’) [Homo sapiens (V-KAPPA
                                      (IGKV1-27*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -
                                      IGKC*01, Km3 (108'-214')]; dímero (226-226":229-229")-
                                      bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQVLESGGD LVQPGGSLRL SCAASGFTFS                     AYAMTWVRQA       PGKGLEWVSA           50
                                       ISGSGGSAYY ADSVKGRFTI SRDNSKNTVY                     LQMNSLRAED       TAVYYCAKDG          100
                                       AWKMSGLDVW GQGTTVIVSS ASTKGPSVFP                     LAPCSRSTSE       STAALGCLVK          150
                                       DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                     GLYSLSSVVT       VPSSSLGTKT          200
                                       YTCNVDHKPS NTKVDKRVES KYGPPCPPCP                     APEFLGGPSV       FLFPPKPKDT          250
                                       LMISRTPEVT CVVVDVSQED PEVQFNWYVD                     GVEVHNAKTK       PREEQFNSTY          300
                                       RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS                     SIEKTISKAK       GQPREPQVYT          350
                                       LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE                     WESNGQPENN       YKTTPPVLDS          400
                                       DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE                     ALHNHYTQKS       LSLSLGK             447

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPAS LSASVGDRVT ITCRASQDIS                     DYLAWYQQKP       GKIPRLLIYT 50
                                       TSTLQSGVPS RFRGSGSGTD FTLTISSLQP                     EDVATYYCQK       YDSAPLTFGG 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                     SVVCLLNNFY       PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                     LSKADYEKHK       VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                  214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          147-203       261-321 367-425
                                                             22''-96'' 147''-203'' 261''-321'' 367''-425''
                                       Intra-L (C23-C104) 23'-88'        134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (CH1 10-CL 126) 134-214' 134''-214'''
                                       Inter-H-H (h 8, h 11)            226-226'' 229-229''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       297, 297''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 tucatinibum
                                        6                                                                    4
 tucatinib                            N -(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-N -[3-methyl-
                                      4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-
                                      4,6-diamine
                                        6                                                                    4
 tucatinib                            N -(4,4-diméthyl-4,5-dihydrooxazol-2-yl)-N -[3-méthyl-
                                      4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phényl]quinazoline-
                                      4,6-diamine
                                        6                                                               4
 tucatinib                            N -(4,4-dimetil-4,5-dihidrooxazol-2-il)-N -[3-metil-
                                      4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)fenil]quinazolina-
                                      4,6-diamina

                                       C26H24N8O2

                                                                                   N
                                       H3C               O

                                        H3C                                             N
                                                    N          N                                                  N
                                                               H
                                                                                HN                    CH3                 N
                                                                                                                      N

                                                                                                      O

 vaborbactamum
 vaborbactam                          {(3R,6S)-2-hydroxy-3-[2-(thiophen-2-yl)acetamido]-
                                      1,2-oxaborinan-6-yl}acetic acid




                                                                                                                                       161
Recommended INN: List 75                WHO Drug Information Vol. 30, No. 1, 2016




 vaborbactam                  acide {(3R,6S)-2-hydroxy-3-[2-(thiophén-2-yl)acétamido]-
                              1,2-oxaborinan-6-yl}acétique

 vaborbactam                  ácido {(3R,6S)-2-hidroxi-3-[2-(tiofen-2-il)acetamido]-
                              1,2-oxaborinan-6-il}acético

                              C12H16BNO5S
                                   S      O                    CO2H
                                              H            H
                                                       O
                                              N    B
                                              H
                                                   OH



 vadastuximabum talirinum #
 vadastuximab talirine        immunoglobulin G1-kappa, anti-[Homo sapiens CD33
                              (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3,
                              gp67, p67)], chimeric monoclonal antibody conjugated to
                              the pyrrolobenzodiazepine (PDB) dimer SGD-1882;
                              gamma1 heavy chain (1-447) [Mus musculus VH (IGHV1-
                              85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens
                              IGHG1*01, G1m17,1 (CH1 (118-215), hinge (216-230),
                              CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446-
                              447)) (118-447)], (220-214')-disulfide with kappa light chain
                              (1'-214') [Mus musculus V-KAPPA (IGKV14-111*01 -Homo
                              sapiens IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                              IGKC*01, Km3 (108'-214')]; dimer (226-226'':229-229'')-
                              bisdisulfide; conjugated, on two site-specific drug
                              attachment engineered cysteines (C239, C239''), to a
                              maximum of 2 pyrrolobenzodiazepine (PDB) dimers SGD-
                              1882, each via a cleavable (valine-alanine dipeptide as
                              cathepsine B cleavage site) maleimidocaproyl type linker

 vadastuximab talirine        immunoglobuline G1-kappa, anti-[Homo sapiens CD33
                              (lectine 3 de type Ig-like liant l’acide sialique, SIGLEC3,
                              SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique
                              conjugué au dimère de pyrrolobenzodiazépine (PDB)
                              SGD-1882;
                              chaîne lourde gamma1 (1-447) [Mus musculus VH
                              (IGHV1-85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo
                              sapiens IGHG1*01, G1m17,1 (CH1 (118-215), charnière
                              (216-230), CH2 S3>C (239) (231-340), CH3 (341-445),
                              CHS (446-447)) (118-447)], (220-214')-disulfure avec la
                              chaîne légère kappa (1'-214') [Mus musculus V-KAPPA
                              (IGKV14-111*01 -Homo sapiens IGKJ4*01) [6.3.9] (1'-107')
                              -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (226-
                              226'':229-229'')-bisdisulfure; conjugué, sur deux cystéines
                              sites de fixation spécifique du linker-produit actif (C239,
                              C239''), à un maximum de 2 dimères de
                              pyrrolobenzodiazépine (PDB) SGD-1882, chacun via un
                              linker clivable (dipeptide valine-alanine clivable par la
                              cathepsine B) de type maléimidocaproyle




162
WHO Drug Information Vol. 30, No. 1, 2016                                                                 Recommended INN: List 75


 vadastuximab talirina                inmunoglobulina G1-kappa, anti-[Homo sapiens CD33
                                      (lectina 3 de tipo Ig-like que liga el ácido siálico, SIGLEC3,
                                      SIGLEC-3, gp67, p67)], anticuerpo monoclonal quimérico
                                      conjugado con el dimero de pyirolobenzodiazepina (PDB)
                                      SGD-1882;
                                      cadena pesada gamma1 (1-447) [Mus musculus VH
                                      (IGHV1-85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo
                                      sapiens IGHG1*01, G1m17,1 (CH1 (118-215), bisagra
                                      (216-230), CH2 S3>C (239) (231-340), CH3 (341-445),
                                      CHS (446-447)) (118-447)], (220-214')-disulfuro con la
                                      cadena ligera kappa (1'-214') [Mus musculus V-KAPPA
                                      (IGKV14-111*01 -Homo sapiens IGKJ4*01) [6.3.9] (1'-107')
                                      -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (226-
                                      226'':229-229'')-bisdisulfuro; conjugado, en dos císteinas
                                      sitios de fijación específicos del linker-producto activo
                                      (C239, C239''), con un máximo de 2 dímeros de
                                      pirrolobenzodiazepina (PDB) SGD-1882, cada uno
                                      mediante un espaciador escindible (dipéptido valina-
                                      alanina escindible por la catepsina B) de tipo
                                      maleimidocaproil
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT                                       NYDINWVRQA   PGQGLEWIGW    50
                                       IYPGDGSTKY NEKFKAKATL TADTSTSTAY                                       MELRSLRSDD   TAVYYCASGY   100
                                       EDAMDYWGQG TTVTVSSAST KGPSVFPLAP                                       SSKSTSGGTA   ALGCLVKDYF   150
                                       PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                                       SLSSVVTVPS   SSLGTQTYIC   200
                                       NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                                       APELLGGPCV   FLFPPKPKDT   250
                                       LMISRTPEVT CVVVDVSHED PEVKFNWYVD                                       GVEVHNAKTK   PREEQYNSTY   300
                                       RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                                       PIEKTISKAK   GQPREPQVYT   350
                                       LPPSRDELTK NQVSLTCLVK GFYPSDIAVE                                       WESNGQPENN   YKTTPPVLDS   400
                                       DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                                       ALHNHYTQKS   LSLSPGK      447

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT INCKASQDIN                                       SYLSWFQQKP   GKAPKTLIYR 50
                                       ANRLVDGVPS RFSGSGSGQD YTLTISSLQP                                       EDFATYYCLQ   YDEFPLTFGG 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                                       SVVCLLNNFY   PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                                       LSKADYEKHK   VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                                                214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96 144-200                261-321    367-425
                                                             22''-96'' 144''-200'' 261''-321'' 367''-425''
                                       Intra-L (C23-C104) 23'-88'        134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 220-214' 220''-214'''
                                       Inter-H-H (h 11, h 14) 226-226'' 229-229''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       297, 297''
                                       Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                       complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

                                       Modified residues / Résidus modifiés / Restos modificados
                                                                                      H3CO
                                                     H2N         CO2H
                                                                                                                  O
                                                         H           S       H
                                                                                                              N       OCH3
                                                                                     and epimer at C*
                                                             O                      et l'épimère en C*
                                                                                     y el epímero al C*   H
                                                                     N                                            N   O
                                       C    239, 239''                           O                                N   O
                                                                                                          H


                                                                                                              N       OCH3
                                                                                                                  O
                                                                             Val Ala N
                                                                                     H
                                                                 O




 velmanasum alfa #
 velmanase alfa                       human lysosomal alpha-mannosidase (Laman,
                                      EC3.2.1.24, mannosidase alpha class 2B member 1),
                                      produced in CHO (Chinese Hamster Ovary) cells, alfa
                                      glycoform




                                                                                                                                              163
Recommended INN: List 75                  WHO Drug Information Vol. 30, No. 1, 2016



 velmanase alfa            alpha mannosidase lysosomiale humaine (Laman,
                           EC3.2.1.24, membre 1 de classe 2B de la mannosidase
                           alpha), produite par la cellule ovarienne de hamster chinois
                           (CHO), forme glycosylée alfa

 velmanasa alfa            alfa manosidasa lisosómica humana (Laman, EC3.2.1.24,
                           miembro 1 de la clase 2B de la manosidasa alfa),
                           producida por células ováricas de hamster chino (CHO),
                           forma glicosilada alfa
                           GGYETCPTVQ        PNMLNVHLLP         HTHDDVGWLK         TVDQYFYGIK         NDIQHAGVQY       50
                           ILDSVISALL        ADPTRRFIYV         EIAFFSRWWH         QQTNATQEVV         RDLVRQGRLE       100
                           FANGGWVMND        EAATHYGAIV         DQMTLGLRFL         EDTFGNDGRP         RVAWHIDPFG       150
                           HSREQASLFA        QMGFDGFFFG         RLDYQDKWVR         MQKLEMEQVW         RASTSLKPPT       200
                           ADLFTGVLPN        GYNPPRNLCW         DVLCVDQPLV         EDPRSPEYNA         KELVDYFLNV       250
                           ATAQGRYYRT        NHTVMTMGSD         FQYENANMWF         KNLDKLIRLV         NAQQAKGSSV       300
                           HVLYSTPACY        LWELNKANLT         WSVKHDDFFP         YADGPHQFWT         GYFSSRPALK       350
                           RYERLSYNFL        QVCNQLEALV         GLAANVGPYG         SGDSAPLNEA         MAVLQHHDAV       400
                           SGTSRQHVAN        DYARQLAAGW         GPCEVLLSNA         LARLRGFKDH         FTFCQQLNIS       450
                           ICPLSQTAAR        FQVIVYNPLG         RKVNWMVRLP         VSEGVFVVKD         PNGRTVPSDV       500
                           VIFPSSDSQA        HPPELLFSAS         LPALGFSTYS         VAQVPRWKPQ         ARAPQPIPRR       550
                           SWSPALTIEN        EHIRATFDPD         TGLLMEIMNM         NQQLLLPVRQ         TFFWYNASIG       600
                           DNESDQASGA        YIFRPNQQKP         LPVSRWAQIH         LVKTPLVQEV         HQNFSAWCSQ       650
                           VVRLYPGQRH        LELEWSVGPI         PVGDTWGKEV         ISRFDTPLET         KGRFYTDSNG       700
                           REILERRRDY        RPTWKLNQTE         PVAGNYYPVN         TRIYITDGNM         QLTVLTDRSQ       750
                           GGSSLRDGSL        ELMVHRRLLK         DDGRGVSEPL         MENGSGAWVR         GRHLVLLDTA       800
                           QAAAAGHRLL        AEQEVLAPQV         VLAPGGGAAY         NLGAPPRTQF         SGLRRDLPPS       850
                           VHLLTLASWG        PEMVLLRLEH         QFAVGEDSGR         NLSAPVTLNL         RDLFSTFTIT       900
                           RLQETTLVAN        QLREAASRLK         WTTNTGPTPH         QTPYQLDPAN         ITLEPMEIRT       950
                           FLASVQWKEV        DG                                                                        962

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           6-309 219-224 363-423 444-452

                           Glycosylation sites (potential) / Sites de glycosylation (potentiels) / Posiciones de glicosilación
                           (potenciales)
                           Asn-84 Asn-261 Asn-318 Asn-448 Asn-596 Asn-602
                           Asn-643 Asn-717 Asn-783 Asn-881 Asn-940


 vesatolimodum
 vesatolimod               4-amino-2-butoxy-8-({3-[(pyrrolidin-
                           1-yl)methyl]phenyl}methyl)-7,8-dihydropteridin-6(5H)-one

 vésatolimod               4-amino-2-butoxy-8-({3-[(pyrrolidin-
                           1-yl)méthyl]phényl}méthyl)-7,8-dihydroptéridin-6(5H)-one

 vesatolimod               4-amino-2-butoxi-8-({3-[(pirrolidin-1-il)metil]fenil}metil)-
                           7,8-dihidropteridin-6(5H)-ona

                           C22H30N6O2



                                   N

                                                            N         N        O                   CH3

                                                                          N
                                                  O         N
                                                            H
                                                                      NH2




 vistusertibum
 vistusertib               3-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-
                           d]pyrimidin-7-yl}-N-methylbenzamide




164
WHO Drug Information Vol. 30, No. 1, 2016                             Recommended INN: List 75




 vistusertib                          3-{2,4-bis[(3S)-3-méthylmorpholin-4-yl]pyrido[2,3-
                                      d]pyrimidin-7-yl}-N-méthylbenzamide

 vistusertib                          3-{2,4-bis[(3S)-3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-
                                      7-il}-N-metilbenzamida

                                       C25H30N6O3


                                                  CH3                       H
                                                                            N
                                       O           H                            CH3
                                              N                   N     O

                                                      N       N
                                                  H
                                                          N
                                            H3C

                                                          O

 volanesorsenum
 volanesorsen                         all-P-ambo-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-
                                      2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-deoxy-5-
                                      methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                                      thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-
                                      thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-
                                      (3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-
                                      P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                                      deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-
                                      methoxyethyl)-5-methyluridine

 volanésorsen                         tout-P-ambo-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-
                                      2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-déoxy-5-
                                      méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                                      thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-
                                      thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-
                                      (3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-
                                      P-thioadénylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                      déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-
                                      méthoxyéthyl)-5-méthyluridine




                                                                                                 165
Recommended INN: List 75                 WHO Drug Information Vol. 30, No. 1, 2016


 volanesorsén              todo-P-ambo-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-
                           (2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-
                           metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-
                           tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-
                           (3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-
                           (3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                           P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-
                           desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-
                           (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-
                           tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-
                           (3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-
                           (2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-
                           P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina

                           C230H320N63O125P19S19
                           (3'-5')(P-thio)(Amoe-Gmoe-mCmoe-Tmoe-Tmoe-dmC-dT-dT-dG-dT-dmC-dmC-dA-dG-dmC-
                           Tmoe-Tmoe-Tmoe-Amoe-Tmoe)
                           d (as prefix) = 2'-deoxy
                           m (as prefix) = 5-methyl
                           moe (as suffix) = 2'-O-[2-methoxy(ethyl)]


 volixibatum
 volixibat                 N-(3-O-benzyl-6-O-sulfo-β-D-glucopyranosyl)-
                           N'-{3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-
                           4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-
                                  6
                           1H-1λ -benzothiepin-5-yl]phenyl}urea

 volixibat                 N-(3-O-benzyl-6-O-sulfo-β-D-glucopyranosyl)-
                           N'-{3-[(3S,4R,5R)-3-butyl-7-(diméthylamino)-3-éthyl-
                           4-hydroxy-1,1-dioxo-2,3,4,5-tétrahydro-
                                  6
                           1H-1λ -benzothiépin-5-yl]phényl}urée

 volixibat                 N-(3-O-bencil-6-O-sulfo-β-D-glucopiranosil)-
                           N'-{3-[(3S,4R,5R)-3-butil-7-(dimetilamino)-3-etil-4-hidroxi-
                                                              6
                           1,1-dioxo-2,3,4,5-tetrahidro-1H-1λ -benzotiepin-
                           5-il]fenil}urea

                           C38H51N3O12S2


                            H 3C

                                                                            HO       O
                                         OH                         O
                                              H                         H
                            H 3C                                                         OH
                                                                N       N
                                                  H             H       H        O
                                   O S                                                   O
                                                                                                  O
                                    O                                                         S
                                                          CH3                                     O
                                                      N                                  HO
                                                      CH3


 voxilaprevirum
 voxilaprevir              (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-{(1R,2R)-2-
                           (difluoromethyl)-1-[(1-methylcyclopropanesulfonyl)
                           carbamoyl]cyclopropyl}-9-ethyl-18,18-difluoro-14-methoxy-
                           3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-
                           tetradecahydro-8H-7,10-methanocyclopropa[18,19]
                           [1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-
                           8-carboxamide




166
WHO Drug Information Vol. 30, No. 1, 2016                                                  Recommended INN: List 75




 voxilaprévir                         (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-{(1R,2R)-2-
                                      (difluorométhyl)-1-[(1-méthylcyclopropanesulfonyl)
                                      carbamoyl]cyclopropyl}-9-éthyl-18,18-difluoro-14-méthoxy-
                                      3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-
                                      tétradécahydro-8H-7,10-méthanocyclopropa[18,19]
                                      [1,10,3,6]dioxadiazacyclononadécino[11,12-b]quinoxaline-
                                      8-carboxamide

 voxilaprevir                         (1aR,5S,8S,9S,10R,22aR)-5-terc-butil-N-{(1R,2R)-2-
                                      (difluorometil)-1-[(1-metilciclopropanosulfonil)
                                      carbamoil]ciclopropil}-9-etil-18,18-difluoro-14-metoxi-
                                      3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-
                                      tetradecahidro-8H-7,10-metanociclopropa[18,19][1,10,3,6]
                                      dioxadiazaciclononadecino[11,12-b]quinoxalina-
                                      8-carboxamida

                                       C40H52F4N6O9S

                                                                      F       F
                                            H
                                                                                       N


                                                  O                       O            N               OCH3
                                            H                                 H
                                            O          NH
                                                  H                                        CH3
                                       H3C                        N                   H
                                                                                  H
                                            H3C       CH3 O
                                                                  O               NH                 CH3
                                                                                           H
                                                                                           N
                                                                                                 S
                                                              F
                                                                                            O O
                                                                                  H O
                                                                      F

 zidebactamum
 zidebactam                           (1R,2S,5R)-7-oxo-2-{2-[(3R)-piperidine-
                                      3-carbonyl]hydrazinecarbonyl}-
                                      1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate

 zidébactam                           hydrogénosulfate de (1R,2S,5R)-7-oxo-2-{2-[(3R)-
                                      pipéridine-3-carbonyl]hydrazinecarbonyl}-
                                      1,6-diazabicyclo[3.2.1]octan-6-yle

 zidebactam                           hidrógenosulfato de (1R,2S,5R)-7-oxo-2-{2-[(3R)-
                                      piperidina-3-carbonil]hidrazinacarbonil}-
                                      1,6-diazabiciclo[3.2.1]octan-6-ilo

                                       C13H21N5O7S

                                                                              O
                                                      O               H                    H H
                                                                                           N               NH
                                                              N                       N
                                                                                      H
                                                                                               O
                                        O O   N
                                          S O
                                       HO                     H




                                                                                                                167
Recommended INN: List 75                             WHO Drug Information Vol. 30, No. 1, 2016



                       AMENDMENTS TO PREVIOUS LISTS
              MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                  MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 73
Dénominations communes internationales recommandées (DCI Rec.): Liste 73
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 73
(WHO Drug Information, Vol. 29, No. 1, 2015)
 
p. 64   albenatidum#
        albenatide      replace the description and the structure by the following ones
        albénatide      remplacer la description et la structure par les suivantes
        albenatida      sustitúyase la descripción y la estructura por las siguientes
                         3.34
                        S -[1-(3-{[2-(2-{2-[exendin-4 Heloderma suspectum precursor-(48-86)-
                                                            6
                        peptidyl (exenatidyl)-L-lysinamide-N -yl]-2-oxo-ethoxy}ethoxy)ethyl]amino}-
                        3-oxopropyl)-2,5-dioxopyrrolidin-3-yl]human serum albumin.
                        Peptide is synthetic, and human serum albumin is produced in
                        Saccharomyces cerevisiae.
                         3.34
                        S -[1-(3-{[2-(2-{2-[précurseur de l’exendin-4 de Heloderma suspectum-
                                                                      6
                        (48-86)-peptidyl (exénatidyle)-L-lysinamide-N -yl]-2-oxo-
                        éthoxy}éthoxy)éthyl]amino}-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl]albumine
                        sérique humaine.
                        Le peptide est synthétique et l'albumine sérique humaine est produite par
                        Saccharomyces cerevisiae.
                         3.34
                        S -[1-(3-{[2-(2-{2-[precursor de la exendina-4 de Heloderma suspectum-
                                                                     6
                        (48-86)-peptidil (exenatidilo)-L-lisinamida-N -il]-2-oxo-etoxi}etoxi)etil]amino}-
                        3-oxopropil)-2,5-dioxopirrolidin-3-il]albúmina sérica humana.
                        El péptido es sintético y la albúmina sérica humana la produce el
                        Saccharomyces cerevisiae.




168
WHO Drug Information Vol. 30, No. 1, 2016                               Recommended INN: List 75



 
 
p. 103 -    pegvaliasum #
104         pegvaliase           replace the description by the following one
            pegvaliase           remplacer la description par la suivante
            pegvaliasa           sustitúyase la descripción por la siguiente

                                 pegylated, recombinant DNA derived Anabaena variabilis
                                 phenylalanine ammonia lyase mutein (S 503, S 565), produced in
                                 Escherichia coli:
                                 [503-serine (C>S),565-serine (C>S)]phenylalanine ammonia-lyase (EC
                                 4.3.1.24) Anabaena variabilis in which at least 6 lysyl residues are
                                   6
                                 N -{6-[ω-methoxypoly(oxyethylene)]hexanoyl} substituted

                                 mutéine (S 503, S 565) de phénylalanine ammoniac-lyase de
                                 Anabaena variabilis, pégylée, produite par Escherichia coli à partir
                                 d'ADN recombinant:
                                 [503-sérine (C>S),565-sérine (C>S)]phénylalanine ammoniac-lyase
                                 (EC 4.3.1.24) de Anabaena variabilis dont au moins 6 résidus
                                             6
                                 lysyl sont N -{6-[ω-méthoxypoly(oxyéthylène)]hexanoyl} substitués

                                 muteína (S 503, S 565) de la fenilalanina amoniaco-liasa de
                                 Anabaena variabilis, pegilada, producida en Escherichia coli a partir
                                 de ADN recombinante:
                                 [503-serina (C>S),565-serina (C>S)]fenilalanina amoniaco-liasa (EC
                                 4.3.1.24) de Anabaena variabilis de cuyos restos lisil 5, por término
                                                6
                                 medio, están N -{6-[ω-metoxipoli(oxietileno)]hexanoil} substituidos
 
 
Recommended International Nonproprietary Names (Rec. INN): List 74
Dénominations communes internationales recommandées (DCI Rec.): Liste 74
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 74
(WHO Drug Information, Vol. 29, No. 3, 2015)


p. 421     somapacitanum #
           somapacitan   replace the description and the structure by the following ones
           somapacitan   remplacer la description et la structure par les suivantes
           somapacitán   sustitúyase la descripción y la estructura por las siguientes

                            [101-{S-[(8S,22S,27S)-8,22,27-tricarboxy-2,10,19,24,29,38,42,42,44-
                                                                                  6
                            nonaoxo-59-(1H-tetrazol-5-yl)-12,15,31,34-tetraoxa-42λ -thia-
                            3,9,18,23,28,37,43-heptaazanonapentacontan-1-yl]-L-cysteine}]human
                            somatropin

                            [101-{S-[(8S,22S,27S)-8,22,27-tricarboxy-2,10,19,24,29,38,42,42,44-
                                                                                  6
                            nonaoxo-59-(1H-tétrazol-5-yl)-12,15,31,34-tétraoxa-42λ -thia-
                            3,9,18,23,28,37,43-heptaazanonapentacontan-1-yl]-L-cystéine}]somatropine
                            humaine

                            [101-{S-[(8S,22S,27S)-8,22,27-tricarboxi-2,10,19,24,29,38,42,42,44-
                                                                                  6
                            nonaoxo-59-(1H-tetrazol-5-il)-12,15,31,34-tetraoxa-42λ -tia-
                            3,9,18,23,28,37,43-heptaazanonapentacontan-1-il]-L-cisteina}]somatropina
                            humana




                                                                                                    169
Recommended INN: List 75                                WHO Drug Information Vol. 30, No. 1, 2016




# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/




       Procedure and Guiding Principles                  /   Procédure   et   Directives   /
       Procedimientos y principios generales
       The text of the Procedures for the Selection of Recommended International
       Nonproprietary Names for Pharmaceutical Substances and General Principles
       for Guidance in Devising International Nonproprietary Names for
       Pharmaceutical Substances will be reproduced in proposed INN lists only.
       Les textes de la Procédure à suivre en vue du choix de dénominations
       communes     internationales    recommandées      pour     les   substances
       pharmaceutiques et des Directives générales pour la formation de
       dénominations communes internationales applicables aux substances
       pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
       El texto de los Procedimientos de selección de denominaciones comunes
       internacionales recomendadas para las sustancias farmacéuticas y de los
       Principios generales de orientación para formar denominaciones comunes
       internacionales para sustancias farmacéuticas aparece solamente en las listas
       de DCI propuestas.




170
